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Abstract 
Ribosomal S6 kinase (S6K) is a member of the AGC family of 
serine/threonine protein kinases and plays a key role in diverse cellular 
processes, including cell growth, survival and metabolism. Activation of 
S6K by growth factors, amino acids, energy levels and hypoxia is 
mediated by the mTOR and PI3K signalling pathways. Dysregulation of 
S6K activity has been implicated in a number of human pathologies, 
including cancer, diabetes, obesity and ageing. The family of S6Ks 
consists of two proteins S6K1 and S6K2, which are encoded by different 
genes. Most of research has been done on S6K1, while little is currently 
known about specific functions of S6K2. Recently, several novel splicing 
variants of human S6K2, termed S6K2-S1, S6K2-S2 and S6K2-S3, have 
been identified in our laboratory. The aim of this thesis was therefore to 
study the function of S6K2-S1 splicing isoform in normal and cancer 
cells and its role in the regulation of mTORC1/S6K signalling. 
 Initially, detailed bioinformatic analysis of human and mouse databases 
in combination with an alternative splicing potential of S6K2 gene 
revealed three novel splicing isoforms. S6K2-S1 splicing isoform is the 
product of exon 9 alternative splicing, which results in the formation of 
a truncated splice variant, lacking the kinase domain. We found that 
S6K2-S1 has the potential to integrate into the mTORC1 signalling 
complex via specific interaction with the substrate-presenting protein 
Raptor. Functional analysis of S6K2-S1 revealed that it could inhibit 
some of mTOR functions in starved conditions and mediate pro-
apoptotic signalling. Furthermore, stable overexpression of S6K2-S1 
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protein in different cell lines inhibited cell migration and dramatically 
reduced anchorage-independent colony growth in soft agar. 
Importantly, S6K2-S1 splice variant reduced A549 cell in vivo tumour 
growth in nude mice, while full length S6K2 promoted in vivo tumour 
formation.  
Together, the data from this thesis revealed the existence of novel S6K2 
splicing isoforms and uncovered a dominant-negative effect of S6K2-S1 
on mTORC1 signalling and its tumour suppressive function in cell-based 
models and xenograft studies.   
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 5 
 
 
Dedication 
There are a number of people to whom I am deeply grateful for the 
completion of this thesis.  
First of all I would like to thank my supervisor, Professor Ivan Gout, for 
giving me the opportunity to join his laboratory as a PhD student. 
During the four years, he has been a dedicated and understanding 
teacher and has supervised my work with a lot of inspiring enthusiasm. 
I am very much grateful to my husband Eugene and my adorable kids 
Maximilian and Anastasia who spent a lot of time being without me. My 
family, especially to my Mum who allowed me to finish my experiments 
and to write this thesis, looking after my kids. 
My colleagues, Alex, Yugo, Ahmed, Mahmoud, Pascale, Nadeem, Eddy 
and many others for the great discussions and new ideas that helped 
solve problems and progress with my work.  
My collaborators at Imperial College London (Prof. M. Seckl and Dr. O. 
Pardo) and at UCL Cancer Institute (Prof. Barbara Pedley’s group), for 
the work they did. Professors Chris Kay and Kaila Srai, for their useful 
suggestions during my thesis committee meetings. 
I thank you all for these contributions great and small, as without you, 
this thesis would not have been written.
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 6 
 
 
Table of Contents 
Declaration ............................................................................................. 2 
Abstract .................................................................................................. 3 
Dedication .............................................................................................. 5 
Table of Contents ................................................................................... 6 
Table of Figures .................................................................................... 12 
Publications .......................................................................................... 16 
Abbreviation ......................................................................................... 17 
1 Introduction ................................................................................. 24 
1.1 The role of signalling pathways in the regulation of cell 
growth……….. .................................................................................... 24 
1.2 Family of ribosomal protein S6 kinases .................................... 25 
1.2.1 AGC family of serine/threonine kinases .......................... 25 
1.3 S6K1 and S6K2 isoforms and their subcellular localisation ....... 26 
1.4 Structure and domain organisation .......................................... 27 
1.5 Regulation of S6K activity ......................................................... 29 
1.5.1 The role of PI3K pathway signalling in the activation of 
S6K……….. ..................................................................................... 31 
1.5.2 mTOR signalling to S6Ks .................................................. 34 
1.5.3 Role of the MAPK/ERK pathway in the regulation of 
S6Ks…………. .................................................................................. 36 
1.5.4 Other positive regulators of S6Ks .................................... 37 
1.5.5 Negative regulation......................................................... 38 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 7 
 
1.6 Cellular Functions of ribosomal protein S6 kinases .................. 39 
1.6.1 Regulation of translation and ribosomal biogenesis ....... 40 
1.6.2 Control of cell cycle progression, cell size and 
proliferation. ................................................................................ 42 
1.6.3 Cell survival ..................................................................... 44 
1.6.4 Cytoskeleton rearrangements ......................................... 46 
1.7 Other targets for S6K and potential functions .......................... 50 
1.8 Dysregulation of the S6K pathway in human pathologies ........ 52 
1.8.1 Malignant transformation ............................................... 52 
1.8.2 Metabolic disorders ........................................................ 55 
1.8.3 Ageing, learning and memory ......................................... 56 
2 Materials and Methods ................................................................ 58 
2.1 General materials ..................................................................... 58 
2.1.1 General laboratory reagents ........................................... 58 
2.1.2 Expression vector and primers ........................................ 58 
2.1.3 Antibodies ....................................................................... 58 
2.2 DNA and RNA manipulation ..................................................... 59 
2.2.1 Oligonucleotide design ................................................... 59 
2.2.2 DNA amplification by the polymerase chain reaction ..... 59 
2.2.3 DNA digestion with restriction endonucleases ................ 59 
2.2.4 Ethanol precipitation of DNA product ............................. 60 
2.2.5 Electrophoresis of DNA ................................................... 60 
2.2.6 Purification of DNA fragments from agarose gel ............. 61 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 8 
 
2.2.7 Dephosphorilation of the vector ..................................... 61 
2.2.8 Ligation of DNA fragments .............................................. 61 
2.2.9 Purification of plasmid DNA ............................................ 62 
2.2.10 Isolation of the Recombinant Bacmid DNA ..................... 63 
2.2.11 mRNA purification ........................................................... 64 
2.2.12 RT-PCR analysis ............................................................... 65 
2.3 Bacterial methodology ............................................................. 66 
2.3.1 Bacterial strains and growth media ................................. 66 
2.3.2 Preparation of competent cells ....................................... 67 
2.3.3 Transformation of E.coli .................................................. 67 
2.3.4 Transformation of DH10Bac™ E. Coli .............................. 68 
2.4 Cell culture methodology ......................................................... 68 
2.4.1 Cryopreservation of cells ................................................ 68 
2.4.2 Insect Cells culture .......................................................... 69 
2.4.3 Mammalian cell culture .................................................. 71 
2.4.4 Characterisation of stable cell lines ................................. 74 
2.5 Production of anti-S6K2-S1 polyclonal antibodies .................... 76 
2.5.1 Generation of rabbit antisera .......................................... 76 
2.5.2 Affinity purification of antibodies ................................... 76 
2.6 Lentivirus generation ............................................................... 77 
2.6.1 Generation of the virus ................................................... 77 
2.6.2 Lentiviral infection .......................................................... 78 
2.7 Protein purification and analysis .............................................. 78 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 9 
 
2.7.1 Preparation of mammalian cells extracts ........................ 78 
2.7.2 Preparation of insect cells extracts ................................. 79 
2.7.3 Estimating of protein concentration ............................... 79 
2.7.4 SDS-PAGE electrophoresis .............................................. 79 
2.7.5 Immunoblotting .............................................................. 80 
2.7.6 Coomassie Blue staining ................................................. 81 
2.7.7 Immunoprecipitation ...................................................... 81 
2.7.8 Affinity purification of S6K2-S1 protein from Sf9 cells ..... 82 
2.8 Xenograft studies in nude mice ................................................ 83 
2.8.1 Preparation of tumour samples ...................................... 83 
3 Analysis of the existence of potential S6K2 splicing isoforms ....... 85 
3.1 Introduction ............................................................................. 85 
3.2 Results ..................................................................................... 88 
3.2.1 Bioinformatic analysis reveals the existence of potential 
S6K2 splicing isoforms .................................................................. 88 
3.2.2 RT-PCR analysis confirms the existence of S6K2-S1 in 
HEK293 cells ................................................................................. 99 
3.2.3 Molecular cloning and mammalian expression of the S6K2-
S1 splicing isoform ...................................................................... 104 
3.2.4 Generation and characterisation of specific polyclonal 
antibodies directed towards S6K2-S1 ......................................... 109 
3.3 Discussion .............................................................................. 115 
4 S6K2-S1 and S6K2wt form a regulatory complex with Raptor and 
mTOR ................................................................................................. 118 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 10 
 
4.1 Introduction ........................................................................... 118 
4.2 Results ................................................................................... 121 
4.2.1 Generation of baculovirus for Raptor and Rictor .......... 121 
4.2.2 Molecular cloning and expression of S6K2-S1 in 
baculovirus expression system ................................................... 128 
4.2.3 S6K2-S1 specifically interacts with Raptor, but not Rictor in 
insect cells .................................................................................. 132 
4.2.4 Lentivirus generation of HEK293 stable cell lines 
overexpressing full length S6K2 and splicing isoform S6K2-S1 .... 134 
4.2.5 Raptor and mTOR coimmunoprecipitate with full length 
S6K2 and splicing isoform S1 in vivo ........................................... 140 
4.3 Discussion .............................................................................. 142 
5 Functional analysis of the S6K2 S1 splicing isoform .................... 145 
5.1 Introduction ........................................................................... 145 
5.2 Results ................................................................................... 146 
5.2.1 Overexpression of full length S6K2 and S6K2-S1 splicing 
isoform affects cell size the opposite way .................................. 146 
5.2.2 S6K2-S1 isoform does not affect cell proliferation ........ 156 
5.2.3 S6K2-S1 can modulate the activity of the mTOR/S6K 
pathway in starved condition ..................................................... 158 
5.2.4 S6K2-S1 is impicated in the regulation of cell migration 163 
5.2.5 Cells overexpressing S6K2-S1 show higher sensitivity to 
drug-induced apoptosis .............................................................. 169 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 11 
 
5.2.6 S6K2-S1 is a potential tumour suppressor, whereas full 
length S6K2 exhibits oncogenic properties ................................. 173 
5.2.7 Xenograft studies in nude mice ..................................... 179 
5.3 Discussion .............................................................................. 183 
6 General discussion and future studies ........................................ 187 
7 Appendix A ................................................................................. 198 
8 Appendix B ................................................................................. 202 
9 Reference list .............................................................................. 204 
 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 12 
 
 
Table of Figures 
Figure 1.1 Schematic domain organization of S6K1 and S6K2 isoforms. .
 ............................................................................................................. 28 
Figure 1.2 Activation mechanism for S6K. ............................................ 31 
Figure 1.3 Signalling pathways upstream of ribosomal protein S6 
kinases.................................................................................................. 33 
Figure 1.4 Downstream substrates and cellular functions controlled by 
S6Ks. ..................................................................................................... 39 
Figure 1.5 S6Ks exist in different complexes. ........................................ 46 
Figure 1.6 S6K1 regulates cell migration. .............................................. 48 
Figure 3.1 Schematic diagram of alternative splicing of human S6K2 
gene and primary structure of potential splicing isoforms. .................. 91 
Figure 3.2 Analysis of S6K2-S1 nucleotide sequence. ........................... 93 
Figure 3.3 Analysis of S6K2-S2 nucleotide sequence.. .......................... 94 
Figure 3.4 Analysis of S6K2-S3 nucleotide sequence. ........................... 95 
Figure 3.5 Protein sequences of S6K2 splicing isoforms. .................... 100 
Figure 3.6 Schematic representation of S6K2 isoforms....................... 101 
Figure 3.7 Analysis of S6K2-S1 expression in HEK293 cell lines by RT-PCR. 
. .......................................................................................................... 103 
Figure 3.8 Molecular cloning of S6K2-S1 splicing isoform into pcDNA3.1 
expression plasmid.. ........................................................................... 106 
Figure 3.9 Generation of stable cell lines overexpressing S6K2-S1. .... 107 
Figure 3.10 Affinity purification of polyclonal anti-S6K2-S1 antibodies.
 ........................................................................................................... 111 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 13 
 
Figure 3.11 Characterisation of affinity purified polyclonal anti-S6K2-S1 
antibodies. ......................................................................................... 114 
Figure 4.1 A model of regulatory interactions of S6K2wt and S6K2-S1 
splicing isoform in TORC1 and downstream signalling. ....................... 120 
Figure 4.2 Generation of recombinant baculovirus and protein 
expression using Baculovirus Expression System ................................ 122 
Figure 4.3 Molecular cloning of EE-tagged Raptor into baculovirus 
expression vector pFastBac1. ............................................................. 124 
Figure 4.4 Molecular cloning of EE-tagged Rictor into baculovirus 
expression vector pFastBac1. ............................................................. 126 
Figure 4.5 Expression of EE-Raptor and EE-Rictor in insects Sf9 cells.. 127 
Figure 4.6 Molecular cloning and baculovirus expression of N-terminally 
tagged Strep-S6K2-S1 and His-S6K2-S1.. ............................................. 129 
Figure 4.7 Molecular cloning, expression and affinity purification of the 
C-terminally FLAG-tagged S6K2-S1 using baculoviral expression system..
 ........................................................................................................... 131 
Figure 4.8 S6K2-S1 specifically interacts with Raptor (mTORC1). ........ 133 
Figure 4.9 Overall strategy for Lentivirus generation. ......................... 135 
Figure 4.10 Molecular cloning of S6K2-S1 splicing isoform and S6K2wt 
into Lentivirus expression vector pLEX. .............................................. 136 
Figure 4.11 Generation of stable cell lines using Lentivirus constructs for 
the expression of S6K2wt and S6K2-S1. .............................................. 139 
Figure 4.12 Coimmunoprecipitation of overexpressed EE-S6K2wt and 
EE-S6K2-S1 with endogenous Raptor and mTOR in HEK293 cells. ...... 141 
Figure 5.1 Cell size analysis of HEK293 and NIH3T3RasC40 cells with 
stable overexpression of S6K2-S1 splicing isoform. ............................ 148 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 14 
 
Figure 5.2 Generation of  MEF TSC2-/- p53 -/- stable cell lines 
overexpressing full-length S6K2 and splicing variant S6K2-S1. ........... 151 
Figure 5.3 Characterisation of MEF TSC2-/- p53-/- stable cell lines 
overexpressing full-length S6K2 and S6K2-S1 splicing isoform.. ......... 153 
Figure 5.4 Overexpression of S6K2-S1 splicing isoform reduces the size 
of MEF TSC2-/- p53 -/- cells.. .............................................................. 155 
Figure 5.5 Overexpression of S6K2-S1 in HEK293 cells does not affect 
cell proliferation. ................................................................................ 157 
Figure 5.6 Overexpression of S6K2-S1 in HEK293 cells affects the 
mTOR/S6K pathway in serum-starved cells. ....................................... 160 
Figure 5.7 Overexpression of S6K2-S1 in MEF TSC2-/- p53 -/- cells affects 
the mTOR/S6K pathway in serum-starved cells. ................................. 162 
Figure 5.8 Generation and characterisation of NIH3T3 RacC40 stable cell 
lines overexpressing S6K2-S1.. ........................................................... 165 
Figure 5.9 Overexpression of S6K2-S1 in NIH3T3RasC40 cells affects 
early cell attachment to the plate. ..................................................... 166 
Figure 5.10 Overexpression of S6K2-S1 in NIH3T3RasC40 cells inhibits 
cell migration measured by wound healing assay. ............................. 168 
Figure 5.11  Staurosporin treated A549 cells with stable overexpression 
of S6K2-S1 shows higher level of cleaved PARP when compared to 
control cells. ....................................................................................... 170 
Figure 5.12 Cells overexpressing EE-S6K2-S1 show higher sensitivity to 
cisplatin-induced apoptosis. ............................................................... 172 
Figure 5.13 Overexpression of S6K2-S1 isoform inhibits anchorage-
independent colony formation in soft agar.   ..................................... 176 
Figure 5.14 Overexpression of S6K2-S1 splicing variant in A549 cells 
supresses colony formation in soft agar.. ........................................... 177 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 15 
 
Figure 5.15 Analysis of tumours growth in a xenograft mouse model..
 ........................................................................................................... 181 
Figure 5.16 Overexpression of S6K2-S1 reduces tumour growth in a 
xenograft mouse model. .................................................................... 182 
Figure 6.1 Mechanism of alternative splicing of S6K1 gene. ............... 189 
 Figure 6.2 Generation of an S6K2-/- allele.. ....................................... 190 
 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 16 
 
 
Publications 
Ismail HM, Myronova O, Tsuchiya Y, Niewiarowski A, Tsaneva I, Gout I. 
“Identification of the general transcription factor Yin Yang 1 as a novel 
and specific binding partner for S6 kinase 2”. Cell Signal. 2013 May; 
25(5): 1054-63. doi: 10.1016/j.cellsig.2013.02.002. Epub 2013 Feb 10 
Myronova O, Munro C, Pedley B, Pardo O, Seckl J.M, Gout I. “The role of 
S6K2 splicing isoforms  in mTOR signalling and cellular functions“, 
manuscript in preparation, 2015 
Ibrahim M, Myronova O, Pardo O, Seckl J.M,  Gout I. “Regulation of 
S6K2 by arginine methylation”, manuscript in preparation, 2015 
 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 17 
 
 
Abbreviation 
AMP 
AMPK 
APC 
ATP 
BAD 
Bcl-2 
Bcl-xL 
BSA 
cAMP  
CBP 
CBP80   
CBC  
C-CAM1 
Cdc42 
cDNA 
CREM   
Deptor 
Adenosine monophosphate 
AMP-activated protein kinase 
Anaphase promoting complex 
Adenosine triphosphate 
Bcl-2-assosiated death promoter 
B-cell lymphoma  2 
B-cell lymphoma-extra-large 
Bovine serum albumin 
Adenosine3`,5`-cyclic monophosphate 
CREB binding protein 
80 kDa subunit of RNA cap-binding complex 
Cap-binding complex  
Cell-cell adhesion molecule 
Cell division control protein 42 homolog 
Complementary DNA 
cAMP-responsive activator modulator 
DEP-domain-cointaining mTOR-interacting protein 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 18 
 
DMEM 
DMSO 
DNA 
dNTP 
DTT 
4E-BP1 
ECL 
EDTA 
eIF4A 
eIF4B 
eEF2K  
E2F  
EJC 
EGF 
EGTA 
 
ELISA 
EMT 
ERα 
Dulbecco’s modified Eagle’s medium 
Dimethyl sulphoxide 
Deoxyribonucleic acid 
Deoxyribonucleoside triphosphate 
Dithiotreitol 
Eukaryotic initiation factor-4E binding protein 1 
Enhanced chemiluminescence 
Ethylenediaminetetra-acetic acid 
Eukaryotic initiation factor 4A 
Eukaryotic initiation factor 4B 
Eukaryotic elongation factor 2 kinase 
Early promoter 2 factor 
Exon junction complex 
Epidermal growth factor 
Ethyleneglycol-bis(-aminoethyl)-N,N,N`,N`-tetraacetic 
acid 
Enzyme-linked immunosorbent assay 
Epithelial to mesenchymal transition 
Estrogen Receptor 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 19 
 
αK 
EST  
FGF 
FBS 
FKBP12 
FTD 
GAP 
GFP 
GSK 
HM 
hSNF5 
 
hnRNPs 
Ig 
IGF-1 
IP 
IRS-1 
KLH 
LAM 
Extracellular signal-regulated kinase 
Expressed sequence tag 
Fibroblast growth factor 
Fetal bovine serum 
FK506-binding protein 12 
Frontotemporal dementia 
GTPase-activating protein 
Green Fluorescent Protein 
Glycogen synthase kinase 
Hydrofobic motif 
SWI/SNF-related matrix-associated actin-dependent 
regulator 
Heterogeneous nuclear ribonucleoproteins 
Immunoglobulin 
Insulin-like growth factor 1 
Immunoprecipitation 
Insulin receptor substrate 1 
Keyhole limpet hemocyanin 
Lymphangioleiomyomatosis 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 20 
 
5`-LTR 
 
LY294002                        
 
mLST8 
MAPK 
MEK 
MOPS 
mRNA  
mRNP 
mSIN1 
 
mTOR 
Ni-NTA 
NLS 
NMD 
NSCL 
OD  
PBS 
Long terminal repeat 
 
morpholine-containing chemical compound, inhibitor 
of phosphoinositide 3-kinases 
Mammaliam lethal with Sec13 protein 8 
Mitogen-activated protein kinase 
MAPK kinase 
3-(N-morpholino)propanesulfonic acid 
Messenger RNA 
Messenger ribonucleic acid protein 
Mammalian stress-activated protein kinase interacting 
protein 
 
Mammalian target of rapamycin 
Nickel-nitrilotriacetic acid 
Nuclear localisation signal 
Nonsense Mediated Decay 
Non-small cell lung cancer 
Optical density 
Phosphate buffered saline  
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 21 
 
PDGF 
PDK1 
PDZ 
PEG 
PH 
PI(3)K 
PKA 
PKB/Akt 
PKC 
PCR  
PP2A 
p90RSK  
PtdIns(3)P 
PtdIns(3,4)P2 
PtdIns(3,5)P2  
PtdIns(3,4,5)P3 
Pre-mRNA 
PRAS40 
Protor-1 
Platelet-derived growth factor 
3`-Phosphoinositide-dependent kinase-1 
Postsynaptic density-95, discs large, zona occludens-1 
Polyethylene glycol 
Pleckstrin homology 
Phosphatidylinositide-3`-kinase 
Protein kinase A 
Protein kinase B 
Protein kinase C 
Polymerase chain reaction  
Protein-serine/threonine phosphatase 2A 
p90 Ribosomal S6 kinase 
Phosphatidylinositol-3-phosphate 
Phosphatidylinositol-3,4-bisphosphate 
Phosphatidylinositol-3,5-bisphosphate 
Phosphatidylinositol-3,4,5-trisphosphate 
Pre-messenger RNA 
Prolin-rich Akt substrate 40 kDa 
Protein observed with Rictor-1 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 22 
 
PTC 
PTEN 
 
PVDF 
Rac-1 
Raf 
Raptor 
Ras 
Rictor 
RNA  
rpS6  
rRNA      
RSK 
RT-PCR 
S6K 
SDS    
SDS-PAGE 
SF2/ASF 
SGK1 
Premature stop codons 
Phosphatase and tensin homologue, deleted on 
chromosome 10 
Polyvinyldene difluoride 
Ras-related C3 botulinum toxin substrate 1 
Rapidly Accelerated Fibrosarcoma 
Regulatory-associated protein of mTOR 
Rat sarcoma 
Rapamycin-insensitive companion of mTOR 
Ribonucleic acid 
Ribosomal protein S6 
Ribosomal RNA 
Ribosomal proteinS6-related kinases 
Real time polymerase chain reaction  
Ribosomal protein S6 kinase 
Sodium n-dodecyl sulfate 
SDS-polyacrylamide gel electrophoresis 
Pre-mRNA-splicing factor SF2/ alternative splicing 
factor 1 
Serum- and glucocorticoid-induced protein kinase 1 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 23 
 
SH3 
SKAR 
snRNA  
snRNPs   
TOS 
TGF 
TM 
TNF 
5`-TOP 
TRAIL 
tRNA 
TSC2 
TSC2 
Tween 20 
WW 
5`-UTR 
XIAP 
Src homology 3 
S6K1 Aly/REF-like target 
Small nuclear RNA 
Small nuclear ribonucleic proteins 
TOR signalling motif 
Transforming growth factor  
Turn motif 
Tumor necrosis factors 
5`-terminal oligopyrimidine tract 
TNF-related apoptosis-inducing ligand 
Transfer RNA 
Tuberous sclerosis 1 protein, hamartin 
Tuberous sclerosis 2 protein, tuberin 
Polyoxyethylenesorbitan monolaurate 
Tryptophan-tryptophan 
5`-untranslated region 
X-linked inhibitor of apoptosis protein 
 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 24 
 
 
1 Introduction 
1.1 The role of signalling pathways in the regulation of 
cell growth 
Mammalian cells sense and promptly respond to changes in their 
environment through the induction of signalling pathways which are 
essential for the development, growth and survival of all organisms. 
Complex signalling mechanisms have developed during evolution of 
multicellular organisms to control and regulate responses to a great 
variety of stimuli and stresses. These pathways are activated by growth 
factors, hormones and nutrients via the interaction with specific cell-
surface receptors. Extracellular signals are then transmitted inside cells 
by multifunctional signalling cascades, which in turn regulate cellular 
processes, such as cell growth and size, cell cycle progression and 
proliferation,  differentiation   etc. (Yang and Xu 2011). 
 Studies in cell-based and animal models have revealed two major 
signalling pathways in the regulation of cell growth, proliferation and 
survival: the MEK/ERK mitogen activated protein (MAP) kinase pathway 
and the PI3K/mTOR signalling pathway.   
In response to mitogenic stimulation, initiation and maintenance of a 
high level of protein synthesis is one of the major responses, which 
contribute to the ability of the cell to progress through the cell cycle, 
leading to cell growth, DNA synthesis, and cell division. This response is 
associated with the formation of multienzyme regulatory complexes 
around activated receptors and the increase in covalent post-
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translational modification of signalling proteins, such as 
phosphorylation, ubiquitination, acetylation etc. (Jastrzebski et al. 
2007). 
The ribosomal protein S6 kinases (S6Ks) are important signalling 
components of nutrient- and mitogen-stimulated pathways involved in 
the regulation of cellular biosynthetic processes, cell growth and energy 
metabolism (Proud 1996).  
1.2 Family of ribosomal protein S6 kinases 
1.2.1  AGC family of serine/threonine kinases  
The ribosomal protein S6 kinase is a member of the AGC superfamily of 
structurally related Ser/Thr protein kinases, which also include protein 
kinase C  (PKC), protein kinase B (PKB/Akt), phosphoinositide-
dependent kinase 1 (PDK1), cyclic-nucleotide-dependent kinases (PKA 
and PKG), and SGK1 (serum- and glucocorticoid-induced kinase 1). 
These kinases have a similar mode of activation and preferentially 
phosphorylate Ser/Thr residues surrounded by basic amino acids, such 
as lysine and arginine. The main feature of the AGC kinase family 
members, except PDK1, is the presence of a C-terminal extension (CT) 
to the catalytic domain that contains a conserved hydrophobic motif 
(HM) with a phosphorylation site, which in many AGC kinases mediates 
a docking interaction with PDK1.  It has been demonstrated that mTOR 
phosphorylates the HM site in AGC kinases, which creates a specific 
binding motif for PDK1. The phosphorylation of the activation loop site 
by PDK1 culminates the activation process of AGC kinases (Peterson and 
Schreiber 1999). 
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1.3  S6K1 and S6K2 isoforms and their subcellular 
localisation 
A family of 70kDa ribosomal S6 kinase include four members (referred 
to as p70 S6K1 and p85 S6K1, p54 S6K2 and p56 S6K2) which are 
encoded by two separate genes (S6K1/S6Kα and S6K2/S6K). 
 Over the last two decades, the majority of published research on 
ribosomal S6 kinases has been done on p70S6K1. This isoform was 
cloned from a rat liver cDNA library more than twenty years ago.  The 
p70 S6K1 is ubiquitously expressed and localises predominantly in the 
cytoplasm.   The p85 S6K1 is a product of an alternative start codon, 
which produces a protein with a 23 amino acids extension at the N-
terminus.  The presence of a nuclear localisation signal (NLS) in the N-
terminal extension targets this isoform to the nucleus (Kozma et al. 
1990).    
 A decade later, a closely related homologue of S6K1 was cloned by 
several groups and named as S6K2 (Gout et al. 1998;Koh et al. 
1999;Shima et al. 1998). The S6K2 gene was also found to generate two 
isoforms by the use of alternative start codon: the short form (p54S6K2) 
and the long form (p56S6K2).  They differ by the presence of additional 
13 amino acids at the N-terminus of p56S6K2, which contain the nuclear 
localisation signal (Gout et al. 1998).  Both S6K2 isoforms contain a 
second nuclear localisation signal at the C-terminus, which targets them 
preferentially to the nucleus (Koh et al 1999).     
The localisation of the S6K1 and S6K2 to different compartments in the 
cell suggests that they may have distinct cellular targets and functions.  
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1.4  Structure and domain organisation 
Both S6K2 and S6K1 share domain homology with many 
serine/threonine kinases. The structure of S6Ks can be divided into 
several functionally significant regulatory regions and domains: an 
acidic N-terminus which contains TOS (TOR signalling) motif; catalytic 
kinase domain that has T-loop; kinase extension domain possessing the 
TM (turn motif) and HM (hydrofobic motif) sites; the C-terminus, 
containing a basic autoinhibitory pseudosubstrate region (Figure 1.1). 
The acidic N-terminus is thought to interact with the basic C-terminal 
autoinhibitory domain and thus this interaction keeps the kinase in a 
closed inactive conformation. 
The catalytic domains of S6K1 and S6K2 exhibit 83% amino acid identity, 
with less homology in their N- and C-terminal regions.  The 
pseudosubstrate C-terminal domains and kinase extensions are also 
analogous and possess a number of conserved serine/threonine 
phosphorylation sites, important for the activation of these kinases   
(Gout et al. 1998;Saitoh et al. 1998;Weng et al. 1998). 
 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 28 
 
 
Figure 1.1 Schematic domain organization of S6K1 and S6K2 isoforms. S6K can be divided into several 
functionally significant regulatory domains: an acidic N-terminus; catalytic kinase domain; kinase 
extension domain; C-terminus, containing a basic autoinhibitory pseudosubstrate region. 
S6K2 and S6K1 differ in their extreme N- and C-terminal domains. At the 
C-terminus, S6K1 has a PDZ binding motif, which is not present in S6K2. 
This domain recruits S6K1 to the cytoskeleton via the interaction with 
neurabin (Burnett et al. 1998). In contrast, S6K2 possesses a unique 
proline-rich sequence in C-terminus regulatory region which may 
mediate the interaction with SH3- or WW domain-containing proteins. 
Moreover, the S6K2 C-terminus contains an amino acid sequence with 
the high homology to a DNA binding motif, known as the AT hook. This 
motif is present in a diverse range of cellular proteins and was found to 
bind to the minor groove of DNA rich in A and T nucleotides, known as 
‘AT-rich’ regions.   
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Recently, a novel S6K1 splice variant named S6K1-isoform 2, or 
p31S6K1, was identified (Ben-Hur et al. 2013;Karni et al. 2007). This 
splicing isoform is a product of a splicing-induced frame shift, which 
lacks half of the kinase domain, kinase extension and autoinhibitory 
regions. The shift in the reading frame results in a unique amino acids 
extension at the C-terminus (Figure 1.1). Interestingly, the p31S6K1 
isoform lacks the kinase activity, but possesses an oncogenic potential 
when tested in cell-based and animal models (Karni et al. 2008). 
Evidence also exists for yet another S6K1 splice isoform with the 
molecular weight of approximately 60kDa, which is expressed at 
detectable level in breast cancer cell lines (Kim et al. 2009). However, 
this might be the product of proteolytic degradation of the full length 
S6K1.  
Although S6K1 and S6K2 share a high degree of identity in their kinase 
domains, they have similar as well as distinct functions in the organism 
(Pende et al. 2000;Pende et al. 2004;Shima, Pende, Chen, Fumagalli, 
Thomas, & Kozma 1998;Um et al. 2004). Structural differences between 
S6K2 and S6K1 suggest that: 1) they can have distinct binding 
partners/substrates; 2) they might be regulated by different 
mechanisms; 3) they may form different molecular complexes; 4) they 
might be localized in distinct compartments within the cell. 
1.5 Regulation of S6K activity 
S6 kinases are activated in response to growth factors, hormones, 
cellular stresses and nutrients. Availability of nutrients and energy is 
critical in the induction of cellular biosynthetic processes which provide 
macromolecules for cell growth and proliferation. 
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 Full activation of S6 kinases requires signals from two major signal 
transduction pathways: the phosphatidylinositol 3-kinase (PI3K) and the 
mammalian target of rapamycin (mTOR). 
 Identification of a number of regulatory phosphorylation sites involved 
in the activation of S6Ks indicates that the process of activation requires 
complex stepwise signalling inputs controlled by different Ser/Thr 
protein kinases. 
The first step in the S6K activation in response to different stimuli 
involves priming phosphorylation of four sites located in the C-terminal 
autoinhibitory pseudosubstrate region (Ser411, Ser418, Ser421 and 
Ser424), which were found to be principal sites of mitogen-induced 
phosphorylation. This step relieves the inhibitory effect, thus inducing 
protein conformation changes leading to further phosphorylation 
events at Ser371 and Thr389 residues. The phosphorylation of these 
sites is blocked in response to rapamycin (specific inhibitor of mTOR) or 
wortmannin (inhibitor of PI3K) treatment. Finally, maximal S6K 
activiation is achieved when PDK-1 phosphorylates Thr229 site in the T-
loop of the catalytic domain (Dennis et al. 1996;Weng et al. 1995). 
Three of these sites are absolutely critical for the S6K activation: 
Thr389, Ser371 and Thr229, as mutations of these residues block the 
kinase activation (Figure 1.2) (Dennis, Pullen, Kozma, & Thomas 
1996;Ferrari et al. 1992;Weng et al. 995).  
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Figure 1.2 Activation mechanism for S6K. The acidic N-terminus interacts with the basic C-terminus 
autoinhibitory domain and keeps the kinase in a closed inactive conformation. The first step in S6 
kinases activation in response to mitogens involves the phosphorylation of four sites located in the 
C-terminal autoinhibitory pseudosubstrate region. Following these phosphorylation events, mTOR 
kinase phosphorylates full-length S6K at Thr389 residue located in hydrophobic motif, which in turn 
allows PDK1 to phosphorylate Thr229 in the kinase domain and fully activate S6 kinase. 
It is important to note that these sites, as well as domains where they 
are located, are conserved in most members of the AGC kinase family. A 
similar mode of activation has therefore been proposed for the 
phosphorylation of these sites and subsequent activation of other 
members of the AGC family.  
1.5.1  The role of PI3K pathway signalling in the activation of 
S6K 
The family of phosphoinositide 3‑kinases (PI3Ks) consists of four classes 
of lipid kinases, which are involved in diverse cellular processes, 
including cell growth and cell survival, angiogenesis and cardiovascular 
homeostasis, metabolic control and the  immune response. Notably, it 
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is one of the most commonly dysregulated signalling pathways in 
cancer. 
The interaction of different mitogens with their receptors on the cell 
surface, results in the activation of phosphatidylinositol 3-kinase (PI 3-
kinase) and the phosphorylation of phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2, PIP2) to generate the phosphatidylinositol 
3,4,5-trisphosphate (PtdIns(3,4,5)P3 or PIP3). PIP3 functions as a second 
messanger and activates various signalling pathways through specific 
interaction with PH domain-containing proteins, including PKB/Akt and 
PDK1 (Liu et al. 2009).   
PDK1 (3-Phosphoinositide Dependent Protein Kinase 1) functions 
downstream of PI3K and is the main regulator for the AGC family of 
kinases. One of the most studied targets of the PI3Ks is 
serine/threonine protein kinase AKT (also known as protein kinase B 
(PKB)). It is activated via generated PIP3, which brings two 
serine/threonine kinases, PDK1 and AKT into close proximity on the 
membrane, where AKT is phosphorylated on Thr308 residue by PDK1. 
Upon activation, AKT phosphorylates and regulates the function of a 
number of essential proteins, leading to inhibition of apoptosis, 
stimulation of glucose uptake and storage, promotion of cell division, 
and others cellular processes. The tumour suppressor PTEN 
(phosphatase and tensin homologue) is the most significant negative 
regulator of the PI3K signalling pathway (Figure 1.3) (Mora et al. 2004). 
S6K was one of the first AGC kinases identified as downstream effectors 
of PI3-kinase. Consistently, activation of S6K in response to growth 
factors is inhibited by specific pharmacological inhibitors of PI3-kinase, 
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wortmannin and LY294002 (Chung et al. 1994). In addition, 
overexpression of constitutively active catalytic subunit of PI3-kinase 
enhances the activity of S6K (Weng et al. 1998). 
S6K is one of the main substrates for PDK1, where activated PDK1 
phosphorylates Thr229 site in the activation T-loop of S6K kinase 
domain (Figure 1.3) (Pullen and Thomas 1997).  
 
 
 
Figure 1.3 Signalling pathways upstream of ribosomal protein S6 kinases. Full activation of S6K 
requires signals from two pathways which are mediated via the phosphatidylinositol 3-kinase (PI3K) 
and the mammalian target of rapamycin (mTOR). 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 34 
 
1.5.2 mTOR signalling to S6Ks 
mTOR is a serine/threonine protein kinase and belongs to the PIKK 
(PI3K-related kinase family). It responds to diverse cellular signals (e.g. 
growth factors, mitogens, hormones, nutrients, energy, and stress) and 
regulates cellular processes such as cell proliferation and growth, 
apoptosis, cell survival and metabolism (Gentilella et al. 2015;Guertin 
and Sabatini 2007;Laplante and Sabatini 2012;Zoncu et al. 2011). 
mTOR forms two different complexes inside mammalian cells: mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1, in 
addition to mTOR contains four regulatory proteins: proline-rich AKT 
substrate 40 kDa (PRAS40); mammalian lethal with Sec13 protein 8 
(mLST8); regulatory-associated protein of mTOR (Raptor); and DEP-
domain-containing mTOR-interacting protein (Deptor). mTORC2 
consists of mTOR; rapamycin-insensitive companion of mTOR (Rictor); 
mLST8; protein observed with Rictor-1 (Protor-1); mammalian stress-
activated protein kinase interacting protein (mSIN1) and Deptor (Ma 
and Blenis 2009). 
Growth factors and hormones activate mTOR via the canonical PI3K 
signalling pathway. Insulin binds to and activates its cell-surface 
receptors. In an activated state, insulin receptor phosphorylates insulin 
receptor substrate 1 (IRS-1), which leads to generation of PIP3 through 
the activation of PI3K. These events promote the recruitment to the 
membrane and activation of Akt. Akt activates mTORC1 by 
phosphorylating tuberous sclerosis 2 protein (TSC2; also known as 
tuberin) to remove its inhibitory effects on mTORC1. In addition, Akt 
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can also act on mTORC1 via direct phosphorylation of its negative 
regulator PRAS40 (Guertin & Sabatini 2007).  
mTOR senses the level of cellular energy and blocks protein translation 
when the AMP:ATP ratio is high. The role of an “energy sensor” for 
mTOR plays AMP-activated protein kinase (AMPK). This kinase is 
activated when the level of AMP increases. Activated AMPK inhibits 
mTOR activity via phosphorylation and activation of its negative 
regulator TSC2. 
Low nutrient conditions strongly inhibit mTOR signalling, and the 
addition of amino acids to starved cells dramatically stimulates the 
mTOR activity. Recent studies found that Rag proteins, a family of 
related small GTPases, are responsible for amino acid-mediated 
activation of mTORC1 (Figure 1.3) (Efeyan et al. 2012;Efeyan and 
Sabatini 2013;Ma & Blenis 2009). 
The most extensively studied downstream targets of mTORC1 are S6Ks 
and eukaryotic translation initiation factor 4E‑binding protein 1 (4E-
BP1), both of which are implicated in the regulation of protein 
biosynthesis. 
Following the phosphorylation of the C-terminal autoinhibitory domain 
of S6K, mTOR kinase phosphorylates the full-length S6K at Thr389 
residue located in the hydrophobic motif, which in turn allows PDK1 to 
phosphorylate Thr229 in the kinase domain and fully activate S6 kinase. 
It is well established that immunosuppressant drug rapamycin (specific 
inhibitor of mTOR) blocks S6K activation by all known stimuli, without 
any effect on PI3K or PDK1 activities (Figure 1.2) (Pullen & Thomas 
1997).  
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1.5.3 Role of the MAPK/ERK pathway in the regulation of S6Ks 
Mitogen-activated protein kinase (MAPK) pathways play an important 
role in the transduction of extracellular signals to cellular 
compartments. One of four mitogen-activated protein kinase (MAPK) 
signaling pathways, the MAPK/Ras/Raf/ERK1/2 (extracellular-signal-
regulated kinase) is at the centre of signalling networks that induce 
proliferation, differentiation, cell survival and apoptosis. Dysregulation 
of the ERK1/2 cascade has been associated with more than half of 
human cancers. 
Activated ERK1/2 can either translocate to the nucleus or stay in the 
cytoplasm. Nuclear localisation of ERK1/2 is essential for DNA 
replication and gene expression. ERK1/2 phosphorylates a number of 
substrates, including transcription factors and a family of 90 kDa 
ribosomal protein S6-related kinases (RSK) (Dhillon et al. 2007). 
MAPK/Ras/Raf/ERK signalling activates the PI3-kinase pathway, where 
Ras GTPase induces the membrane translocation and activation of the 
catalytic subunit of class 1A PI3K kinase. This event activates both PI3K 
and mTOR signalling pathways which leads to the activation of S6Ks. In 
addition, mTOR can be activated directly by RSK, which is a downstream 
effector of MAPK/Ras/Raf/ERK signalling. In an activated state, RSK 
phosphorylates TSC2 and inhibits its negative activity towards mTORC1 
(Lawrence et al. 2008).  
The MAPK/Ras/Raf/ERK cascade is one of the main pathways implicated 
in the phosphorylation of the autoinhibitory C-terminal domain of S6Ks, 
but this process is still not well-understood. It was shown that ERK1/2-
dependent kinases are involved in the regulation of S6K2, but not S6K1. 
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S6K2 responds to the ERK inhibition in a much more sensitive manner 
than S6K1 (Linjun Wang et al. 2001). That might be explained by the 
amino acids differences in the C-terminal end of both kinases. It was 
demonstrated that the deletion of the C-terminal autoinhibitory domain 
in S6K1 and S6K2 has distinct consequences on the mode of activation. 
In case of S6K2, the activity is increased and the kinase becomes 
hypersensitive to PI3K signalling, whereas S6K1 activity is slightly 
inhibited (Martin et al. 2001b).  
1.5.4  Other positive regulators of S6Ks 
Protein kinase C (PKC) is a family of Ser/Thr kinases, which are involved 
in diverse cellular functions and signalling pathways. The members of 
atypical or novel PKC family were found to interact with mTOR and 
PDK1, suggesting that they may be involved in the activation of S6Ks. It 
has been demonstrated that S6Ks interact with the kinase domain of 
PKC, and this interaction is implicated in the activation of S6Ks 
(Richardson et al. 2004). Interestingly, it was shown that S6K2 is more 
sensitive to the activation by PKC than S6K1. This fact provides 
additional information to the differences in the regulation of S6K1 and 
S6K2 (Martin et al. 2001a). It was also reported, that S6K2, but not 
S6K1, is specifically phosphorylated by PKC at Ser486 in the C-terminal 
regulatory region, which abrogates nucleocytoplasmic shuttling of this 
isoform (Valovka et al. 2003).  
Signalling via small GTPases Rac and Cdc42 has been also implicated in 
the regulation of S6Ks. Rac1 and Cdc42 are members of the Rho family 
of small GTPases, which are important for the regulation of actin 
cytoskeleton. These two proteins were shown to form regulatory 
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complexes with S6K1, leading to the increase in its kinase activity (Chou 
and Blenis 1996). At the same time S6K1 can stimulate the activity of 
Rac1 and Cdc42 and this activation is associated with cytoskeletal 
reorganisation (Ip et al. 2011).  
1.5.5  Negative regulation  
Several signalling events have been identified which are implicated in 
downregulating the S6K activity: a) the action of tumor suppressors 
PTEN and TSC1/2 and b) dephosphorylation of S6Ks. 
Protein phosphatases are responsible for removing the phosphate 
group from the protein and alter the protein function. Protein 
phosphatase type 2A (PP2A) is a serine/threonine phosphatase, 
conserved in all eukaryotes. PP2A regulates DNA replication, 
transcription, metabolism, cell division, translation, apoptosis and other 
essential cellular processes.  
The protein phosphatase PP2A has been identified as a major 
phosphatase involved in the inactivation of S6K. Rapamycin treatment, 
amino acid withdrawal and osmotic stress lead to rapid 
dephosphorylation and inactivation of S6Ks. Studies have shown that 
PP2A directly binds and dephosphorylates S6K (Parrott and Templeton 
1999;Peterson et al. 1999). mTOR directly regulates PP2A function and 
inhibits its activity in cells. This process is dependent upon nutrient 
availability and is sensitive to rapamycin (Peterson, Desai, Hardwick, & 
Schreiber 1999).  
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1.6 Cellular Functions of ribosomal protein S6 kinases 
Activation of S6Ks leads to phosphorylation of a number of downstream 
targets, such as ribosomal protein S6, eukaryotic elongation factor 2 
kinases (eEF2K), eukaryotic initiation factor 4B (eIF4B), insulin receptor 
substrate (IRS-1) and many others. They regulate different cellular 
processes, such as protein synthesis, glucose homeostasis, mRNA 
processing, cell growth and cell survival (Fenton and Gout 2011;Iadevaia 
et al. 2014) (Figure 1.4).  
 
 
 
 
Figure 1.4 Downstream substrates and cellular functions controlled by S6Ks. Activation of S6Ks leads 
to phosphorylation of a number of downstream targets, which regulate different cellular processes. 
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Most of the studies have been done for S6K1 and limited information is 
available about S6K2 specific functions. While both kinases have mostly 
common substrates, the structural and functional differences between 
these two enzymes indicate that they might exist in different regulatory 
complexes and have distinct targets.   
1.6.1 Regulation of translation and ribosomal biogenesis 
Hormones and growth factors stimulate protein synthesis, but in 
response to various extracellular stresses this process is inhibited. In 
mammalian cells the control of mRNA translation involves changes in 
the phosphorylation and function of multiple components of the 
translational machinery. These components include ribosomal proteins, 
initiation and elongation factors (eIFs and eEFs correspondingly) 
(Iadevaia, Liu, & Proud 2014;Ma & Blenis 2009).  
One of the most studied substrates for S6K is ribosomal protein S6 
(rpS6), which is implicated in the upregulation of protein biosynthesis 
needed for cell growth and proliferation. RpS6 is one of the major 
ribosomal proteins, which is a part of 40S ribosomal subunit. RpS6 
directly interacts with mRNA on 40S subunit, and its phosphorylation 
increases the binding affinity of 40S subunit to mRNA and thus 
enhances total protein biosynthesis (Jefferies et al. 1997). 
Phosphorylation of rpS6 in response to mitogens is an extremely 
conserved process, and several kinases are able to perform this 
function, such as S6Ks and p90RSK (Pende, Um, Mieulet, Sticker, Goss, 
Mestan, Mueller, Fumagalli, Kozma, & Thomas 2004). 
Phosphorylation sites of rpS6 are represented by serine residues 
located at the carboxyl-terminus of the protein and the process of 
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phosphorylation proceeds in the order, 
Ser236>Ser235Ser240>Ser244>Ser247. Interestingly, p90RSK appears 
to phosphorylate only Ser235 and Ser236, S6K1 and S6K2 are capable to 
phosphorylate all five C-terminal rpS6  residues (Ferrari, Bannwarth, 
Morley, Totty, & Thomas 1992). 
The phosphorylation of rpS6 is considered to control the translation of 
the 5´-TOP (tract of pyrimidine) mRNA in a positive manner, this mRNAs 
tend to encode components of the translation machinery. 
In addition to its role in rpS6 phosphorylation, S6K has been implicated 
in the regulation of other proteins involved in the control of protein 
translation, such as cap-binding complex component eIF4B (eukaryotic 
translation initiation factor 4B). This phosphorylation is important for 
the recruitment of eIF4B to the translational pre-initiation complex. 
Upon activation S6K phosphorylates eIF4B on Ser422 within the RNA-
binding region, and promotes the helicase activity of eIF4A (eukaryotic 
translation initiation factor 4A). RNA helicase activity of eIF4A is needed 
to unwind extensive secondary structures in the 5´ UTR (untranslated 
regions) of specific mRNAs, which encode proteins important for cell 
cycle progression and cell survival. 
A role for S6K1 in the regulation of the elongation step of translation is 
indicated by the demonstration that it phosphorylates eukaryotic 
elongation factor-2 kinase (eEF2K) at Thr56. This kinase negatively 
regulates translation elongation and S6K relieves this inhibition by 
direct phosphorylation.  In this study, S6K2 demonstrated lower 
phosphorylation activity toward eEF2K compared to S6K1.  This 
suggests that eEF2K phosphorylation may be a target for S6K1 in the 
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regulation of cell growth, a process in which S6K2 plays less important 
role (Wang et al. 2001).  
It was demonstrated that p90RSK can phosphorylate both eIF4B and 
eEF2K under the same conditions. As a result, the overlapping substrate 
specificities of S6K and p90RSK allow distinct signalling pathways to 
regulate process of translation.  
It was recently reported that S6K1 and S6K2 deficient mice had a defect 
in ribosomal biogenesis at a transcriptional level (Chauvin et al. 2014). 
By performing whole-genome microarray of total and polysomal mouse 
liver RNA researchers showed that transcription of more than seventy 
five percent of ribosomal biogenesis factors is controlled by both S6K1 
and S6K2. 
1.6.2 Control of cell cycle progression, cell size and 
proliferation  
mTOR plays a central role in the coordination of cell growth and 
division, ensuring that cells reach a certain mass before they proceed 
into the process of cell division. Well-known downstream effectors of 
mTOR, S6Ks have been linked to the regulation of cell size in a number 
of studies. 
Much of the information we know about the functions of S6Ks was 
obtained from genetic studies in mice and Drosophila.  Drosophila has 
only one S6K gene and its deletion leads to the death of most flies 
during early development. Survived flies live only for a few weeks and 
females are sterile.  S6K1−/− flies are smaller than wild type and the 
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decrease in cell size is mostly due to a decrease in individual cell size 
rather than cell number (Montagne et al. 1999).   
Studies in mice showed, that deletion of S6K1 is not fatal, but the mice 
are around 20% smaller at birth, and rpS6 phosphorylation is not 
dramatically affected. Expression of S6K2 was significantly increased in 
all tissues from S6K1-deficient mice. It proved that S6K1 and S6K2 
functions are redundant and that a deletion of the S6K1 gene results in 
a compensatory increase in the S6K2 level. Interestingly, mice deficient 
for S6K1 exhibit hypoinsulinaemia, resulting in glucose intolerance. This 
is due to smaller pancreatic beta cells, which consequently produce less 
insulin (Pende et al. 2000).       
S6K2−/− mice grow to normal size, but had significantly decreased levels 
of S6 phosphorylation. These results suggest that S6K2 and S6K1 might 
have specific functions through distinct substrates (Pende et al.2004). 
 Mice deficient for both genes showed a dramatic decline in viability 
due to perinatal lethality. Surviving mice exhibit growth reduction but 
have normal proliferation. Despite the severe suppression of S6 
phosphorylation in cells from S6K1−/−/S6K2−/− mice, the translation of 5’-
TOP mRNAs and cell cycle progression were not dysregulated. These 
data show a redundancy between the S6K and the MAPK pathways in 
regulating protein translation in response to mitogens (Pende et al.s 
2004). 
Data from the S6K1−/− and S6K2−/− deficient mice did not show any 
dramatic effect on cell cycle progression and cell proliferation. There 
are some data indicating that the overexpression of S6K1 in NIH-3T3 
cells induces the expression of cyclin E required for G1 progression 
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(Chou et al. 2003).  But taken together all available information, one can 
speculate that although S6K1 has the potential to enhance the entry 
into S-phase, it is not required for cell cycle progression and may 
function in this way only in certain cell types or under specific 
conditions.       
1.6.3 Cell survival 
A balance between cell death and survival is a main mechanism to 
prevent the development of tumours. The PI3K/Akt/mTOR pathway is 
one of the most studied cell survival and cell death signalling pathways 
in human cancers.  It is now well established that both S6Ks are 
implicated in the regulation of cell survival and apoptosis, involving 
different mechanisms.  
S6K1 has been linked to cell survival and cell death through the 
regulation of a number of pro- and anti-apoptotic proteins. S6K1 
phosphorylates pro-apoptotic protein BAD (Bcl-2-associated death 
promoter) at Ser136. This phosphorylation prevents BAD from 
interaction with anti-apoptotic factors Bcl-2 (B-cell lymphoma 2) and 
Bcl-xL (B-cell lymphoma-extra-large) to promote cell death (Harada et 
al. 2001). It was shown that reduction in AKT/mTOR/S6K1 signalling 
leads to the inhibition of Bcl-2. Silencing of S6K1 in human 
neuroblastoma SK-N-SH cells induced apoptosis accompanied by a 
decrease in the phosphorylation of BAD (Saito et al. 2012). Moreover, 
astrocytes deficient for S6K1 and S6K2 had a defect in BAD 
phosphorylation and in the expression of Bcl-2 and Bcl-xL proteins 
(Harada et al. 2001;Pastor et al. 2009). 
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Additionally, S6K1 may also regulate cell survival through 
phosphorylation of Mdm2 (murine double minute), a negative regulator 
of the p53 tumor suppressor. Upon genotoxic stress and DNA damage, 
the mTOR-S6K1 pathway is activated through p38α MAPK. The 
activated S6K1 forms a complex with Mdm2 and inhibits Mdm2-
mediated p53 degradation, promoting p53 induction.  At the same time 
deactivation of mTOR-S6K1 signalling leads to nuclear localization of 
Mdm2 and an alteration in p53-dependent cell death. These results 
reveal the S6K1–Mdm2 complex as a new link between 
nutrients/energy/ growth factors status and the response to DNA 
damage (Lai et al. 2010).  
In small cell lung cancer, S6K2 has been implicated in FGF-mediated 
chemoresistance and cell survival. Protein kinase C-ε (PKCε) interacts 
with S6K2 via the Raf/MAPK (mitogen-activated protein kinase) 
signaling pathway and mediates the pro-survival effects of S6K2 (Figure 
1.5A). Complex PKCε/S6K2/BRaf induces the expression of anti-
apoptotic proteins XIAP (X-linked inhibitor of apoptosis protein) and Bcl-
xL (Pardo et al. 2001).  
Recently, S6K2 rather than S6K1 was shown to be required for the 
survival of breast cancer cells. Silencing of S6K2 resulted in a significant 
increase in TRAIL (TNF-related apoptosis-inducing ligand) and TNF-α 
(Tumor necrosis factors) mediated apoptosis. In contrast to S6K1, 
downregulation of S6K2 inhibits AKT signalling and activate cell death 
via the regulation of Bid (pro-apoptotic Bcl-2 protein). This finding has a 
significant implication in the treatment of the breast cancer (Sridharan 
and Basu 2011).  
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Figure 1.5 S6Ks exist in different complexes. (A) Stimulation cells with FGF2 leads to formation of the 
complex between S6K2, BRaf and PKC and promote S6K2 activation and cell survival. (B) S6K1 can 
regulate pioneer round of translation by phosphorylating CBP80 and it is implicated in mRNA 
processing via interaction with nuclear protein SKAR. (C) S6K2 interacts with hnRNPs, upon 
stimulation mTORC1 binds to this complex and promotes the activity of S6K2 and cell proliferation. 
1.6.4 Cytoskeleton rearrangements 
Cytoskeleton is organized to maintain cell shape, polarity and structural 
integrity. It coordinates important cellular processes such as cell 
adhesion, motility, migration and cell invasion. Reorganisation of actin 
cytoskeleton by polymerization and depolymerisation leads to 
morphological changes in cells, which stimulate migration. 
Dysregulation of cell migration plays an important role in embryonic 
development, immune response and wound healing, inflammation and 
cancer metastasis. 
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A lot of signalling proteins are implicated in cell migration, from cell 
receptors to transcription factors. Dowsteram signalling from activated 
cell receptors, implicated in migration, is mediated by secondary 
messangers such as phospholipase C, PKC, Ca2+, Rho and Rac small 
GTPases, PI3K and MAPK. 
Rho GTPases family of proteins is a central point for migration 
signalling. This family includes 22 different members, and the best-
studied members are RhoA, Rac1 and Cdc42 proteins. They regulate cell 
motility, cell-cell adhesion and the interaction with the extracellular 
matrix as well as intracellular trafficking of proteins required for cells 
migration.  
Rho GTPases are thought to rearrange the cytoskeleton by regulating 
the polymerization of actin into filaments that form the base of the 
cytoskeleton. Rac and Cdc42 stimulate the activation of the proteins to 
generate cellular extensions at the front of cells, which are required for 
cell movement (Yang et al. 2006).  
Several studies have proposed a role for S6K1 in cytoskeleton 
reorganisation and, potentially, cell motility. S6K1 was shown to 
associate with and be activated by the small GTPases Rac1 and Cdc42 
(Chou & Blenis 1996).  At the same time S6K1 can stimulate the activity 
of both Rac1 and Cdc42 and their downstream target p21-activated 
kinase (PAK1), stimulating cell migration. In addition, overexpression of 
Cdc42 and Rac1 leads to an increase level of S6K1 in cells. 
Downregulation of S6K1 expression or its activity resulted in dramatic 
inhibition of actin cytoskeleton reorganization and decreased cell 
migration, with a related decrease in Cdc42, Rac1 and PAK1 activation 
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(Figure 1.6) (Ip, Cheung, Ngan, & Wong 2011;Yang, Wang, & Zheng 
2006). 
 
 
 
 
 
Figure 1.6 S6K1 regulates cell migration. S6K regulates cell migration through regulation of Rac1 and 
Cdc42 activity and through binding, cross-linking and stabilizing cofilin filaments. 
 
 
Ip, Cheung, Ngan, & Wong, 2011 
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Additionally, the expression of active p70S6K1 in chicken embryo 
fibroblasts (CEF) is sufficient to stimulate cell migration and actin 
filaments re-modelling (Qian et al. 2004). Moreover, in migrating Swiss 
3T3 fibroblasts, S6K1 is co-localised with actin-based structures of the 
leading edge, which is required for cell motility. And treatment of these 
cells with rapamycin resulted in the disruption of actin stress fibres 
formation (Berven and Crouch 2000). 
S6K1 is highly activated in ovarian cancer and was shown to play a 
significant role in the metastasis development and progression (Ip, 
Cheung, Ngan, & Wong 2011;Ip and Wong 2012). Ectopic expression of 
constitutively active S6K1 in ovarian cancer cells promoted directional 
cell migration and stimulated reorganization of the actin cytoskeleton 
(Ip, Cheung, Ngan, & Wong 2011). Interestingly, S6K1 was shown to 
stimulate the phenotypic changes of cells during the progression of 
ovarian cancer. Activation of S6K1 results in loosing by cells epithelial 
and gaining fibroblast-like properties, named epithelial to mesenchymal 
transition (EMT). EMT is thought to play an important role in 
invasiveness of the tumour, when cell lose their adhesion and increase 
migration and invasion abilities. S6K1 are able to downregulate E-
cadherin, important for cell adhesion, and to upregulate the expression 
of N-cadherin and vimetin, which are the markers for mesenchymal 
phenotype (Pon et al. 2008). Based on these studies, there is a strong 
link between S6K and cell migration, which is implicated in the 
progression of the cancer and metastasis. 
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1.7 Other targets for S6K and potential functions 
There are a number of other targets of S6Ks, which are implicated in 
mRNA splicing and translation. It was shown, that S6K1 can regulate 
pioneer round of translation by phosphorylating CBP80, component of 
the cap-binding complex (CBC). S6K1 stimulate the activity of CBC80 to 
bind to 5' Cap of pre-mRNAs, and subsequently regulates pre-mRNA 
splicing, translation, nonsense-mediated mRNA decay and mRNA 
export. This phosphorylation was shown to be sensitive to rapamycin 
treatment (Figure 1.5B) (Wilson et al. 2000).    
Recently a further link between S6K1 and the control of RNA processing 
was shown. Nuclear protein SKAR (homology to the Aly/REF family of 
RNA binding proteins) was identified in a yeast two-hybrid screening as 
a new target specific for S6K1, not S6K2.  S6K1 phosphorylates SKAR at 
Ser383/385 residues in vitro and these phosphorylations are mitogen-
dependent and sensitive to rapamycin in vivo. SKAR is thought to link 
transcription with pre-mRNA splicing and mRNA export. Decreasing 
SKAR levels by siRNA makes cells smaller. Taking into account the 
specific role of S6K1, but not S6K2 in cell growth, SKAR might be one of 
the effectors for S6K1 important for cell growth signalling (Figure 1.5B) 
(Ma et al. 2008;Richardson, Broenstrup, Fingar, Julich, Ballif, Gygi, & 
Blenis 2004). 
A regulatory link between S6K2 signalling, cell cycle progression and 
proliferation has been recently revealed. S6K2 was found to be in a 
complex with heterogeneous nuclear ribonucleoproteins (hnRNPs), 
nuclear RNA-binding proteins important for post-transcriptional 
modification of the newly synthesized pre-mRNA, its splicing and 
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transport from nucleus. One of the hnRNPs, hnRNP-F is found to be in 
complex with S6K2. Upon serum stimulation, mTORC1 binds to this 
complex and promotes the activity of S6K2, and subsequent cell 
proliferation. Increased cell proliferation by overexpression of hnRNP-F 
is rapamycin sensitive (Figure 1.5C) (Goh et al. 2010). 
A common downstream target for S6K1 and S6K2 kinases is IRS-1 
(insulin receptor substrate 1), which is phosphorylated by S6Ks at 
Ser302 residue. Phosphorylation of IRS-1 at Ser302 is sensitive to 
rapamycin and downregulation of S6Ks. Moreover, it prevents IRS-1 
binding to insulin receptor and plays a crucial role in mediating a 
negative feedback signalling to PI3K. Additionally, S6K1 and S6K2 
decrease protein level of IRS1, by unknown mechanism (Harrington et 
al. 2004). The downregulation of IRS-1 signalling by S6Ks, named 
negative feedback loop, explains why S6K1−/− deficient mice are 
protected against the development of insulin resistance. Analysis of the 
adipose tissue from these mice, kept on a high fat diet, reveals a 
dramatic reduction in IRS-1 phosphorylation (Um et al.2004). 
Rictor is one of the main components of mTORC2, which plays an 
important role in the regulation of AKT and PKC. S6K1 was reported to 
phosphorylate Rictor at Thr1135 residue in vivo and in vitro, and this 
process is rapamycin sensitive. Interestingly, this phosphorylation event 
does not affect the formation of mTORC2, its cellular localisation or 
kinase activity. Mutation of this site to alanine, results in mTORC2-
dependent increase in AKT phosphorylation, indicating that 
phosphorylation of Rictor by S6K1 inhibits mTORC2 and Akt signalling 
(Julien et al. 2010). 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 52 
 
S6Ks may be directly linked to the regulation of transcription and gene 
expression by targeting transcription factors. S6K1 in breast cancer cell 
lines has been shown to increase transcriptional activity of the Estrogen 
Receptor (ERα) by its direct phosphorylation at Ser167. Phosphorylation 
at this site is a prognostic marker for breast cancer progression and 
contributes to the development of drug resistance (Yamnik et al. 2009). 
 Moreover, S6K1 has been shown to phosphorylate the cAMP response 
element binding protein (CREB) isoform, CREM on a conserved residue 
required for its transcriptional activity (de Groot et al. 1994). Recently, 
S6K1 has been implicated in the activation of RNA polymerase I-
dependent DNA transcription via signalling to the transcription factor, 
UBF-1 (Hannan et al. 2003).   
1.8 Dysregulation of the S6K pathway in human 
pathologies 
1.8.1 Malignant transformation  
Uncontrolled cell division and cell growth are regarded as the 
consequence of dysregulated signalling pathways inside the cells. Many 
of the identified proto-oncogenes encode proteins involved in the 
regulation of growth, differentiation and developmental signals and are 
often mutated in cancers. Upstream and downstream signalling of 
mTOR, are frequently dysregulated in tumors. This has increased 
interest in studying the role of the mTOR/S6K signalling pathway in the 
development of malignant transformation (Hanahan and Weinberg 
2000).  
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Most of our knowledge about the S6K signalling pathway developed 
from the study of two tumour suppressor genes upstream of mTOR, 
TSC1 and TSC2 (hamartin and tuberin respectively). There is a wide 
range of common inactivating mutations in TSC1 and TSC2 tumour 
suppressor genes, including nonsense mutations, large genomic 
deletions, splice site mutations and missense mutations, which results 
in the development of tuberous sclerosis syndrome (TS). TSC2 
mutations are also implicated in the development of 
lymphangioleiomyomatosis (LAM), a proliferative disorder that mostly 
affects women and results in lung cyst formation. 
TSC2 forms an active signalling complex with TSC1, which functions as a 
critical regulator of growth signalling via mTORC1. TSC2, via its GTPase-
activating protein (GAP) domain at C-terminus, directly binds to and 
controls the activity of a small GTPase Rheb.  This interaction increases 
hydrolysis of GTP associated with Rheb, leading to the inhibition of 
mTORC1 activity. Loss of function of the TSC1-TSC2 complex leads to 
constitutively activated mTORC1 pathway, resulting in cell size 
enlargement, ribosome biogenesis and increased protein synthesis. 
Importantly, activation of S6Ks, downstream targets of mTORC1, results 
in the inhibition of phosphatidylinositol 3-kinase (PI3K) signalling and 
AKT activation, via promoting a negative-feedback mechanism affecting 
IRS proteins (Huang et al. 2008;Huang and Manning 2008;Pollizzi et al. 
2009a;Pollizzi et al. 2009b).  
 Patients with the dominant autosomal disorder, tuberous sclerosis 
complex (TSC) all have mutations in either TSC1 or TSC2, and it results in 
the progression of hamartomas (benign tumours) in different tissues, 
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predominantly in the brain, heart, kidneys, eyes and skin (McManus and 
Alessi 2002). This disease related to the high occurrence of autism 
spectrum disorders, epilepsy, and cognitive deficits. Cancer 
development related to this syndrome is very rare.  It has been shown 
that upregulation of S6K signalling is a main mark of the development of 
TSC disorder (Goncharova et al. 2002;Kenerson et al. 2002).   
The S6K1 gene is located in the chromosome 17q23 region, and genetic 
analysis revealed that this part of the genome is frequently amplified in 
breast cancer cell lines. This amplification was accompanied by 
consequent increases in the expression of S6K1 at mRNA and protein 
levels (Barlund et al. 1997;Barlund et al. 2000;Courjal and Theillet 
1997).  In addition, it was showed that the overexpression of S6K1 in 
primary breast tumours associates with lower survival rates in patients, 
compared to those without S6K amplification (Barlund, Monni, 
Kononen, Cornelison, Torhorst, Sauter, Kallioniemi, & Kallioniemi 2000). 
These results showed evidence that S6K1 itself can demonstrate 
oncogenic activity in addition to being activated as a result of upstream 
regulations.  
In addition to breast tumours, S6K1 was found to be constitutively 
activated to different degrees in a panel of human pancreatic and lung 
cancer cells, while treatment with rapamycin abrogates the 
transformed phenotype in these cell lines (Grewe et al. 1999). Recently, 
new S6K1 splice form named S6K1-isoform 2, or p31S6K1, was 
identified. This splice variant possesses transforming activity in 
fibroblasts, whereas full length S6K1 does not, and the expression of 
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S6K1-isoform 2 is essential for cellular transformation mediated via 
splicing factor SF2/ASF (Karni, Hippo, Lowe, & Krainer 2008). 
 
1.8.2  Metabolic disorders 
The role of S6Ks in metabolism was clearly shown in animal models, 
where the deletion of S6K1 in mice leads to a number of metabolic 
changes. In this model, an important role for S6K1 signalling in the 
control of glucose homeostasis has been demonstrated.  S6K1 deficient 
mice display a phenotype that closely parallels to the preclinical type 2 
diabetes (Kozma et al. 1990;Pende et al. 2004). 
 S6K1-/- mice have increased insulin sensitivity and do not develop 
insulin-resistance on a high-fat diet. These effects are mediated via the 
S6K negative feedback regulation of insulin receptor signalling. S6K1 
deficient mice are lean, have 5 times higher b-oxidation of fatty acids 
and oxygen consumption. Therefore, the mRNA levels of numerous 
genes implicated in energy combustion and oxidative phosphorylation 
are upregulated in white adipose tissue and muscles from these mice. 
Such mice have normal glucose level during fasting, but are intolerant 
to glucose because of noticeably decreased level of circulating insulin.  
Decreased level of insulin is caused by a small size and mass of 
pancreatic -cells, which produce less insulin (Um et al. 2004). 
The mTOR/S6K1 pathway has been implicated in an early adipocyte 
differentiation, as   S6K1-/- mice had lower number of adipocytes than 
the wild type (Carnevalli et al. 2010;Castaneda et al. 2012). The 
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dysfunctions of S6K1 deficient mice clearly demonstrate the critical role 
of this kinase in the metabolic disease development. 
 
1.8.3 Ageing, learning and memory 
It has been known for a long time that caloric restriction and 
inactivation of components within the insulin signalling pathway extend 
lifespan and decrease age-dependant diseases in different animal 
models. Inhibition of the mTOR signalling has a dramatic effect on life 
expectancy in worms, yeast, flies and mice. Notably, the same effect 
was observed when animals were treated with rapamycin or it’s 
analogous. 
It was demonstrated, that S6K1-/- deficient mice live significantly longer 
than the wild type, and this effect is contributed to increased energy 
metabolism and AMPK signalling. Additionally, S6K1-/- deficient mice 
show decrease aging-related pathologies, including bone, motor and 
immune pathologies (Pende et al. 2004;Shima et al. 1998;Um et al. 
2004). All these results show that the mTOR/S6K pathway plays an 
important role in aging and life expectancy.  
Recent studies also revealed an important role of mTOR/S6K signaling in 
the regulation of memory and learning. S6K1-/- mice showed behaviour 
dysfunctions associated with cognitive processing, whereas S6K2 
knockout mice displayed memory impairment (Antion et al. 
2008a;Antion et al. 2008b). Additionally, reduced S6K2 activity 
correlated with GRN gene mutation (PGRN S116X) in neurons in patient 
with frontotemporal dementia (FTD) (Almeida et al. 2012). 
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2 Materials and Methods 
2.1 General materials 
2.1.1 General laboratory reagents 
All general purpose chemicals were purchased from Sigma-Aldrich, 
ThermoFisher Scientific or Melford Laboratories Ltd unless otherwise 
stated. General cell culture reagents were purchased from PAA 
Laboratories. Fetal Bovine Serum (FBS) was purchased from Hyclone 
(Thermo Fisher Scientific). Prestain molecular weight markers, DNA 
markers and restriction enzymes were obtained from Thermo Fisher 
Scientific.  
2.1.2 Expression vector and primers 
pcDNA3.1 (+) vector, pcDNA4/TO inducible expression plasmid, 
pFastBac™1 baculovirus expression vector and plasmids for lentivirus 
generation pLEX-MCS, PLP1, PLP2, PLP-VSVG were purchased from 
Invitrogen. Designed oligonucleotide primers were ordered from MWG 
Company. 
2.1.3 Antibodies 
Anti-phospho S6 Ser240/244, anti-phospho Akt Ser473, anti-phospho 
4EBP1 Thr37/46 antibodies were purchased from Cell Signaling 
Technology; anti-Actin antibodies from Sigma-Aldrich; anti-phospho S6K 
Thr389, anti-Raptor, anti-Rictor, anti-mTOR antibodies from Millipore. 
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2.2 DNA and RNA manipulation 
2.2.1 Oligonucleotide design 
Oligonucleotide primers with specific tags were designed using known 
DNA sequence of the template and restriction enzyme sites were 
created to allow subcloning of fragments. Annealing temperatures (Tm) 
for each primer were calculated using the equation: Tm (ºC) =2(A+T) 
+4(G+C).  
2.2.2 DNA amplification by the polymerase chain reaction 
The polymerase chain reaction (PCR) was used to amplify required 
regions of DNA from the templates. PCR was performed in a 25 µl 
volume containing 2.5 µl 10 mM dNTPs, 2.5 µl 50% DMSO diluted in 
water, 200 pmoles of each primer and PfuUltraTM II Fusion HS DNA 
polymerase (Stratagene) in 10X PfuUltraTM II reaction buffer 
(supplemented with 2 mM MgSO4) diluted with ddH2O. Plasmids were 
used as a template DNA for the PCR reaction with concentration 5-
30ng. PCR amplification was performed using a Thermal Cycler (Peltier, 
MJ Research). Samples were denatured at 98ºC for 30 sec, annealed at 
a temperature appropriate for the length and sequence of the 
oligonucleotide primers (54ºC) for 30 sec, and extended at 72ºC for 80 
sec. 30 cycles were used to amplify DNA fragments. Final extension was 
applied at 72ºC for 3 min. Quantity and quality of DNA samples were 
checked by gel electrophoresis (section 2.2.5). 
2.2.3 DNA digestion with restriction endonucleases 
Restriction enzymes were obtained from standard commercial sources 
(Thermo Fisher Scientific) and digests were performed in the 
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appropriate digestion buffer, as recommended.  1µg DNA was digested 
with 1-3U of restriction enzyme in a volume of 20 µl. Reaction mixtures 
were incubated at 37ºC for 1-2 hours and DNA fragments were 
analyzed by gel electrophoresis (section 2.2.5). If the restriction 
fragments were used for purification and ligation 2-5 µg of DNA were 
used. 
2.2.4 Ethanol precipitation of DNA product 
After restriction, PCR product and vector were desalted and 
concentrated by ethanol precipitation. To precipitate the DNA, PCR 
product was diluted with an equal volume of ddH2O.  3M sodium 
acetate pH 4.5 was added in quantity 10% of total mixture volume. 2 
volume of 100% ethanol were added to the mixture, mixed gently and 
placed -20ºC for at least 15 min. DNA solution after was centrifuged at 
13000 rpm for 10 min. Supernatant was carefully removed not 
disturbing the DNA pellet. The DNA was washed with 0.5 ml of 70% 
ethanol, air-dried for 5-10 min and redissolved in an appropriate 
volume of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA).  
2.2.5 Electrophoresis of DNA  
The electrophoretic mobility of DNA molecules depends on their size.  
0.9% (w/v) agarose gels were mostly used. The required amount of 
agarose was added to TAE buffer (40 mM Tris-Acetate, 1 mM EDTA) and 
heated to allow the agarose to dissolve. The solution was cooled to 
approximately 60ºC and GelRedTM dye (Biotium) was added with 
recommended concentration.  Melted agarose solution was then 
poured into a tray and allowed to harden at room temperature. DNA 
samples were mixed with 6X loading buffer (Thermo Fisher Scientific), 
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loaded into the gel and fragments were separated by electrophoresis in 
TAE buffer at 90-100 V. Standard molecular weight markers (1 kb DNA 
ladder Gene Rule, Thermo Fisher Scientific) were used alongside the 
samples. DNA was visualized under a long-wave UV light. 
2.2.6 Purification of DNA fragments from agarose gel 
For purifying DNA from the agarose gel, the DNA fragment of interest 
was cut out from the gel with a scalpel and purified using the Wizard SV 
Gel and PCR Clean-Up system (Promega), according to the 
manufacturer’s recommendations. 
2.2.7 Dephosphorilation of the vector 
To minimize self-ligation of the linearized vector, dephosphorylation of 
the 5’ ends was performed using Alkaline Phosphatase (New England 
Biolabs), which catalyzes the removal of 5´ phosphate groups from DNA. 
Reaction was performed in total volume of 25 µl in supplemented 
buffer, and 2-5U of Alkaline Phosphatase were added following 
manufacturer’s recommendations. The mixture was kept at 37ºC for 1 
hour. After DNA mixture was loaded onto the agarose gel and DNA was 
purified using the Wizard SV Gel and PCR Clean-Up system (Promega) 
(section 2.2.6). 
2.2.8 Ligation of DNA fragments 
The Rapid DNA Ligation Kit (Thermo Fisher Scientific) was used to clone 
DNA fragments into plasmids; all procedure was performed following 
manufacturer’s recommendations. To perform ligation reactions and 
minimize self-ligation of plasmids a 1:3 molar ratio of vector:insert was 
used, recommended concentration for vector 10-100ng. The reaction 
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was carried out at room temperature in Rapid ligation buffer in the 
presence of 5U of T4 DNA ligase in total volume of 20 µl. After 
incubation for 5 min, 2 µl of reaction solution was used to transform 
competent XL-1 Blue E. coli cells. 
2.2.9 Purification of plasmid DNA 
Plasmid DNA was purified using GeneJetTM Plasmid Purification kit 
(Thermo Fisher Scientific), following the manufacturer’s manual. The 
plasmid purification protocol is based on a modified alkaline lysis 
procedure, followed by binding of plasmid DNA to anion-exchange resin 
under appropriate low salt and pH conditions.  
The bacterial pellet from an overnight shaker-culture of XL-1 Blue E. coli 
was resuspended in resuspension buffer (50 mM Tris-HCl, pH 8.0, 10 
mM EDTA, 100 µg/ml RNase A) and an equal ammount of Lysis buffer 
(200 mM NaOH, 1% SDS) was added to the cell suspension. Following 5 
min incubation at room temperature, the lysate was neutralized with 
0.5 volume of chilled neutralization buffer (3 M potassium acetate, pH 
5.5) and incubated for 5 min. Bacterial lysate was centrifuged at 13000 
rpm for 5 min. The supernatant was added to a spin-column containing 
anion-exchange resin and centrifuged at 13000 rpm for 1 min. The resin 
was washed two times with Wash buffer (50 mM MOPS, pH 7.0, 1 M 
NaCl, 15% isopropanol) and buffer was removed by centrifugation at 
13000 rpm for 1 min. DNA was eluted with an appropriate volume of 
Elution buffer (50 mM Tris-HCl, pH 8.5, 1.25 M NaCl, 15% isopropanol). 
Quantity and quality of DNA samples were checked by gel 
electrophoresis (section 2.2.5). 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 63 
 
The plasmids were analyzed by restriction analysis to confirm the 
presence and correct orientation of the insert (section 2.2.3). 
Restriction enzyme or combinations of enzymes were used. 
2.2.10 Isolation of the Recombinant Bacmid DNA 
2 ml of an overnight bacterial culture DH10Bac™ E. Coli were 
centrifugated at 3000 rpm for 5 min. All medium was thoroughly 
removed.  For isolation of bacmid DNA Thermo Fisher Scientific kit was 
used. 0.4 ml of Cell Resuspension Buffer was added (E1) (15mM Tris-HCl 
(pH 8.0), 10 mM EDTA, containing RNase A at 0.1 mg/ml), to resuspend 
the bacterial pellet. Cells were lysed by adding 0.4 ml of Cell Lysis 
Solution (E2) (200 mM NaOH, 1% SDS) and mixed gently by inverting the 
capped tube five times (do not vortex) following incubation at room 
temperature for 5 min. After 0.4 ml of Neutralization Buffer was slowly 
added (E3) (3 M potassium acetate, pH 5.5) and mixed gently. Samples 
were put on ice for 5-10 min. The debris was removed by centrifugation 
at top speed in a microcentrifuge at room temperature for 10 min. 
Supernatant was gently transferred to the tube with 0.8 ml of absolute 
100% isopropanol, mixed carefully and placed on ice for 10 min. After 
the sample was centrifuged at 13000 rpm for 15 min, supernatant was 
discarded; DNA pellet was washed with ice-cold 70% ethanol, air-dried 
for 5-10 min and redissolved in an appropriate volume of TE buffer.  
DNA was allowed to dissolve for at least 10 min on ice and stored at -
20ºC. 5 μl of this bacmid preparation can be used for transfection of 
insect cells. 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 64 
 
2.2.11 mRNA purification 
RNeasy Mini Kit from Quigene was used for mRNA purification. 5 x 106 
of HEK293 cells were collected and centrifuged for 5 min at 1000rpm in 
a centrifuge tube. Supernatant was carefully aspirated and pellet was 
resuspended in 600 μl of RLT Buffer. Cell lysate was homogenized by 
passing through a blunt 20-gauge needle (0.9 mm diameter) fitted to an 
RNase-free syringe at least 5 times. 600 μl of 70% ethanol was added to 
the homogenized lysate and mixed well by pipetting. Sample was 
transferred to an RNeasy spin column placed in a 2 ml collection tube. 
Sample was centrifuged for 15s at 10,000 rpm, the flow-through was 
discarded and 350 μl of RW1 buffer was added to the RNeasy spin 
column. Sample was centrifuged for 15s 10,000 rpm the flow-through 
was discarded. 80 μl of DNase I incubation mix (10 μl of DNase I stock 
solution diluted in 70 μl of RDD buffer) was applied directly into the 
RNeasy spin column membrane, and incubated for 15 min at room 
temperature. Next RNeasy spin column was washed by adding 350 μl of 
Buffer RW1 and centrifuged for 15 s at 10,000 rpm. Next 500 μl of RPE 
buffer was added to the column, column was centrifuge for 15 s at 
10,000 rpm. After spin column was put in a new 2 ml collection tube 
and centrifuged at full speed for 1 min. Next the spin column was 
placed in a new 1.5 ml collection tube, 30–50 μl of RNase-free water 
was added directly to the spin column membrane, RNA was eluted from 
the membrane centrifuged for 1 min at 10,000 rpm. Concentration of 
purified RNA was measured by nandrop. 
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2.2.12 RT-PCR analysis 
For the generation of first-strand cDNA from purified mRNA Thermo 
Scientific RevertAid Premium Reverse Transcriptase was used. Into a 
sterile nuclease-free tube 0.5 μg of purified mRNA, 100pm of 
Oligo(dT)18 primer, 0.5 mM final concentration of dNTP Mix were added 
on ice in the indicated order and the volume was adjusted to 14.5 μl 
with DEPC-treated Water. Next the following components were added 
to the mixture in the indicated order: 4 μl of 5X RT Buffer, 0.5 μl of 
Thermo Scientific RiboLock RNase Inhibitor and 1 μl of RevertAid 
Premium Reverse Transcriptase. The mixture was mixed gently and 
centrifuged briefly. Sample was incubated for 30 min at 50ºC, the 
reaction was terminated by heating at 85ºC for 5 minutes. The reverse 
transcription reaction product can be directly used in PCR or stored at -
20ºC for up to one week.1 μl of the reaction mix was used to perform 
RT-PCR. RT-PCR was performed in a 25 µl volume containing 2.5 µl 10 
mM dNTPs, 0.5 µl 50% DMSO diluted in water, 200 pmoles of each 
primer and 0.5 µl of  PfuUltraTM II Fusion HS DNA polymerase 
(Stratagene) in 10X PfuUltraTM II reaction buffer (supplemented with 2 
mM MgSO4) diluted with ddH2O. Reaction was performed using a 
Thermal Cycler (Peltier, MJ Research). First samples were denatured at 
98ºC for 3 min, than at 97ºC for 30 sec, annealed at a temperature 
appropriate for the length and sequence of the oligonucleotide primers 
(58ºC) for 30 sec, and extended at 72ºC for 45 sec. 33 cycles were used 
to amplify DNA fragments. Final extension was applied at 72ºC for 10 
min. Quantity and quality of DNA samples were checked by gel 
electrophoresis (section 2.2.5). 
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2.3 Bacterial methodology 
2.3.1 Bacterial strains and growth media  
Escherichia coli XL-1 Blue competent cells (New England Biolabs) 
Genotype: endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 
proAB+ lacIq Δ(lacZ)M15] hsdR17(rK
- mK
+). Tetracycline resistant (carried 
on the F plasmid).  
MAX Efficiency
® 
DH10Bac™ E. Coli (Invitrogen) Genotype: F- endA1 
recA1 galE15 galK16 nupG rpsL ΔlacX74 Φ80lacZΔM15 araD139 
Δ(ara,leu)7697 mcrA Δ(mrr-hsdRMS-mcrBC) λ-.Tetracycline and 
kanamycin resistance encoded  by the helper plasmid and bacmid. 
Resistance to gentamycin would be possible if the cells had been 
transformed with the pFastBac1 donor vector. 
Luria Bertani (LB) medium and Luria Agar were bought from Sigma, and 
prepared following recommendation then autoclaved at 121ºC for 15 
min. Ampicillin was prepared as 100 mg/ml stock solutions in ddH2O, 
stored at -20ºC and used at a final concentration 100 μg/ml. Kanamycin 
and chloramphenicol were prepared as 50mg/ml stocks in ddH2O or 
ethanol and used at concentrations of 50μg/ml respectively. 
Tetracycline were prepared as 10mg/ml stocks in ethanol and used at 
final concentrations of 10μg/ml. 
Super Optimal broth with Catabolite repression (SOC) medium contains 
0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM Glucose. Note: Glucose and MgCl2 were 
added after autoclaving. Final solution was sterilized by passing it 
through a 0.2 µm filter. 
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For Blue/white selection of DH10Bac™ transformants LB agar plates 
containing 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml 
tetracycline, 100 µg/ml Bluo-gal, and 40 µg/ml IPTG at their final 
concentration were used. 
2.3.2 Preparation of competent cells 
Chemically competent cells were prepared by the following procedure. 
Single colony of bacterial strain was inoculated in 5 ml of LB medium, 
then transferred in 250ml LB medium in a flask and incubated with 
shaking at 37ºC, until the OD600 reached 0.6. The culture was cooled on 
ice and the bacteria were then pelleted at 5000 rpm for 5 min and 
resuspended in 50 ml ice-cold TFB1 buffer (30mM potassium acetate, 
50mM MnCl2, 100 mM RbCl, 10mM CaCl2, 15% (v/v) glycerol, pH 5.8) by 
gentle shaking/pipetting. The bacteria were repelleted at 5000 rpm for 
5 min and gently resuspended in 5 ml of TFB2 buffer (10 mM NaMOPs, 
75 mM CaCl2, 10 mM RbCl, 15% (v/v) glycerol, pH 6.5). Finally, 0.1 ml 
aliquots were “snap‐frozen” in liquid nitrogen in pre-chilled screw-
cap microcentrifuge tubes and stored at -70ºC. 
2.3.3 Transformation of E.coli 
100 µl of competent cells were defrosted on ice and 2μl of DNA ligation 
mix (or 5-50 ng of plasmid DNA) were added. After 30 min incubation 
on ice, cells were induced to take up the DNA by heat-shock at 42ºC for 
45 sec, chilled on ice for 2 min and let to recover in 1 ml of LB medium 
for 1 hour at 37ºC in shaking incubator (225 rpm).  The cells were 
pelleted by centrifugation at 3,000 rpm for 5 min and pellet was 
resuspended in 100 µl of LB medium. Cell suspension was spread onto 
pre-warmed LB agar plate containing the appropriate selective 
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antibiotic and incubated overnight at 37ºC.  Next day, 5-10 transformed 
colonies from agar plate were picked and cultured overnight at 37ºC in 
shaking incubator (225 rpm) in LB medium containing appropriate 
selective antibiotics.  
2.3.4 Transformation of DH10Bac™ E. Coli 
100 µl of competent cells were defrosted on ice and 1ng of plasmid 
DNA was added. After 30 min incubation on ice, cells were induced to 
take up the DNA by heat-shock at 42ºC for 45 sec, chilled on ice for 2 
min and let to recover in 1 ml of SOC medium for 4 h at 37ºC in shaking 
incubator (225 rpm).  
The cells were pelleted by centrifugation at 3,000 rpm for 5 min and 
pellet was resuspended in 100 µl of SOC medium. Cell suspension was 
spread onto pre-warmed selective agar plate for Blue/white selection 
containing the appropriate selective antibiotic (section 2.3.1) and 
incubated at 37ºC for 24-72 hours. Blue/white selection was used to 
identify colonies containing the recombinant bacmid. Once white 
colonies were identified, they were grown in 3 ml of LB medium, 
containing 50 µg/ml kanamycin, 7 µg/ml gentamicin and 10 µg/ml 
tetracycline overnight. Isolation of recombinant bacmid was performed 
as described in section 2.2.10. 
2.4 Cell culture methodology 
2.4.1 Cryopreservation of cells 
Cells for freezing should be healthy and in logarithmic phase of growth. 
Cells on the 100 mm tissue culture plate were washed twice with 2 ml 
of Dulbecco’s phosphate buffered saline (PBS) and detached by adding 
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1 ml trypsin-EDTA as gently as possible to minimize damage to the cells.  
Cells were incubated at room temperature (or at 37ºC if required) until 
cells detached from the plastic. Cells were gently resuspended in trypsin 
and 10 ml of fresh medium was added to neutralize the trypsin.  Then, 
cells were centrifuged at 500 rpm for 5 min and medium was aspirated 
to the smallest volume without disturbing the cells. Cell pellet was 
resuspended gently in 3 ml of freezing medium (growth medium with 
20% FBS and 10% DMSO) aliquoted into 3 cryogenic storage vials.  Vials 
were placed on ice and the freezing procedure was started within 5 
min. Vials were put in an insulated box placed in a -70ºC freezer, then 
transferred into liquid nitrogen storage. Cells growing in suspension 
were diluted in freezing medium to a concentration of 1-5×107/ml. 
2.4.2 Insect Cells culture 
2.4.2.1 Maintenance of insects cells 
Spodoptera frugiperda Sf9 insect cells were diluted every 2-3 days to a 
density of 1×106 cells/ml and incubated at 28ºC. They should be healthy 
with greater than 95% viability and should be in the logarithmic phase 
of growth. Insect-XPRESSTM Medium (Lonza) supplemented with 5% FBS 
and antibiotics (Penicillin and Streptomycin at a final concentration 100 
U/ml and 100 μg/ml), were used for growing cells.  
2.4.2.2 Transfection of insects cells 
Sf9 insect cells were healthy, growing in the logarithmic phase with a 
density of 1-2×106 cells/ml before proceeding to transfection. Cells 
were seeded in a 6-well tissue culture plate at density 1×106 cells/ml 
per well in 2 ml of Insect-XPRESSTM Medium (with antibiotics and FBS). 
Plate was left at 28ºC for at least 1 h to allow cells to attach. In two 
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sterile tubes, two following solutions were prepared. Solution A: For 
each transfection, 5 μl of purified baculovirus DNA (section 2.2.10) 
diluted into 100 μl Insect-XPRESSTM Medium without FBS and 
antibiotics. Solution B: For each transfection, 7 μl ESCORTTM IV (Sigma) 
transfection Reagent diluted into 100 μl  Insect-XPRESSTM Medium 
without FBS and antibiotics. Solution B was added to the tube 
containing Solution A, mixed gently, and incubated at room 
temperature for 15-30 min. After 0.8 ml of Insect-XPRESSTM Medium 
without FBS and antibiotics were added to each tube containing 
lipid/DNA complexes and mixed gently. While lipid/DNA complexes 
were forming, Sf9 cells in a 6-well tissue culture plate were washed 
once with 2 ml per well of Insect-XPRESSTM Medium without FBS and 
antibiotics. Medium was aspirated, and 1ml of diluted lipid/DNA 
complexes was overlaid onto the washed cells. Plates were incubated 
for 5 h in a 28ºC incubator. After the transfection mixture was removed 
and replaced with 2ml per well of Insect-XPRESSTM Medium 
(supplemented with antibiotics and FBS) and incubate at 28ºC for 72 h. 
The medium containing virus was harvested at 72 h post-transfection, 
filtered through sterile 0.45 μm low-protein binding filter and stored at 
+4ºC or at -80ºC.  
2.4.2.3 Amplification of the Baculoviral stock 
10 ml of Sf9 insect cells in a flask with cell density 1-2×106/ml, growing 
exponentially in Insect-XPRESSTM Medium supplemented with 5% of 
Fetal Bovine Serum and antibiotics, were infected with 0.5 ml of the 
virus stock. Flask was incubated at 27ºC for 72 h. 
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Cells and growth medium containing virus were collected from flask and 
put into centrifuge tubes, centrifuged at 2000 rpm for 5 min at +4ºC. 
Supernatant containing virus was collected and filtered through sterile 
0.45μm low-protein binding filter. The virus stocks can be stored at 4ºC 
for up to 1 year, protected from light, or at -80ºC for longer. Cell pellet 
was used for analysis of protein expression, might be frozen at -20ºC. 
2.4.2.4 Infection of insects cells 
500ml of Sf9 cells in the logarithmic growth phase with a density of 1–
2×106 cells/ml were infected with 1ml of the virus stock. After infection 
cells were monitored every day in the microscope to see the efficiency 
of infection. After 48-72h cells were collected by centrifugation at 2000 
rpm for 5 min and analyzed immediately or frozen at  -80ºC. 
2.4.3 Mammalian cell culture 
2.4.3.1 Tissue culture medium 
 HEK 293T, NIH3T3RasC40, A549, TSC2-/- p53-/- MEF cells were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM).  All 
complete media were supplemented with heat-inactivated sterile 10% 
FBS, supplemented with L-glutamine and penicillin/ streptomycin at a 
final concentration 100 U/ml and 100 μg/ml.  All cells were grown in 
humidified 37ºC incubators at 10 % CO2.  
2.4.3.2 Maintenance of cell lines 
Cells were passaged every two to four days, or as required. Cell were 
examined under the microscope before each splitting, they should look 
healthy with no more than 90% confluency. The medium was aspirated, 
cells were washed once in PBS and trypsin-EDTA was added.  Cells were 
incubated at room temperature (or at 37ºC if required) until they 
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detached from the plastic. Cells were gently resuspended in trypsin and 
fresh medium was added to neutralize the trypsin.  Cell suspension was 
gently pipetted up and down repeatedly in order to break up any 
clumps of cells before dilution into new plates with fresh medium at 
desired ratio (usually 1:5). 
2.4.3.3 Transient transfection 
 HEK 293 (NIH-3T3 cells) cells were transfected using ExGen 500 reagent 
(MBI Thermo Fisher Scientific) following manual.  This protocol allows 
transfection of the cells in normal medium (in the presence of serum 
and antibiotics).  The day before transfection, cells were plated at 5 x 
105 cells per 60 mm dish to give 50-80% confluency at the time of 
transfection.  When different dish sizes were used the number of 
seeded cells was scaled up or down according to the manufacturers’ 
instructions.  DNA-ExGen complexes were prepared for transfection by 
diluting 5 g of plasmid DNA and 17l of ExGen 500 (per construct per 
60 mm dish) in 200 l of sterile filtered 150 mM NaCl and vortexed for 
10 seconds.  The mixture was incubated at room temperature for 10 
minutes to allow formation of the DNA-ExGen 500 complexes.  During 
this incubation, the medium from cells was removed and replaced with 
2 ml of fresh complete DMEM. The transfection mixture was added to 
the cells drop-wise and the medium was replaced the following day.  
Cells were typically harvested 48 hours after transfection. 
2.4.3.4 Generation of stable cell lines 
The pcDNA3.1(+) vector contain the neomycin resistance gene for 
selection of stable cell lines using neomycin (GeneticinR 418). Minimum 
concentration for GeneticinR    418, required to kill untransfected host 
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cells, was determined as 800 μg/ml. Cells were transiently transfected 
with pcDNA™3.1 constructs using standard protocol for ExGen 500. 
Untransfected cells were used as a negative control and the pcDNA3.1 
empty plasmid as a positive control for selection.  After 48 hours post 
transfection, cells were split into fresh medium, containing 800 μg/ml 
GeneticinR 418. Under this concentration of antibiotic, only cells with 
integrated plasmid will survive.  Cells were fed with selective medium 
every 3–4 days. Complete selection can take from 2 to 3 weeks, until 
GeneticinR-resistant cells give separate colonies. For monoclonal 
selection these colonies were picked up separately using special cloning 
disk and grown separately till they reach confluency. For polyclonal 
selection all cells from the plate were pooled together. After cells were 
harvested and checked for the expression of the protein. 
In case where  pcDNA™4TO constructs were used for generating stable 
cell lines, selective antibiotic Zeocin was used  with working 
concentration 100 µg/ml. Whole selection procedure is the same as 
described for pcDNA™3.1(+) vector. 
2.4.3.5 Starvation and stimulation of cells 
HEK 293 cells were plated the day before starvation, so at the time of 
starvation they were about 50% of confluency. Media from the plates 
were aspirated carefully and new media without FBS (supplemented 
with penicillin/ streptomycin) was added to the plate. After 30 hours of 
starvation, cell were stimulated by adding 10% FBS to the media for 1 
hour following by collection and lysis of the cells (2.7.1). 50 000 cells of 
MEF TSC2-/- p53-/- stable cell lines overexpressing S6K2-S1 (clone 8), 
S6K2wt (clone 3) and an empty vector were seeded into a 6cm plate. 
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Next day media was changed for the starvation media without FBS and 
left for 48h. Then, cells were stimulated with media containing 10% FBS 
for 2hr. Cells were harvested, lysed and analysed in Western blotting 
with corresponding antibodies. 
2.4.4 Characterisation of stable cell lines 
2.4.4.1 Analysis of cell growth and cell size 
Total and viable cell number, cell size, cell aggregation factor and 
percentage of viability were measured by using CASY Model TT cell 
counter (Innovatis), which uses electronic pulse area analysis for 
measurements. Corresponding stable cell lines cells were plated in 
medium containing appropriate selective antibiotic and growth under 
standard condition. Cell numbers were calculated every day over the 
next four days. First, the medium was collected, followed by a single 
wash with PBS. Cells were trypsinized by addition of trypsin for 2 min at 
370C, cells were resuspended and this suspension was mixed with 
previously collected growth medium. 10 µl or 100 µl of resuspended 
cells were added to 10 ml of CASYTON solution (Innovatis) and samples 
were analysed using CASY machine. 
2.4.4.2 Colony formation assay in soft agar 
 This assay was used to measure the ability of cells to grow in an 
anchorage-independent manner.  In a 6-well tissue culture plate, 1 ml 
base layer of 0.8% (w/v) agarose was prepared by adding 200 µl of 
autoclaved 4% (w/v) agarose solution to 800 µl of DMEM medium 
supplemented with 10% FCS. Plates were left in the hood for 30 min for 
agarose to solidify and to dry out from condensate. HEK 293 (or A549) 
of approximately 80% confluency were carefully washed in pre-warmed 
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PBS and incubated with trypsin/EDTA for 2 min at 37ºC. The cells were 
resuspended in pre-warmed cell culture medium and the number of 
cells determined by counting using a CASY machine (section 2.4.4.1). 1 
ml of DMEM media containing 2000 HEK 293 cells (or 10000 of A549 
cells) was mixed with 100µl of autoclaved 4% (w/v) agarose solution to 
get top layer of 0.4% agarose. The cell suspension was plated over the 
base layer 0.8% agarose and allowed to solidify. Plates were incubated 
at 37ºC for 2 weeks. Then, plates were stained with 0.005% crystal 
violet for 3h at 37ºC and photographed.  Colonies from soft agar plates 
were counted using ImageJ software. 
2.4.4.3 Drugs treatment 
3×105 A549 stable cell lines overexpressing EE-S6K2-S1, EE-S6K2wt and 
empty vector were seeded into 6cm plate. Next day 1μM of 
staurosporine (or 50 μM cisplatin) diluted in DMSO was added to the 
plates, DMSO alone was added to the control plates.  Cells treated with 
staurosporine were collected after 3, 5 hours of incubation (for cisplatin 
treatment cells were collected after 24, 48 hours) and analysed in 
Western blotting with corresponding antibodies. 
2.4.4.4 Wound healing assay 
NIH 3T3 RacC40 stable cell lines overexpressing S6K2-S1 splicing isoform 
and an empty vector were plated at 1×106 cells in 6cm tissue culture 
plate in complete DMEM media. Wound was made to the 90% 
confluent monolayer of cells with a yellow plastic pipette tip to create a 
cleared line. The medium was removed and replaced with DMEM media 
containing 1% FBS and antibiotic. The cells were incubated at 37ºC, and 
cell movement were photographed at different time points. 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 76 
 
2.5 Production of anti-S6K2-S1 polyclonal antibodies 
2.5.1 Generation of rabbit antisera  
The synthetic peptide used for immunization was synthesized and 
coupled to activated keyhole limpet hemocyanin (KHL). Polyclonal 
specific antibodies to S6K2-S1 isoform were raised by immunizing two 
rabbits with KHL-coupled synthetic peptide. Following a standard 
immunization protocol, sera were collected at various times and 
analysed using an ELISA with a control or S6K2-S1 peptide.  The above 
procedures were carried out by Eurogentec Ltd (Belgium). Generated 
antibodies were affinity-purified using S6K2-S1 peptide coupled to 
cyanogen bromide activated Sepharose beads (Sigma) through sulfo-
SMCC (Sigma) linker. 
2.5.2 Affinity purification of antibodies 
2.5.2.1 Preparation of Sepharose 
1 ml of 50% cyanogen bromide activated Sepharose beads, pre-washed 
once with 1 ml of 1 mM HCl  and 2 times with 1 ml of ddH2O, were 
mixed with 1 ml 100mM ethylenediamine (pH 10.0 adjusted with HCl)  
and incubated at +4ºC overnight, after beads were washed 3 times with 
1 ml of ddH2O.  
5 mg of sulfo-SMCC (Sigma) linker was dissolved in 1 ml of ddH2O and 
added to Sepharose beads and incubated at 4ºC for 1 hour. Then beads 
were washed 3 times with 1 ml of PBS (phosphate buffer pH 7.4).  3.5 
mg of the synthetic peptide were dissolved in 1 ml of PBS and added to 
the washed beads. Mixture was incubated at room temperature for 2 h 
or overnight at +4ºC. Then beads were washed 3 times with 1 ml of PBS. 
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Supernatant was removed and 1 ml of 10 mM cysteine dissolved in PBS 
was added to the beads and incubated for 2 h. Then beads were 
washed 3 times with 1 ml of PBS and stored at +4ºC in PBS with 0.002% 
of NaAz to prevent contamination. 
2.5.2.2 Affinity purification 
15 ml of generated anti-S6K2-S1 polyclonal antiserum was centrifuged 
at 5000 rpm at +4ºC for 10 min. Clarified serum was then mixed with 15 
ml of PBS and loaded into a column prepared with peptide coupled to 
Sepharose beads). The column was allowed to empty by gravity flow 
and then washed extensively with PBS and last time with PBS containing 
500 mM NaCl. Bound antibody was eluted with 0.1 M glycine, pH 3.0 
and collected as 1ml fractions into tubes containing 100 µl of 1 M Tris-
HCl, pH 8.0. Protein concentration was measured as described in 
section 2.7.3. Peak protein fractions were combined and dialysed twice 
against PBS and once against 50% glycerol/PBS and stored at -20ºC. 
Affinity purified antibodies were screened for antigen reactivity by 
immunoblot analysis. 
2.6 Lentivirus generation 
2.6.1 Generation of the virus 
The gene of interest was cloned into the cloning vector pLEX. HEK 293 
cell were seeded one day before co-transfection in 10cm plate. Next 
day 70% confluent HEK 293 cells were transiently co-transfected with 
5.4 μg pLEX/constructs, 3.5 μg pPLP1 and 1.3 μg pLP2 (packaging 
vectors), 1.8 μg pLP/VSVG (envelope coding vector) using standard 
protocol for ExGen 500 transfection. As a positive control Lentivirus 
expression vector (pLEX) containing Green Fluorescent Protein (GFP) 
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was used for fluorescent detection. The cells produce the viral 
structural proteins that self-assemble into pseudovirus particles, each 
containing a cloned gene of your interest. The cells replicate 
pseudoviruses containing expression constructs and release them into 
the growth medium. After 24h post-transfection medium was removed 
and cells were supplemented with fresh medium. After 48h of 
incubation, the medium with the recombinant lentiviruses was filtered 
through sterile 0.45 μm low-protein binding filter and kept at -80ºC. 
2.6.2 Lentiviral infection 
One day before infection, HEK 293 cells were seeded in a 6-well plate 5-
10×104  cells per well in 2 ml of complete medium. Prior infection old 
medium was removed and appropriate amount of lentivirus mixed with 
fresh medium up to 2 ml of total volume were added to cells. 2 μg/ml of 
polybrene was used to increase the efficiency of infection. After 
overnight incubation medium was replaced with fresh medium. Cells 
were grown and split when required. For selection of stable cell lines, 2 
μg/ml of puromycin was added to the medium every 3 days. After 
antibiotic selection cells were tested for recombinant protein 
expression. 
2.7 Protein purification and analysis 
2.7.1 Preparation of mammalian cells extracts 
 Plates were removed from the incubator and cells were washed with 
ice cold PBS twice. After  lysis buffer was added  (10 mM Tris HCl (pH 
7.5),  150 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 % Triton X-100, 1mM 
DTT, complete EDTA-free protease inhibitor cocktail (Roche)).  Cells 
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were scraped from the dishes and put into cooled mirocentrifuge 
eppendorfs.  Tubes were kept on ice for 30 minutes prior to 
centrifugation at 13,000 g +4ºC for 20 minutes. Supernatants were 
decanted into new tubes and the protein concentration in each sample 
was measured by Bradford assay (section 2.7.3).  
2.7.2 Preparation of insect cells extracts  
Pellets of Sf9 cells were lysed in lysis buffer (PBS, pH 7.4, 0.5% Triton X-
100, and 1mM PMSF).  Lysates were incubated on ice for 30 minutes 
and centrifuged at 13,000g +4ºC for 20 minutes to pellet the insoluble 
cell debris. Supernatant was collected into fresh tubes and the protein 
concentration was measured by Bradford assay (section 2.7.3). 
2.7.3 Estimating of protein concentration  
To estimate protein concentration in cell lysates the colorimetric 
method with Coomassie Protein Reagent (Pierce) was used. The 
method is based on the absorbance shift from 465 to 595 nm which 
occurs when Coomassie brilliant blue G-250 binds to proteins in an 
acidic solution. 0.5 ml of Coomassie Protein Reagent was diluted in 0.5 
ml of ddH2O and 1 μl of cell lysate was added to the mixture and mixed. 
After 5 min of incubation at room temperature the absorbance was 
measured at OD595 and compared with a blank. The protein 
concentration was then determined by comparison of absorbance 
values with a bovine serum albumin (BSA) standard curve. 
2.7.4 SDS-PAGE electrophoresis 
For the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) Mini-
PROTEAN TGX™ (BioRad) precast Tris-glycine 10% and 4-20% gradient 
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gels were used.  Gels were taken from the packaging; the well comb 
and insulating strip covering the electrode were removed. The gel was 
inserted into the Mini-PROTEAN Tetra cell™ (BioRad) according to the 
manufacturer’s instructions. The buffer chambers were filled with 
premade running buffer (BioRad) and samples were loaded into the 
wells. Gels were run at constant potential of 200 V until the dye front 
reached the end. Gels were used for immunoblotting (section 2.7.5) or 
for Coomassie Blue staining (section 2.7.6). 
2.7.5 Immunoblotting  
After electrophoresis tris-glycline gels were removed from precast 
frame and placed onto premade polyvinylidene difluoride (PVDF) 
membrane between two layers of filter paper soaked in transfer buffer 
(BioRad). Trans-Blot® Turbo™ blotting system (BioRad) were used for 
semi-dry transfer.  
After transfer PVDF membrane was blocked for 1 hour with 5% skim dry 
milk in TBST buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1 % 
Tween 20). For phospho-specific antibodies 1% BSA in TBST was used 
for blocking the membrane. After blocking, membranes were washed in 
TBST 3 times for 10 minutes. Primary antibodies were diluted as 
recommended in TBST containing 2% BSA and 0.02 % sodium azide (to 
allow storage of diluted antibodies at +4ºC). Membranes were 
incubated with primary antibodies overnight at +4ºC prior to washing 3 
times for 10 minutes each at room temperature.  Secondary antibodies 
(anti-rabbit and anti-mouse conjugated to horseradish peroxidase, 
Promega) were diluted 1:10,000 in TBST buffer with 5% skim dry milk.  
Membranes were incubated with secondary antibodies for 1 hour at 
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room temperature and washed 3 times for 10-15 minutes each before 
development by enhanced chemiluminescence (ECL).  For ECL, equal 
volumes of ECL solution 1 (50 mM Tris-HCl pH 8.5, luminol, coumaric 
acid) and solution 2 (50 mM Tris-HCl pH 8.5, 0.02 % H2O2) were mixed 
together and added to the membrane for 1 minute at room 
temperature.  Excess ECL solution was removed by blotting the 
membrane on a paper towel and the membrane was wrapped in Saran 
Wrap ready for exposure to X-ray film or scanning using a Fluor-S 
imager (Biorad). Where appropriate, bands were quantified using the 
Quantity One image processing software (Biorad).       
2.7.6 Coomassie Blue staining 
 Following electrophoresis, gels were stained for the presence of 
protein by soaking in premade Coomassie Blue stain (Generon) for 20-
30 min, followed by washing in ddH2O with agitation. The gel was then 
dried under vacuum at 80ºC for 1 hour. Coomassie brilliant blue binds 
to proteins stoichiometrically, so this staining method is preferable 
when relative amounts of protein are to be determined by 
densitometry. 
2.7.7 Immunoprecipitation 
Cell lysates were prepared as described in sections 2.7.1 and 2.7.2.  
Immunoprecipitations were performed on equal amounts of total 
protein (as determined by 2.7.3) and the final volume in each tube was 
made up with lysis buffer to an equal level. 1ug of antibodies and 30µl 
of 50% protein A or G-Sepharose suspension (prewashed in ice-cold  
lysis buffer 3 times) were added to each sample and incubated on a 
rotating wheel for at least 1 hours at +4ºC. The immune complexes 
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were then pelleted by low speed centrifugation at 3000 rpm for 2 
minutes and washed 3 times with ice-cold lysis buffer. After last wash 
lysis buffer was removed as much as possible and 30µl of 2SDS-PAGE 
sample buffer were added. The samples were boiled for 5 minutes 
before separation by SDS-PAGE (2.7.4). 
2.7.8 Affinity purification of S6K2-S1 protein from Sf9 cells 
Sf9 cells were infected with the S6K2-S1 baculovirus as described in 
section 2.4.2, lysates were collected and prepared as described in 
section 2.7.2.  
The anti-FLAG M2 affinity resin (Sigma) was used for purification S6K2-
S1. Resin was prewashed in lysate buffer and loaded into the clean 
chromatography column. Empty column was rinsed twice with PBS. 
Buffer was allowed to drain from the column and residual of the buffer 
was left in the column to aid in packing the ANTI-FLAG M2 affinity gel. 
Resin was thoroughly resuspended by gentle inversion and allowed gel 
bed to drain. Column was activated by washing the gel with three 
sequential column volumes of 0.1 M glycine HCl, pH 3.5. After, resin 
was washed with 5 column volumes of PBS for equilibration and a small 
amount of buffer was left on the top of the column. 
Cell lysate was centrifuged and supernatant was filtered through sterile 
0.45 μm low-protein binding filter to remove debris. Sample was loaded 
onto the column under gravity flow two times with the slow flow rate. 
Column was washed with 10–20 column volumes of PBS and the 
column was allowed to drain completely. Elution of the bound FLAG 
fusion protein was performed by competitive elution with five one-
column volumes of a solution containing 100 g/ml FLAG peptide in 
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PBS. For regeneration, immediately after use, column was washed with 
three column volumes of 0.1 M glycine HCI, pH 3.5 and re-equilibrated 
in PBS until the effluent was at neutral pH. Column was stored in PBS 
buffer containing 0.02% sodium azide. Collected elution protein was 
dialysed once against PBS and once against 50% glycerol/PBS at +40C 
and stored at -20ºC. 
2.8 Xenograft studies in nude mice 
Generated A549 stable cells expressing empty vector, S6K2wt and S6K2-
S1 were injected subcutaneously into flank of nude mice (1 × 106 
cells/site in 100 μl mixed with 100 μl of Matrigel (BD Bioscience)), using 
a 25-gauge needle. The mice were divided into three groups with 8 mice 
in each: (a) implanted A549 cells overexpressing an empty vector (group 
1), (b) implanted A549 overexpressing full-length S6K2 (group 2), and (c) 
implanted with A549 cells overexpressing splicing isoform (group 3). 
Tumor growth was followed for up to two month. Tumour size was 
measured 2 times weekly and volume was calculated as 
volume=(length×width×depth)/π. Mice were euthanized when the 
tumor diameter reached 1.1-1.2 cm. Subcutaneous tumors were 
devided into four parts and frozen immediately at −80 ºC. One part was 
used for Western blot analysis.  
2.8.1 Preparation of tumour samples 
Tumour samples were removed from the freezer and defrosted on ice. 
After  0.5 ml of lysis buffer was added to each tumour sample  (10 mM 
Tris HCl (pH 7.5),  150 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 % Triton X-
100, 1mM DTT, 1mM PMSF, complete EDTA-free protease inhibitor 
cocktail (Roche)). Samples were disrupted using TissueLyser II Qiagene 
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machine. After homoginasion samples were incubated on ice for 30 
minutes prior to centrifugation at 13,000 g +4ºC for 20 minutes to 
remove insoluble material. Supernatants were decanted into fresh 
tubes and the protein concentration in each sample was measured by 
Bradford assay (section 2.7.3). 
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3 Analysis of the existence of potential S6K2 
splicing isoforms 
3.1 Introduction 
Alternative splicing is an important mechanism implicated in the 
regulation of protein diversity and gene expression. In higher 
eukaryotes, splicing of precursor messenger RNA (pre-mRNA) into a 
mature mRNA transcript occurs by the removal of introns from the 
transcribed gene, and multiple mRNAs can be produced from a single 
pre-mRNA, resulting in functionally and structurally distinct proteins. 
This process is tightly regulated by the spliceosome – a macromolecular 
complex formed of pre-mRNA, small nuclear ribonucleic proteins 
(snRNPs), splicing factors and more than a hundred regulatory proteins 
(Graveley 2009). Seventy-five percent of all alternatively generated 
spliced transcripts are functional and the remaining twenty-five percent 
targeted by Nonsense Mediated Decay (NMD) mechanism (Matlin et al. 
2005). 
Deregulation in the balance between splicing isoforms or generation of 
the aberrant alternative splicing variants are implicated in the 
development of different pathological disorders. Studies investigating 
the role of alternative splicing events in the development of human 
diseases are just starting to come out (Yamaguchi et al. 2010).   
The expression of many tumour-suppressor and oncogene genes is 
tightly regulated by alternative splicing. Many genes implicated in cell 
proliferation, cell survival, apoptosis are alternatively spliced, and often 
spliced products have an opposite effects on these processes. This 
suggests that the functions of different proteins are controlled by a 
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crucial balance between their antagonistic alternatively spliced variants 
(Pedrotti et al. 2010;Valacca et al. 2010).  
For about seventy percent of the alternatively spliced genes, splicing 
variants are produced by full or partial exon exclusion in the coding 
mRNA sequence. For example, tumour suppressor cell-cell adhesion 
molecule (C-CAM1), implicated in the regulation of cell adhesion, has a 
short splicing variant. It does not include exon 7, which encodes its 
cytoplasmic domain important for insulin receptor signalling. Significant 
overexpression of this isoform was reported in 51 NSCL (non-small cell 
lung cancer) samples compared with normal samples (Wang et al. 
2000). 
Ninety-nine percent of all exons are flanked by the GT and AG intronic 
dinucleotides at the 5’ and 3’ splice ends correspondingly. Single point 
mutation of these sites usually leads to differential inclusion of the 
bordering exon. For instance, a GT to AT splice site mutation in 
SWI/SNF-related matrix-associated actin-dependent regulator (hSNF5) 
gene causes the constitutive loss of exon 7, a frame shift in coding 
sequence and a production of truncated protein, which is implicated in 
the development of infant brain tumours (Taylor et al. 2000). Similarly, 
an AG to AT mutation leads to the removal of exon 4 in the anaphase 
promoting complex (APC)  gene and this correlates with the 
development of liver cancer metastases (Kurahashi et al. 1995). 
 Generation of cryptic exon–containing transcripts by intron retention 
and alternative choice between two splice sites is another splicing 
mechanism (Venables 2006;Venables and Burn 2006). For example, 
oligomeric extracellular matrix glycoprotein Tenascin-C has a larger 
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splicing variant, generated by the inclusion of eight extra exons. 
Notably, only longer isoform can induce cell migration by the loss of 
focal adhesion and protect cancer cells from the immune-surveillance 
(Puente Navazo et al. 2001). 
In mammals, ribosomal S6 kinases (S6Ks) represent a family composed 
of two distinct genes, S6K1 (RPS6KB1) and S6K2 (RPS6KB2).  Generation 
of two isoforms for both S6K1 and S6K2 were reported (Gout et.al. 
1998;Jefferies et al. 1997;Reinhard et al. 1994). They are produced 
through alternative translation start sites in exon 1 and characterised by 
their localisation either in nucleus or cytoplasm. p85S6K1 and p56S6K2 
correspond to long nuclear forms and p70S6K1 and p54S6K2 to short 
cytoplasmic forms. In this thesis, full length S6K1 and S6K2 are referred 
as cytoplasmic forms, unless otherwise stated. 
The existence of additional S6K1 short splicing isoforms has been 
recently reported (Karni et al. 2007). In humans, they are produced by 
the inclusion of one of the alternative exons (a or c) located before exon 
7. Both splicing events introduce a frame shift and a premature stop 
codon. These two kinase inactive isoforms are identical to the full 
length S6K1 in their N terminus, but have different C-terminal ends. 
Notably, both splicing isoforms contain only half of their kinase domains 
and therefore lack the kinase activity. It was shown that the alternative 
splicing of RPS6KB1 (S6K1) gene and the expression of truncated 
isoforms are regulated by SF2/ASF splicing factor (Ben-Hur et al. 
2013;Karni et al. 2008). High expression level of short splicing variants 
was reported in breast cancer tumour samples and cell lines. 
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Additionally, the overexpression of S6K1 short isoforms induced 
transformation of human breast epithelial cells (Ben-Hur et l. 2013).   
To our knowledge, no splicing variants for S6K2 have been reported so 
far. Molecular cloning of full-length S6K2 in our laboratory revealed 
cDNA clones with the potential to encode new splicing isoforms. In this 
chapter, we report for the first time and provide evidence for the 
existence of S6K2 splice variants.   
3.2 Results 
3.2.1 Bioinformatic analysis reveals the existence of potential 
S6K2 splicing isoforms  
Full length S6K2 was cloned from a human HEK293 cDNA library in our 
laboratory (Gout et al. 1998).  Additionally, cDNA clones which might 
correspond to new splicing isoforms were identified and named clone 1, 
2 and 3. These splicing isoforms are further referred to as S6K2-S1, 
S6K2-S2 and S6K2-S3. Sequencing analysis of these clones showed that 
they were generated during alternative splicing of S6K2 pre-mRNA. 
Initially, our efforts were focused on confirming the existence of these 
splicing variants using bioinformatic approach. 
3.2.1.1 Alternative splicing of S6K2 gene has the potential to 
generate new splicing isoforms 
Human S6K2 gene is located on chromosome 11 q13.2, 
(chr11:67,195,935-67,202,878). S6K2 gene is relatively small and 
contains 6944 nucleotides with an ORF (Open Reading Frame) of 1449 
nucleotides.  Bioinformatic analysis of the human S6K2 gene and the 
coding mRNA sequence (Appendix A) shows that it is encoded by 15 
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exons listed in Table 3.1. Classic intronic GT and AG splice sites exist at 
each of the intron/exon boundaries, apart from intron flanked with the 
exon 9 at the 3’ splice end. This intron has a non-classic splice site GC. 
Taking into account that splice site point mutations is one of the most 
common mechanisms of alternative splicing, we can assume that there 
is a very high possibility of exon 9 splicing. 
Because of the significant homology between human and mouse S6K2, 
it was logical to check if mouse S6K2 gene has the same mutated splice 
site. Analysis of the mouse gene and the coding mRNA sequence 
revealed the presence of the same evolutionary conserved mutated GC 
splice site in the region of exon 9 (data not shown).  
Sequencing analysis of cDNA clones, isolated from the HEK293 cDNA 
library, confirms the existence of S6K2-S1 and S6K2-S2 as products of 
alternative splicing of exon 9. Schematic diagrams of the splicing 
mechanism for both isoforms are presented in Figure 3.1A.  
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EX
O
N
 
N
U
M
B
ER
 NUCLEOTIDE SEQUENCE 
1 ATGGCGGCCGTGTTTGATTTGGATTTGGAGACGGAGGAAGGCAGCGAGGGCGAGGGCGAGCC
AGAGCTCAGCCCCGCGGT 
2 AGGACGCATGTCCCCTTGCCGAGTTGAGGGCAGCTGGCCTAGAGT 
3 AGGCCTGTGGGACACTATGAAGAGGTGGAGCTGACTGAGACCAGCGTGAACGTTGGCCCAGA
GCGCATCGGGCCCCACTGCTTTGAGCTGCTGCGTGTGCTGGGCAAGGGGGGCTATGGCAAGG
T 
4 AGGTGTTCCAGGTGCGAAAGGTGCAAGGCACCAACTTGGGCAAAATATATGCCATGAAAGTC
CTAAGGAAGGT 
5 AGGCCAAAATTGTGCGCAATGCCAAGGACACAGCACACACACGGGCTGAGCGGAACATTCTA
GAGTCAGTGAAGCACCCCTTTATTGTGGAACTGGCCTATGCCTTCCAGACTGGTGGCAAACT
CTACCTCATCCTTGAGTGCCTCAGTGGT 
6 AGGTGGCGAGCTCTTCACGCATCTGGAGCGAGAGGGCATCTTCCTGGAAGATACGGCCTGGT 
7 AGCTTCTACCTGGCTGAGATCACGCTGGCCCTGGGCCATCTCCACTCCCAGGGCATCATCTA
CCGGGACCTCAAGCCCGAGAACATCATGCTCAGCAGCCGT 
8 AGGCCACATCAAACTGACCGACTTTGGACTCTGCAAGGAGTCTATCCATGAGGGCGCCGTCA
CTCACACCTTCTGCGGCACCATTGAGTACATGT 
9 AGGGCCCCTGAGATTCTGGTGCGCAGTGGCCACAACCGGGCTGTGGACTGGTGGAGCCTGGG
GGCCCTGATGTACGACATGCTCACTGGATCGGC 
10 AGCCGCCCTTCACCGCAGAGAACCGGAAGAAAACCATGGATAAGATCATCAGGGGCAAGCTG
GCACTGCCCCCCTACCTCACCCCAGATGCCCGGGACCTTGTCAAAAAGGT 
11 AGTTTCTGAAACGGAATCCCAGCCAGCGGATTGGGGGTGGCCCAGGGGATGCTGCTGATGTG
CAGGT 
12 AGAGACATCCCTTTTTCCGGCACATGAATTGGGACGACCTTCTGGCCTGGCGTGTGGACCCC
CCTTTCAGGCCCTGTCTGGT 
13 AGCAGTCAGAGGAGGACGTGAGCCAGTTTGATACCCGCTTCACACGGCAGACGCCGGTGGAC
AGTCCTGATGACACAGCCCTCAGCGAGAGTGCCAACCAGGCCTTCCTGGT 
14 AGGGCTTCACATACGTGGCGCCGTCTGTCCTGGACAGCATCAAGGAGGGCTTCTCCTTCCAG
CCCAAGCTGCGCTCACCCAGGCGCCTCAACAGTAGCCCCCGGGCCCCCGT 
15 AGCCCCCTCAAGTTCTCCCCTTTTGAGGGGTTTCGGCCCAGCCCCAGCCTGCCGGAGCCCAC
GGAGCTACCTCTACCTCCACTCCTGCCACCGCCGCCGCCCTCGACCACCGCCCCTCTCCCCA
TCCGTCCCCCCTCAGGGACCAAGAAGTCCAAGAGGGGCCGTGGGCGTCCAGGGCGCTAG 
Table 3.1 Intron/exon ends of human S6K2 gene. The human S6K2 gene has 15 exons that encodes 
full length S6K2 polypeptide.  NNNNN – exons, NN – classic intron ends, NN – non-classic intron 
ends, NNN – standard start/stop codon. 
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Figure 3.1 Schematic diagram of alternative splicing of human S6K2 gene and primary structure of 
potential splicing isoforms. Human S6K2 gene (S6K2wt) is alternatively spliced to generate three 
isoforms. (A) S6K2-S1 is generated through alternate splicing of full exon 9; S6K2-S2 incorporates 
only a part of exon 9. (B) S6K2-S3 splicing variant is produced by the intron inclusion in front of exon 
6. Constitutive exons are shown as green boxes, and exon extension is shown in red box. Introns are 
shown as horizontal lines, and splicing events are indicated by angled lines. 
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S6K2-S1 splicing isoform is generated by skipping of the full exon 9 (91 
nucleotides) which results in a coding sequence shown in Figure 3.2A. 
On the other hand, S6K2-S2 splicing variant includes a fragment of exon 
9 (69 nucleotides). The splicing machine recognises the classical GT 
splice site inside the coding sequence of exon 9 and removes 22 
nucleotides at the end of this exon. Generated nucleotide sequence is 
presented in Figure 3.3A. In both cases the splicing events introduce a 
frame shift in coding sequence and premature stop codons. 
Analysis of cDNA nucleotide sequence corresponding to S6K2-S3 shows 
that it is generated by aberrant splicing of intron 5, resulting in the 
inclusion of a cryptic exon in the transcript. The splicing machine 
recognises the classical acceptor AG splice site in the intron 5 sequence 
and includes it in the coding region. This cryptic exon contains a 
premature termination codon Figure 3.4A. Schematic representation of 
the S6K2-S3 splicing mechanism is shown in Figure 3.1B.  
In order to identify potential S6K2 splicing isoforms, the GenBank 
Human expressed sequence tag (EST) database was searched for the 
presence of the unique exon/exon junction sequences. A BLAST search 
for the S6K2-S1 splicing isoform demonstrated the presence of two 
homologous clones: BE879750.1 and BI907520.1 (Figure 3.2B). 
Moreover, comparison analysis of the S6K2-S2 splicing variant against 
the EST database yielded homology with 3 clones: AV705502.1, 
AV705144.1 and BX337503.2 (Figure 3.3B).  
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Figure 3.2 Analysis of S6K2-S1 nucleotide sequence. (A) Coding nucleotide sequence of S6K2-S1. 
Underlined sequence was used for screening human EST database. (B) ClustalW2 alignment of S6K2-
S1 nucleotide sequence with EST clones. The arrows indicate the position of the splicing fusion 
junction between exons 8 and 10.  
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Figure 3.3 Analysis of S6K2-S2 nucleotide sequence. (A) Coding nucleotide sequence of S6K2-S2. 
Underlined sequence was used for screening human EST database. (B) ClustalW2 alignment of S6K2-
S2 nucleotide sequence with EST clones. The arrows indicate the position of the splicing fusion 
junction between part of the exon 9 and exon 10. 
A 
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Figure 3.4 Analysis of S6K2-S3 nucleotide sequence. (A) Coding nucleotide sequence of S6K2-S3. 
Underlined sequence was used for screening human EST database. (B) ClustalW2 alignment of S6K2-
S3 nucleotide sequence with EST clones. The arrows indicate the position of the splicing fusion 
junction between exon 5 and intron sequence included in the coding region.  
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Unexpectedly, as seen from Figure 3.4B, more than fifteen EST-clones 
homologous to human S6K2-S3 were obtained. Furthermore, screening 
of the GenBank Mouse EST database showed the existence of 3 EST-
clones with the potential to encode mouse S6K2-S3 splicing isoform 
(data not shown). 
The list of all identified human EST-clones, corresponding to S6K2-S1, 
S6K2-S2 and S6K2-S1, is summarized in Table 3.2. These results 
demonstrate that S6K2 splicing variants may be expressed in a variety 
of normal tissues and organs, including testis, cerebellum, foetal brain, 
placenta, adrenal gland, leucocytes and epithelial cells. Notably, S6K2 
splice variants are also found in a range of human malignancies, such as 
epidermoid carcinoma, amelanotic melanoma, large cell lung 
carcinoma, cervical and rectum cancer. Furthermore, we believe that 
additional S6K2 splicing isoforms remained to be identified. 
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 Reference: Tissue type: Organ: 
S6
K
2
-S
1
 
http://www.ncbi.nlm.nih.gov/nucest/BE879750.1  
large cell carcinoma, 
undifferentiated 
lung 
http://www.ncbi.nlm.nih.gov/nucest/BI907520.1  leukocyte  
 
S6
K
2
-S
2
 http://www.ncbi.nlm.nih.gov/nucest/BX337503.2  placenta cot 25-
normalized   
http://www.ncbi.nlm.nih.gov/nucest/AV705502.1 
http://www.ncbi.nlm.nih.gov/nucest/AV705144.1 Adrenal gland  
http://www.ncbi.nlm.nih.gov/nuccore/BX538119  human rectum tumor 
 
S6
K
2
-S
3
 
http://www.ncbi.nlm.nih.gov/nucest/BE018075.1  
cervical carcinoma cell 
line 
cervix 
http://www.ncbi.nlm.nih.gov/nucest/BG748826.1  
normal pigmented retinal 
epithelium 
eye 
http://www.ncbi.nlm.nih.gov/nucest/DC394569.1  testis 
 
http://www.ncbi.nlm.nih.gov/nucest/DA091729.1  cerebellum 
 
http://www.ncbi.nlm.nih.gov/nucest/DC352664.1  fetal brain 
 
http://www.ncbi.nlm.nih.gov/nucest/DR001273.1  fetal brain 
fetal 
brain 
http://www.ncbi.nlm.nih.gov/nucest/DN601754.1  
human embryonic stem 
cells  
http://www.ncbi.nlm.nih.gov/nucest/BI915444.1  
 
brain 
http://www.ncbi.nlm.nih.gov/nucest/BM804913.1  
 
ovary 
(pool of 
3) 
http://www.ncbi.nlm.nih.gov/nucest/BI767165.1  
 
pooled 
lung and 
spleen 
http://www.ncbi.nlm.nih.gov/nucest/BY797633.2  eye 
 
http://www.ncbi.nlm.nih.gov/nucest/BI767174.1  
 
pooled 
lung and 
spleen 
http://www.ncbi.nlm.nih.gov/nucest/BQ924955.1  
epidermoid carcinoma, 
cell line 
lung 
http://www.ncbi.nlm.nih.gov/nucest/BX377754.2  
placenta cot 25 
normalized  
http://www.ncbi.nlm.nih.gov/nucest/BI836595.1  
 
pooled 
spleen 
and  
pancreas 
http://www.ncbi.nlm.nih.gov/nucest/CX753710.1  
pluripotent cell line 
derived from blastocyst 
inner cell mass 
blastocy
st 
http://www.ncbi.nlm.nih.gov/nucest/BM915476.1  
amelanotic melanoma, 
cell line 
skin 
Table 3.2 Analysis of human EST-clones corresponding to S6K2-S1, S6K2-S2 and S6K2-S3 splicing 
variants.  
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3.2.1.2  Analysis of amino acid sequences corresponding to new 
splicing variants 
 Full length S6K2 protein is 482 amino acids in length and its predicted 
molecular weight is approximately 55kDa. Generated S6K2-S1 and 
S6K2-S2 transcripts have the potential to encode proteins of 273 and 
296 amino acids in length correspondingly. Predicted molecular weight 
of S6K2-S1 is approximately 32 kDa, whereas S6K2-S2 is about 34 kDa. 
S6K2-S3 splice variant is much shorter, 153 amino acids in length, and 
has a predicted molecular weight of 16kDa (Figure 3.5). As presented in 
Figure 3.5, all three splicing variants are identical to full length S6K2 at 
their N-terminus. S6K2-S1 and S6K2-S2 proteins have identical and 
unique 38 amino acids extension at the C-terminus (highlighted in red in 
Figure 3.5), as in both cases splicing transcripts have the same frame 
shift in their coding sequences. Potentially, this specific sequence can 
function in determining subcellular localization, interaction with binding 
partners, formation of regulatory complex and downstream signalling 
for both splicing isoforms. Amino acid analysis of this unique 38 amino 
acids C-terminal sequence reveals that it is enriched in positively 
charged arginine and lysine residues.  To access whether this sequence 
is present in any other identified proteins we searched various protein 
databases. A BLAST screening for the presence of this unique sequence 
does not reveal any significant homology with known proteins. The 
presence of unique 38 amino acids extension in S6K2-S1 and S6K2-S2 
variants offers the opportunity for generation specific antibodies 
against these isoforms, as described in chapter 2.5. Interestingly, the 
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protein sequence of the S6K2-S3 splicing isoform is identical to the N-
terminal end of full length S6K2. 
Notably, all three splice isoforms lack at least half of the kinase domain, 
kinase extension and autoinhibotory regions.  S6K2-S1 and S6K2-S2 
have only one key activation site, pT228, which is phosphorylated by 
PDK1 (Figure 3.6).  S6K2 full length and all identified splicing isoforms 
possess at their N-terminus the TOR signalling (TOS) motif, important 
for targeting S6K2 to the mTORC1 signalling cascade. 
In this thesis most of the work is focused on studying the role and 
functions of S6K1-S1.  
3.2.2 RT-PCR analysis confirms the existence of S6K2-S1 in 
HEK293 cells 
To confirm the existence of endogenous S6K2-S1 splicing isoform we 
examined the presence of the corresponding mRNA transcript using RT-
PCR analysis. 
As described above, S6K2-S1 and S6K2-S2 splicing isoforms are 
generated by the alternative splicing of exon 9. To begin with, we 
specifically designed a set of primers (Appendix B), which amplified the 
cDNA corresponding to exons 8-12 of the human S6K2 gene, as shown 
in Figure 3.7A. In this experiment, we expected 3 different PCR products 
corresponding to full length S6K2, S6K2-S1 and S6K2-S2, with different 
molecular weights depending on the splicing of exon 9. To start with, 
high quality total mRNA from HEK293 cells was isolated and first strand 
cDNA was generated (data not shown). This preparation was used as a 
template for the RT-PCR amplification. 
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Figure 3.5 Protein sequences of S6K2 splicing isoforms. Unique sequences corresponsing to S6K2-S1 
and S6K2-S2 isoforms C-terminal amino acid sequences are highlighted in italic red.   
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Figure 3.6 Schematic representation of S6K2 isoforms. The full length S6K2 is 482 amino acids in 
length with the predicated molecular weight of 55kDa. The S6K2-S1 splicing isoform is 273 amino 
acids in length and has predicted molecular weight of approximately 32 kDa. The S6K2-S2 splicing 
isoform encodes a protein of 296 amino acids in length  and has predicted molecular weight of 
approximately 34 kDa. Both isoforms lack half of the kinase domain and the C-terminal regulatory 
region. The shift in the reading frame results in a unique C-terminal 38 amino acid sequence 
presented by red boxes. The S6K2-S3 splicing variant is 153 amino acids in length and is completely 
identical to the N-terminus of full length S6K2. 
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As shown in Figure 3.7B, RT-PCR analysis of mRNA transcripts derived 
from HEK293 cells revealed the presence of 2 amplified products. The 
top band of approximately 380bp corresponds to the full length S6K2 
splice variant (386bp), and the band below, with the lower molecular 
weight of approximately 290bp, corresponds to S6K2-S1 splicing 
isoform (295bp). Based on the intensity of the signals we can conclude 
that mRNA level of full length S6K2 in HEK293 cells is much higher when 
compared to that of S6K2-S1. This explains the fact, that due to the 
overload of the PCR product, in order to detect a weak signal for the 
splicing isoform, the band corresponding to the full-length S6K2 ran 
slightly lower than expected. 
Theoretically, we expected the appearance of the third band, 
corresponding to the S6K2-S2 isoform, but unfortunately we did not 
observe any additional signal in this area. This could be explained by the 
fact that the amplified products of full length S6K2 and S6K2-S2 differ 
by just 22 nucleotides and might overlap when separated by gel 
electrophoresis. 
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Figure 3.7 Analysis of S6K2-S1 expression in HEK293 cell lines by RT-PCR.  (A) Schematic presentation 
of expected RT-PCR amplified products corresponding to DNA fragments of full length S6K2 and 
splicing isoforms. (B) Agarose gel electrophoresis of RT-PCR products amplified from cDNA derived 
from HEK293 cells with a set of specific primers. Total mRNA was extracted from HEK293 cell lines, 
converted into cDNA and used as a template for RT-PCR amplification with a specific set of primers. 
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3.2.3 Molecular cloning and mammalian expression of the 
S6K2-S1 splicing isoform 
Molecular cloning of S6K2 from the HEK293 cDNA library in our 
laboratory resulted in the identification of a large panel of cDNA clones 
corresponding to the full length S6K2 and several cDNA clones with the 
potential to encode novel splicing isoforms. One of these clones, 
BlSK/S6K2 clone 1, was used for molecular cloning of S6K2-S1. 
Sequencing of the full length insert of the BlSK/S6K2 clone 1 was 
completed to verify its mRNA and deducted protein sequences. 
 In subsequent studies, BlSK/S6K2-S1 clone 1 was used as a template for 
molecular cloning into various expression vectors by PCR amplification 
with specific sets of primers.  To express S6K2-S1 in mammalian cells, 
the full length coding sequence was cloned into pcDNA3.1 and 
pcDNA4TO expression vectors. To do so, the forward primer was 
designed to introduce BamH1 restriction site and the tag sequence at 
the N-terminus.  The initiation start codon was placed in front of the tag 
and in frame with the S6K2-S1 protein coding sequence. The reverse 
primer had a stop codon and a restriction site for Not1. All primers used 
in this work are listed in Appendix B.  
As shown in Figure 3.8A, a band of approximately 1500bp was 
specifically amplified in the PCR set up. The size of the amplified DNA 
fragment corresponded with that expected from the PCR priming. The 
band was excised from the gel and amplified DNA was purified by 
Thermo Fisher Scientific DNA extraction kit.  After digestion with BamH1 
and Not1 restriction enzymes, amplified DNA was cloned into pre-
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digested pcDNA 3.1 (or pcDNA4TO) mammalian expression vectors. 
Subcloning of S6K2-S1 into pcDNA3.1 was successful, as indicated by 
the restriction analysis and agarose gel electrophoresis of one of the 
resulting constructs with BamH1 and Not1 enzymes (Figure 3.8B). 
Sequence analysis of generated pcDNA3.1/S6K2-S1 clones confirmed 
the presence of correct sequence. 
To check if generated pcDNA3.1/S6K2-S1 construct had the ability to 
express the protein of interest, it was transiently transfected into 
HEK293 cells along with an empty vector. After 48 hours post 
transfection, cells were analysed for the expression of S6K2-S1 splicing 
isoform in Western blotting using specific anti-S6K2-S1 antibodies 
(described in the next chapter). As seen in Figure 3.9A, S6K2-S1 
expression was confirmed by the presence of a strong immunospecific 
band in cells transfected with the pcDNA3.1/S6K2-S1 plasmid compared 
to the control. 
To proceed further with our work and to study the function of the S6K2-
S1 in cells, we decided to generate stable cell lines overexpressing the 
S6K2-S1 splicing isoform. To begin with, HEK293 stable cell lines 
overexpressing S6K2-S1 were generated using pcDNA3.1/S6K2-S1 
construct. However, the expression of the splicing isoform in these cell 
lines was so low, that in a Western blot using 40µg of total lysate only a 
very weak immunoreactive signal appeared (data not shown). 
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Figure 3.8 Molecular cloning of S6K2-S1 splicing isoform into pcDNA3.1 expression plasmid. (A) 1% 
Agarose gel electrophoresis of PCR amplified S6K2-S1. cDNA clone from human HEK293 cDNA library 
was used as a template. (B) Restriction analysis of pcDNA3.1/Strep-S6K2-S1 construct and an empty 
pcDNA3.1 vector. Purified plasmids were digested with BamH1 and Not1 restriction enzymes and 
then separated by 1% agarose gel electrophoresis.  
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Figure 3.9 Generation of stable cell lines overexpressing S6K2-S1. (A) Expression analysis of S6K2-S1 
splicing isoform by transient transfection. HEK293 cells were transiently transfected with Strep-
tagged S6K2-S1 and empty vector, using a standard protocol for the ExGene 500 transfection 
reagent. After 48 hours, cells were  lysed and analysed by Western blotting with anti-S6K2-S1 affinity 
purified antibodies. Anti-actin antibodies were used as a control of equivalent protein loading. (B) 
Generation of monoclonal stable cell lines overexpressing S6K2-S1. 48 hours after transient 
transfection, HEK293 cells were split into fresh medium with selective antibiotic. Cells were fed with 
selective medium every 3–4 days, until antibiotic-resistant cells produced separate colonies. These 
colonies were grown separately till they reached confluency. Next, selected clones were checked for 
the S6K2-S1 expression in Western blotting using anti-S6K2-S1 antibodies. 30mg of total cell lysate 
was used for loading. Anti-actin antibodies were used as a control of equivalent protein loading.  
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 108 
 
Furthermore, the expression of S6K2-S1 in these cells gradually 
disappeared. This might be explained by the weak Geneticin selection 
as it took up to 3 weeks to generate cell lines, and as a result cells 
become resistant to antibiotic. The other possible explanation is that 
the overexpression of S6K2-S1 affects cell survival/selection; therefore 
cells do not tolerate high expression level of the splicing isoform. 
Based on these observations, first we decided to use pcDNA4TO/S6K2-
S1 construct, as it had different antibiotic resistance. Second we 
performed monoclonal selection of stable cell lines, as it gave us the 
possibility to generate cell lines with different expression level of the 
splicing variant. Briefly, HEK293 cells were transfected with 
pcDNA4TO/S6K2-S1 and an empty vector. Two days after transfection, 
cells were transferred into the fresh medium with selective antibiotic 
(Zeocin at 100 µg/ml). Cells were cultured in a selective medium until 
antibiotic-resistant cells produced separate colonies. The expression of 
S6K2-S1 was tested in 12 isolated colonies (clones). We observed a 
diverse range of S6K2-S1 overexpression in tested clones. However, the 
expression efficiency of S6K2-S1 in generated stable clones was still very 
low. Expression analysis of selected clones allowed us to isolate only 
one clone with relatively high level of S6K2-S1 overexpressed, while 9 
and 2 clones exhibited low and medium expression respectively (data 
not shown).   Based on these results, we selected 3 clones with different 
expression levels of S6K2-S1 splicing isoform: clone 1, 7 and 9, to work 
with (Figure 3.9B). Detailed functional analysis of these stable cell lines 
is described in chapter 3 of the thesis. 
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3.2.4 Generation and characterisation of specific polyclonal 
antibodies directed towards S6K2-S1 
Specific antibodies against S6K2-S1 can be directed to a unique 38 
amino acid sequence at the C-terminus of splicing isoform. 
Bioinformatic analysis of this sequence for the best immunogenic region 
revealed that the best hit corresponding to the extreme C-terminal end 
of S6K2-S1. Based on this analysis, we synthesised a 16mer peptide, 
containing unique C-terminal sequence of S6K2-S1 and a cysteine 
residue at the N-terminus for coupling to activated KHL (see below).   
 
Anti-S6K2-S1 polyclonal antibodies were raised by immunizing two 
rabbits with the synthetic peptide, coupled to activated keyhole limpet 
hemocyanin (KHL). After completing the immunization protocol, serum 
from both rabbits was collected and tested by ELISA against the 
antigenic peptide. ELISA results showed a good immune response to 
injected peptide in both rabbits, so we used the final bleed serum from 
for affinity purification of S6K2-S1 specific antibodies.  
Initially, we tested the immunoreactivity of collected sera in Western 
blotting. To do so, HEK 293 cells were transiently transfected with 
empty pcDNA3.1 vector and pcDNA3.1/Strep-S6K2-S1 construct. 48 
hours after transfection, cells were lysed and analysed by Western 
blotting with anti-S6K2-S1 polyclonal serum. As shown in Figure 3.10A, 
diluted serum specifically recognized an immunoreactive band, 
corresponding to overexpressed Strep-tagged S6K2-S1, with a predicted 
molecular weight of 37 kDa. This band was not present in the control 
sample of cells transfected with pcDNA3.1 empty vector.  
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Then, we performed affinity purification of anti-S6K2-S1 polyclonal 
antibodies from the serum collected from both rabbits. Specific 
antibodies can be purified from the serum of immunized animals by 
binding to and elution from the immobilized antigen. For generation of 
affinity matrix, synthetic peptide was coupled to cyanogen bromide 
activated sepharose through a Sulfo-SMCC linker. Generated affinity 
matrix was then incubated with the immune serum.  Nonspecific 
binding to the affinity matrix was removed by washing the column with 
phospate saline buffer (PBS). Specifically associated IgG antibodies were 
then eluted from the column with 0.1M glycine and collected as 1 ml 
fractions. Fractions corresponding to the peak of eluted antibodies 
were combined and dialysed against 1xPBS. After further dialysis in 50% 
glycerol/PBS, purified antibodies were stored at -20ºC. SDS-PAGE and 
Coommassie blue staining of eluted fractions clearly shows the 
presence of both heavy and light chains of purified antibodies 
corresponding to molecular weight of 55 and 25 kDa (Figure 3.10B). 
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Figure 3.10 Affinity purification of polyclonal anti-S6K2-S1 antibodies. (A) Anti-S6K2-S1 serum 
specifically recognises overexpressed S6K2-S1.  HEK 293 cells were transfected with Strep-tagged 
S6K2-S1, lysed and analysed in Western blotting with anti-S6K2-S1 serum (1:1000). Anti-actin 
antibodies were used as a control of equivalent protein loading. (B) SDS-PAGE analysis of affinity 
purified anti-S6K2-S1 polyclonal antibodies. Polyclonal serum was loaded onto a column prepared 
with S6K2-S1 C-terminal peptide coupled to Sepharose beads, column was washed with PBS and 
antibodies were eluted. Antibody containing fractions were combined, dialysed and stored at -20ºC. 
HC-heavy chain of antibodies, LH-light chain of antibodies, BSA – bovine serum albumin standard.  
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The specificity of affinity purified antibodies was then tested in Western 
blotting.  As shown in Figure 3.11A, affinity purified antibodies 
specifically recognize in lysates of transfected HEK293 cells Strep-tagged 
S6K2-S1 protein with a molecular weight of approximately 37 kDa, 
compared to the control sample. Interestingly, antibodies generated in 
two rabbits show a different pattern of immunoreactivity in Western 
blotting. Antibodies produced in rabbit 1 show lower non-specific 
binding and detect two strong immunoreactive bands with molecular 
weight of approximately 35-36kDa in control and S6K2-S1 
overexpressing cells. Notably, these immunoreactive bands run just 
below the signal of overexpressed Strep-tagged S6K2-S1. We believe 
that faster migrating bands correspond to endogenous S6K2 splicing 
isoforms. On the other hand, antibodies generated in rabbit 2 recognise 
overexpressed S6K2-S1 protein, but show no additional 
immunoreactive signals which might correspond to endogenous S6K2-
S1 splicing variant. Taking these data into account, we decided to use in 
further studies antibodies raised in rabbit 1, as they have the potential 
to recognize both recombinant and endogenous S6K2-S1 splicing 
isoform. Unfortunately, generated affinity purified polyclonal antibodies 
were not effective in the immunoprecipitation assay, which significantly 
restricted their application (data not shown). 
Using affinity purified anti-S6K2-S1 antibodies we tested a panel of 6 
different cell lines for the presence of endogenous S6K2-S1 protein. As 
shown in Figure 3.11B, a weak immunoreactive band which runs below 
the signal corresponding to overexpressed EE tagged S6K2-S1 is 
detected in tested cell lines. This might indicate the presence of 
endogenous S6K2-S1 splicing variant. Notably, 5 cell lines have an 
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additional immunoreactive band just above the signal of overexpressed 
S6K2-S1 protein. This band might correspond to S6K2-S2 splicing 
variant, which is bigger than S6K2-S1 by 23 amino acids and possesses 
the same unique C-terminus. 
 In summary, bioinformatics of EST clones, sequence analyses of 
isolated S6K2 specific cDNA clones from HEK293 cDNA library, as well as 
the expression analysis of transiently expressed and endogenous 
proteins reveal the existence of novels S6K2 splicing isoforms. Taking 
into account that identified S6K2 splice isoforms can only encode the N-
terminal regions of the kinase domain, the lack of the kinase activity 
would be the unique features of these splice variants.  
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Figure 3.11 Characterisation of affinity purified polyclonal anti-S6K2-S1 antibodies. (A) Testing the 
specificity of purified antibodies.  HEK 293 cells were transiently transfected with pcDNA3.1 empty 
vector and Strep-tagged S6K2-S1.  48 hours post transfection, cells were lysed and analysed in 
Western blotting with affinity purified anti-S6K2-S1 polyclonal antibodies (1:500). (B) Protein 
expression analysis of S6K2-S1 in different cell lines. 60µg of total cell lysate from different cell lines 
(HEK293 - Human Embryonic Kidney 293 cells, HEPG2 - Hepatocellular carcinoma human, A549 - 
adenocarcinomic human alveolar basal epithelial cells, HELA - human epithelial cervical cancer, 
MCF7 - human breast adenocarcinoma cell line, MEF - mouse embryonic fibroblasts) were used for 
Western blotting. PVDF membrane was blotted with anti-S6K2-S1 antibodies. Anti-actin antibodies 
were used as a control of equivalent protein loading. 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 115 
 
3.3 Discussion 
The work presented in this chapter studies S6K2 gene and its potential 
mechanism of alternative splicing. To date, not much research has been 
done in this area and we are not aware of any published data on the 
existence of identified S6K2 splicing isoforms.  It has been recently 
reported that S6K2 gene variations correlate with the greater risk of 
developing gastric cancer and poor survival (Yoshida S et al., 2013). 
Additionally, it was shown that variations in intron 2 of S6K2 gene are 
linked with the higher risks of developing Alzheimer’s disease (Vazquez-
Higuera et al. 2011). However, the role of S6K2 gene polymorphism and 
alternative splicing events in the development of human pathologies 
remain to be investigated. 
Regulation of alternative splicing by a large number of splicing factors 
and other proteins is a multicomplex process.  SF2/ASF splicing factor 
has been shown to play an important role in regulating alternative 
splicing of RPS6KB1 (S6K1) gene and the expression of different 
isoforms (Karni et al.2008).  The authors reported the identification of a 
novel S6K1 splice variant, which was found later to possess the 
oncogenic potential (Ben-Hur et al. 2013). We recognize the importance 
of studying regulatory mechanism of S6K2 gene alternative splicing, but 
our efforts have been mainly focused on elucidating their function in 
the mTOR/S6K signalling pathway and cellular processes. 
In this chapter, the evidence is provided for the existence of novel S6K2 
splicing isoforms by using three different experimental approaches. 
 First, detailed bioinformatic analysis of the S6K2 gene revealed high 
possibilities for alternative splicing especially in exon 9. Sequence 
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analysis of S6K2-S1 and S6K2-S2 cDNA clones, originated from HEK293 
cells, confirmed alternative splicing of exon 9. Additionally, a number of 
EST-clones in GenBank Human database, corresponding to potential 
S6K2 splicing isoforms, have been identified. Interestingly, more than 
fifteen EST clones homologous to human S6K2-S3 splice variant were 
obtained. These findings prompted us to further investigate the role of 
identified S6K2 isoforms in health and disease and our work was mainly 
focused on studying the S6K2-S1 splicing variant. 
Secondly, we confirmed the existence of the S6K2-S1 splicing variant at 
the level of transcription, using RT-PCR analysis. In this study, we used 
cDNA derived from HEK293 cells, as this was the original source for 
molecular cloning of full length S6K2 and its splicing isoforms. RT-PCR 
analysis confirmed that both full length S6K2 and S6K2-S1 transcripts 
are present in the selected cell line. It is known that many splicing 
isoforms are expressed in a tissue specific manner, so it would be very 
interesting to analyse in the future the expression pattern of full length 
S6K2 and its splicing isoforms in different cell lines and tissues. 
Thirdly, the expression of S6K2-S1 at the protein level was confirmed by 
immunoblotting of cell lysates using isoform specific antibodies. To 
allow the detection of S6K2-S1 isoform at the protein level, we 
generated specific polyclonal antibodies directed against the extreme C-
terminal end of S6K2-S1. Generated antibodies detected overexpresed 
S6K2-S1 protein and showed high level of specificity. Screening of a 
panel of different cell lines in Western blotting revealed the presence of 
weak but specific immunoreactive bands which might correspond to 
endogenous S6K2-S1 and S6K2-S2 isoforms. 
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Amino acid analysis of a unique C-terminal sequence of S6K2-S1 showed 
that it is enriched with positively charged arginine and lysine amino 
acids. Post-translational modification of these amino acid residues 
(acetylation, methylation and ubiquitination) and their contribution in 
mediating specific protein-protein interactions might be implicated in 
the regulation of subcellular localization, formation of regulatory 
complexes, downstream signalling and cellular functions. The N-
terminus of all three splicing isoforms are identical to full length S6K2 
and possesses the TOS motif. This five-amino acid sequence (FDLDLE) is 
important for mTORC1/S6K2 signalling. Therefore, our efforts have 
been focused on investigating the potential role of S6K2-S1 in the 
regulation of mTORC1 signalling which is described in the next chapter 
of this thesis. 
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4 S6K2-S1 and S6K2wt form a regulatory 
complex with Raptor and mTOR  
4.1 Introduction 
mTOR forms two functionally different protein complexes inside 
mammalian cells, named mTORC1 and mTORC2. Both complexes 
contain a number of common molecules, but differ by the presence of 
substrate presenting components: Raptor in TORC1 and Rictor in 
TORC2.  
Raptor (regulatory associated protein of mTOR) was identified as a 
binding partner of mTOR and was shown to be an important regulator 
of mTORC1 functions (Hara et al. 2002). Key downstream targets for 
mTORC1 are S6 kinase and translational inhibitor 4EPB1, implicated in 
the regulation of ribosomal biogenesis and protein synthesis. It was 
shown that removal of Raptor from mTORC1 dramatically reduced the 
ability of mTOR to phosphorylate its substrates (S6K and 4EPB1), 
whereas overexpression of Raptor promoted in vitro kinase activity of 
mTOR (Hara et al.2002). Additionally, siRNA knock down of Raptor in 
mammalian cells resulted in decreased phosphorylation of S6K and a 
small cell size (Kim et al. 2002). 
It was suggested that Raptor functions as a scaffolding protein to 
present substrates for the phosphorylation by mTOR, as it was shown 
that both 4EBP1 and S6K physically associate with Raptor (Hara K., 
2002). This hypothesis was confirmed in studies when two mTOR 
substrates were found to contain a five-amino acid sequence called the 
TOR signaling motif (TOS motif), responsible for direct interaction with 
Raptor. Importantly, mutation in TOS motif diminishes S6K and 4EBP1 
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interaction with Raptor, and these mutants had a very low level of 
phosphorylation by mTOR (Nojima et al. 2003;Schalm et al. 2003a). 
Rictor (Rapamycin-insensitive companion of mTOR) was identified as a 
binding partner of mTOR in mTORC2, which regulates the 
phosphorylation of Protein Kinase C α (PKCα) and Protein Kinase B (PKB) 
(Sarbassov et al. 2004). 
Figure 4.1A shows a model of regulatory interaction between the TOS 
motif (FDLDLE) of S6K2wt and Raptor, which allows mTOR to 
phosphorylate and subsequently activate S6K2wt. The S6K2-S1 splicing 
isoform possesses at its N-terminus the TOS sequence, so it has the 
ability to bind Raptor and form the complex with mTOR (Figure 4.1B). In 
this complex, S6K2-S1 may function as a dominant negative regulator of 
mTORC1 signalling, as it does not have the mTOR site for 
phosphorylation (T388) in the kinase domain. 
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Figure 4.1 A model of regulatory interactions of S6K2wt and S6K2-S1 splicing isoform in TORC1 and 
downstream signalling. (A) S6K2wt possesses at the N-terminus the TOS motif (TOR Signalling 
sequence, FDLDLE). The TOS motif mediates specific interaction of S6K1/2 with Raptor, which allows 
mTOR to phosphorylate and activate S6K2wt. (B) S6K2-S1 splicing isoform has the ability to bind 
Raptor via its TOS sequence and to complex with mTOR. As S6K2-S1 does not possess the site for 
mTOR phosphorylation (T388) and the kinase domain, it may act as a dominant-negative regulator of 
mTORC1 signalling. 
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In this chapter, we present evidence for specific association between 
S6K2-S1 splicing isoform and Raptor using two approaches. First, we 
expressed S6K2-S1, Raptor and Rictor using baculovirus expression 
system. Coinfection of insect cells with corresponding viruses followed 
by immunoprecipitation and Western blot analysis demonstrated 
specific interaction of S6K2-S1 with Raptor, but not Rictor. Second, we 
generated recombinant Lentiviruses for the expression of S6K2wt and 
splicing isoform and made a HEK293 stable cell lines. 
Immunoprecipitation of stably expressed S6K2wt and splicing isoform 
S6K2-S1, showed the formation of the regulatory complex with 
endogenous Raptor and mTOR.  
4.2 Results 
4.2.1 Generation of baculovirus for Raptor and Rictor 
Baculovirus Expression System provides fast and efficient method for 
generation of recombinant baculoviruses. This method is based on a 
site-specific transposition of an expression cassette from pFastBac1 
vector into a baculovirus shuttle vector (bacmid) propagated in E. coli 
host strain DH10Bac. Transfection of generated recombinant bacmid 
into insect cells, allows the production of a recombinant baculovirus, 
which can be used to infect insect cells and to express protein of 
interest. Figure 4.2 hows overall strategy for baculovirus generation. 
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Figure 4.2 Generation of recombinant baculovirus and protein expression using Baculovirus 
Expression System. The gene of interest is cloned into a pFastBac donor vector; recombinant plasmid 
is transformed into MAX Efficiency
® 
DH10Bac™ E. Coli competent cells, which contain bacmid with a 
mini-attTn7 target site and the helper plasmid.  The mini-Tn7 element on pFastBac vector can 
transpose to the mini-attTn7 target site on the bacmid in the presence of transposition proteins 
provided by the helper plasmid. Colonies containing recombinant bacmids are identified by the 
disruption of lacZα gene and selected via blue/white screening. High molecular weight mini-prep 
DNA is prepared from selected E.coli clones containing the recombinant bacmid; this DNA is then 
used to transfect insect cells for production of the virus. 
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Full length coding sequences of Raptor and Rictor were PCR amplified, 
using specific sets of primers. The EE-tag sequence (MEFMPME) was 
introduced at the N-terminus to allow the immunodetection of 
expressed recombinant proteins using specific monoclonal anti-EE 
antibodies. As a template for PCR reaction we used constructs from 
Addgene database (8513:HA-Raptor, 11367:myc-Rictor, David Sabatini). 
Primers for amplification listed in the Appendix B. 
The product of PCR amplification (~4000 bp) corresponded to calculated 
molecular weight of EE-tagged Raptor and was cloned into pFastBac1 
expression vector using BamHI/EcoRI restriction sites (Figure 4.3A). 
After ligation six clones were selected and digested with BglI restriction 
enzyme to identify Raptor insertion. Restriction analysis of clone 2 and 
3 confirmed the presence of EE-Raptor, when compared to an empty 
pFastBac1 vector (Figure 4.3B). These constructs were used for bacmid 
preparation and baculovirus generation.  Restriction analysis of clone 6 
showed different digestion pattern from expected and was not used for 
further studies. 
As shown in Figure 4.4A, the size of PCR amplified EE-tagged Rictor was 
around 4700 bp, which corresponds to the calculated 4776 bp value. 
The product of PCR amplification was digested with XhoI/KpnI 
endonucleases and cloned into pFastBac1 expression vector.  
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Figure 4.3 Molecular cloning of EE-tagged Raptor into baculovirus expression vector pFastBac1. (A) 
Agarose gel electrophoresis of PCR amplified full length coding sequence of Raptor with the EE-tag 
epitope and empty pFastBac1 cloning vector, digested with BamHI and EcoRI restriction enzymes. (B)  
Restriction analysis of selected clones 2, 3 and 6 for pFastBac1/EE-Raptor and an empty pFastBac1 
vector. Purified plasmids were digested with BglI restriction enzyme for 1h and then separated by 1% 
Agarose gel electrophoresis 
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Figure 4.4B shows digestion analysis of created constructs (clones 3, 5 
and 6) using EcoRV restriction enzyme. The results of restriction clearly 
indicate on the presence of EE-Rictor insert in all selected clones, 
compared to an empty pFastBac1 vector. These clones were used for 
the production of recombinant baculoviruses. 
 MAX Efficiency
® 
DH10Bac™ E. Coli cells were transformed with selected 
pFastBac1/EE-Raptor (clone 2 and 3) and pFastBac1/EE-Rictor (clone 3, 
5, 6 and 7) constructs for bacmid preparation. Baculoviruses were 
generated as described in Materials and Methods. Sf9 insect cells were 
infected with corresponding baculoviruses and the expression of EE-
Raptor and EE-Rictor was analysed by immunoprecipitation using 
mouse monoclonal anti-EE-tag antibodies. 
Raptor is a protein with the molecular weight of 150kDa, and contains a 
conserved N-terminal domain (the RNC domain), three HEAT domains, 
and seven WD40 motifs located near the C-terminus. Rictor is a 192 kDa 
protein, and it contains conserved domains that are important for the 
substrate recruitment and for the formation of TORC2. As seen from 
Figure 4.5, all selected clones corresponding to EE-tagged Raptor and 
Rictor, show high level of protein expression with expected molecular 
weights, when compared to the control sample. Generated viruses 
were used for coimmunoprecipitation studies as described further. 
. 
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Figure 4.4 Molecular cloning of EE-tagged Rictor into baculovirus expression vector pFastBac1. (A) 
Agarose gel electrophoresis of PCR amplified full length coding sequence of Rictor with the EE-tag 
epitope and an empty pFastBac1 vector, digested with KpnI and XhoI restriction enzymes. (B)  
Restriction analysis of selected clones 3, 5 and 6 for pFastBac1/EE-Rictor and an empty pFastBac1 
vector. Purified plasmids were digested with EcoRV restriction enzymes and then separated by 1% 
Agarose gel electrophoresis.  
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Figure 4.5 Expression of EE-Raptor and EE-Rictor in insects Sf9 cells.  Exponentially growing Sf9 
insects cells (1-2×106  cells/ml) were infected with 0.2ml of corresponding baculoviruses (EE-Raptor 
and EE-Rictor). After 3 days of infection, cells were collected by centrifugation and lysed. 
Recombinant EE-Raptor and EE-Rictor were immunoprecipitated from the cell extract using protein 
G-Sepharose loaded with mouse monoclonal anti-EE-tag antibodies (equal amounts  of total cell 
extracts were incubated with beads). After incubation for 1h, beads were washed 3 times in lysis 
buffer and 20µl of protein loading dye was added. Samples were boiled for 5min, separated by SDS-
PAGE and stained with Coomassie blue. HC - heavy chain of antibodies, LH - light chain of antibodies, 
BSA – bovine serum albumin standard. 
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4.2.2 Molecular cloning and expression of S6K2-S1 in 
baculovirus expression system 
To clone S6K2-S1 into baculovirus expression system previously 
generated pcDNA4TO/Strep-S6K2-S1 construct for expression in 
mammalian cells was used. The Strep-tagged S6K2-S1 sequence was re-
cloned into pFastBac1 baculovirus expression vector using BamHI/NotI 
restriction sites and 3 clones were selected for analysis. Figure 4.6A 
shows restriction analysis of clone 2 using BamHI/NotI endonucleases. 
The results of restriction clearly indicate the presence of the expected 
insert, in comparison to an empty pFastBac1 vector. Selected clones 
were used for baculovirus generation and infection of Sf21 insect cells. 
As shown in Figure 4.6B, all selected clones drive a good expression of 
Strep-S6K2-S1 protein in transiently transfected Sf9 cells when tested 
by Western blotting of total cell lysates. The highest expression was 
detected for clone 2, so it was used for further infections. 
Unfortunately, immunoprecipitation (IP) and affinity purification of 
Strep-S6K2-S1 from Sf9 cell infected with amplified bacolovirus using 
Strep-Tactin was not successful.  
Therefore, we decided to generate recombinant baculoviruses with the 
N-terminal HIS tagged S6K2-S1. The product of PCR amplification, 
corresponding to HIS-S6K2-S1 (Figure 4.6C,) was cloned into pFastBac1 
expression vector using BamHI/NotI restriction sites. Positive clones 
were identified and used for baculovirus generation. Infection of Sf9 
cells with amplified stock of generated baculoviruses resulted in a high 
level of HIS-S6K2-S1 expression, as detected by Western blotting with 
anti-S6K1-S1 antibody (Figure 4.6D).  Unfortunately, in line with  
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Figure 4.6 Molecular cloning and baculovirus expression of N-terminally tagged Strep-S6K2-S1 and 
His-S6K2-S1. (A) 1% Agarose gel electrophoresis shows the digestion of pFastBac1/Strep-S6K2-S1 
(clone 2) and pFastBac1 vector with BamH1 and Not1 restriction enzymes, to illustrate the presence 
of S6K2-S1 insert comparing to an empty vector. (B) Expression of Strep-S6K2-S1 isoform in Sf21 
insect cell line.  SF21 cells were transfected with a bacmid, corresponding to Strep-S6K2-S1 (clone 1-
3), after 48 hours media was collected for the preparation and amplification of the virus stock, cells 
were lysed and analysed in Western blotting. Immunoprecipitation of Strep-S6K2-S1 expressed in 
SF21 cells. 5ml of cells were infected with the Strep-S6K2-S1 baculovirus, after 3 days post-infection 
cells were collected and lysed. Strep-S6K2-S1 was immunoprecipitated using Strep-beads, separated 
by SDS-PAGE and stained with Coomassie blue. (C) 1% Agarose gel electrophoresis of PCR amplified 
His-S6K2wt and His-S6K2-S1. (D) Expression of His-S6K2-S1 in Sf21 insect cell lines.  SF21 cells were 
transfected with His-S6K2-S1 (clone 1-2) bacmid, after 48 hours media was collected for preparation 
of the virus stock. Cells were lysed, His-S6K2-S1 were immunoprecipitated (IP) using Ni-NTA-beads, 
TCL (total cell lysate) and IP were separated using SDS-PAGE and analysed in Western blotting. NS - 
non-specific signal.  
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previous results, affinity purification of His-S6K2-S1 using Ni-NTA-resin 
was not successful. 
Taken together these results indicated that in baculovirus expression 
system both Strep and His tags at the N-terminus of S6K2-S1 are not 
accessible for affinity purification on Strep-Tactin or Ni-NTA-resin 
respectively.  
To overcome this problem, we decided to generate C-terminal FLAG-
tagged S6K2-S1. Specifically, designed primers listed in Appendix B were 
used for the PCR reaction. Figure 4.7A shows that molecular weight of 
PCR amplified C-terminal FLAG-tagged S6K2-S1 corresponds to 
calculated 855 bp. This amplified fragment was digested with 
BamHI/NotI restriction enzymes and cloned into pFastBac1 vector. Sf9 
cells were infected with generated baculoviruses for selected clones 
and the expression of S6K2-S1-FLAG was monitored by Western blotting 
and immunoprecipitation.  This analysis revealed high level of S6K2-S1-
FLAG expression in total cell lysates by Western blotting (Figure 4.7B) 
and in the immune complexes (Figure 4.7C). Recombinant S6K2-S1-
FLAG was expressed in Sf21 insect cells and affinity purified using anti-
FLAG M2 affinity resin (Sigma) as described in Materials and Methods 
section. As shown in Figure 4.7D, elution fractions from the affinity 
column contain a major band of approximately 35kDa, which correlated 
with the calculated molecular mass of S6K2-S1-FLAG. Combined 
fractions were combined and stored for further studies in the storage 
buffer with 50% glycerol. 
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Figure 4.7 Molecular cloning, expression and affinity purification of the C-terminally FLAG-tagged 
S6K2-S1 using baculoviral expression system. (A) Agarose gel electrophoresis of PCR amplified C- and 
N- terminal FLAG-tagged S6K2-S1, digested with BamHI and NotI restriction enzymes and gel 
purified. (B) Western blot analysis of S6K2-S1-FLAG expression in Sf21 cells.  SF21 cells were 
transfected with bacmid containing S6K2-S1 with the C-terminal FLAG tag (clone 1-3). After 48 hours, 
virus was collected for amplification, cells were lysed and analysed in Western blotting. NS - non-
specific signal. (C) Immunoprecipitation of S6K2-S1-FLAG from SF21 cells infected with corresponding 
recombinant baculovirus. 5ml of cells were infected with the S6K2-S1-FLAG baculovirus (clone 1-3). 3 
days post-infection cells were collected and lysed. FLAG tagged S6K2-S1 was immunoprecipitated 
using anti-FLAG M2 affinity resin (Sigma), the immune complexes separated by SDS-PAGE and the gel 
stained with Coommassie blue. (D) Affinity purification of S6K2-S1-FLAG. For large-scale protein 
purification, 300ml of Sf21 cells were infected with generated baculovirus. 72 hours later, cells were 
harvested and lysed. Cell lysate was filtered, centrifuged and loaded onto the prepared anti-FLAG 
M2 affinity column. Specifically associated protein was then eluted with FLAG-peptide solution. 5ul 
of eluted fractions were analysed by SDS-PAGE and Coommassie staining. BSA – bovine serum 
albumin standard. 
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4.2.3 S6K2-S1 specifically interacts with Raptor, but not Rictor 
in insect cells 
Taking into account that S6K2-S1 splicing isoform possesses the TOS 
motif at its N-terminus, we speculated that it can interact with Raptor 
and form the regulatory complex with mTOR. To test this hypothesis, I 
tested the ability of S6K2-S1 to associate with Raptor and Rictor, and to 
form mTORC1 and mTORC2. In this study, Rictor was used as a negative 
control, as it does not recognise the TOS motif and functions as a 
substrate-presenting protein of mTORC2, but not TORC1. In this study, 
we used a panel of baculoviruses, which drive the expression of S6K2-
S1-FLAG, EE-Raptor and EE-Rictor. To test the interaction between 
S6K2-S1 and Raptor or Rictor, Sf21 insect cells were infected with 
corresponding baculoviruses in various combinations. The expression of 
recombinant EE-Raptor, EE-Rictor and S6K2-S1-FLAG in total cell lysates 
was verified by Western blotting with anti-EE and anti-S6K2-S1 
antibodies (Figure 4.8 top panel).  EE-Raptor and EE-Rictor were 
immunoprecipitated with protein G-Sepharose carrying anti-EE 
antibodies from Sf9 cells co-infected with recombinant baculoviruses 
which drive the expression of S6K2-S1-FLAG, EE-Raptor and EE-Rictor.  
The immunoprecipitates (IP) were analysed in Western blotting using 
anti-EE and anti-S6K2-S1 antibodies. As shown in Figure 4.8(bottom 
panel), S6K2-S1-FLAG is specifically detected in immune complexes with 
EE-Raptor, but not with EE-Rictor, when compared to control samples. 
The membrane was blotted with anti-EE antibodies to test the 
efficiency of immunoprecipitation of EE-Raptor and EE-Rictor.  Although 
the expression of EE-Rictor was not high and significant degradation of 
the recombinant protein was clearly observed in the immune blot of 
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total cell lysates, the anti-EE immune complexes contained large 
amount of EE-Rictor. These results demonstrate that S6K2-S1 splicing 
isoform binds to Raptor specifically and has the potential to form a 
signalling complex with mTOR.  
 
 
Figure 4.8 S6K2-S1 specifically interacts with Raptor (mTORC1). SF21 insects cells were infected 
with corresponding baculoviruses (EE-Raptor, EE-Rictor and S6K2-S1-Flag), after 3 days of infection 
cells were collected and lysed in lysis buffer. Equal amounts  of total cell lysate were loaded onto 
beads, EE-Raptor and EE-Rictor  were immunoprecipitaed with protein G-Sepharose carrying anti-EE 
antibodies. Cell lysates (TCL) and anti-EE immunoprecipitates (IP) were analysed in Western blotting 
using anti-EE and anti-S6K2-S1 antibodies. These results were obtained in at least three individual 
experiments. 
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4.2.4 Lentivirus generation of HEK293 stable cell lines 
overexpressing full length S6K2 and splicing isoform 
S6K2-S1  
To further validate the above findings, we decided to generate HEK293 
stable cell lines overexpressing full length S6K2 and S6K2-S1 splicing 
isoform. 
For the generation of stable cell lines we used recombinant lentiviruses. 
In our laboratory, a 3rd generation HIV-1-based Lentivirus expression 
system has been established. It allows the production of a replication 
incompetent lentivirus and facilitates the delivery and expression of the 
gene of interest. It offers maximal biosafety, when compared to 
previous generations of lentiviral systems. It contains 4 different 
plasmids for transfection into HEK293T producer cells (2 packaging 
plasmids - pLP1, pLP2; an envelope plasmid pLP/VSVG; and a transfer 
plasmid pLEX). The main differences in the 3rd generation Lentiviral 
system are as follows: a) the Tat protein has been deleted from the 
packaging completely; b) the Rev protein is expressed on an 
independent plasmid; c) the 5’LTR of the transfer plasmid has been 
modified to include a conventional promoter and delete a portion of 
the LTR. Once the lentivirus stock is produced, it can be used to infect 
different types of dividing or non-dividing mammalian cells and 
provides stable, long-term expression of a target gene. Figure 4.9 
represents a schematic strategy for lentivirus generation. 
In brief, S6K2-S1 and S6K2wt were recloned from previously generated 
constructs into pLEX transfer plasmid, using BamHI/NotI and 
BamHI/EcoRI restriction sites respectively (Figure 4.10A). 
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Figure 4.9 Overall strategy for Lentivirus generation. Gene of your interest cloned into Lentivirus 
expression vector (pLEX) co-transfected into HEK293T cell lines together with three packaging 
plasmids (pLP1, pLP2 and pLP/VSVG) using transient  transfection standart protocol for TurboFect 
(ThermoFisher). As a positive control Lentivirus expression vector (pLEX) containing Green 
Fluorescent Protein (GFP) was used for fluorescent detection. The cells produce the viral structural 
proteins that self-assemble into pseudovirus particles, each containing a cloned gene of your 
interest. The cells replicate pseudoviruses containing expression constructs and release them into 
the growth medium. Virus harvested 48-72h posttransfection and filtered using sterile low protein 
binding 0.45µm PVDF filter. Virus can be aliquoted and stored at -80°C 
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Figure 4.10 Molecular cloning of S6K2-S1 splicing isoform and S6K2wt into Lentivirus expression 
vector pLEX. (A) Schematic representation of the pLEX cloning vector. Puro-Mammalian selectable 
marker for selection after viral transduction, Zeo-Bacterial selection marker, 5'LTR-5' long terminal 
repeat, CMV-RNA Polymerase II promoter, WPRE-Woodchuck hepatitis post-transcriptional 
regulatory element, IRES-Internal ribosome entry site, 3’sin-LTR 3' Self inactivating long terminal 
repeat, Zeo-Bacterial selection marker, SV40 ori and SV40 prom-origin of replication  Simian 
vacuolating virus 40 promoter, f1ori-origin of replication from a f1 phage. (B) Agarose gel restriction 
analysis of pLEX/S6K2wt and pLEX/S6K2-S1 selected constructs and an empty pLEX vector. Purified 
plasmids were digested with BamHI and Not1 (EcoRI for S6K2wt construct) restriction enzymes for 
1h and then separated by 1% Agarose gel electrophoresis.  (C) Expression analysis of selected 
pLEX/S6K2wt and pLEX/S6K2-S1 constructs in HEK293 cells. HEK293 cells were transiently 
transfected with corresponding plasmids using standard protocol for Exgene transfection. After 48h 
of transfection cells were collected and analysed in Western blotting with corresponding antibodies.  
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Figure 4.10B shows restriction analysis of selected pLEX constructs for 
EE-S6K2wt, FLAG-S6K2-S1, EE-S6K2-S1 and Strep-S6K2-S1 using 
corresponding endonucleases. The results of restriction analysis clearly 
show the presence of inserts with predicted molecular weight in all 
selected clones, when compared to empty pLEX vector. The expression 
of recombinant proteins from generated pLEX constructs was then 
tested by transient transfection of HEK293 cells using Exgene 500. As 
shown in Figure 4.10C, all selected clones mediate good level of 
expression for EE-S6K2wt, FLAG-S6K2-S1, EE-S6K2-S1 and Strep-S6K2-S1 
when total lysates were tested by Western blotting with corresponding 
antibodies.  
Then, lentivuruses for all selected constructs were generated as 
described in Material and Methods chapter. HEK293 cells were infected 
with lentiviruses which drive the expression of EE-tagged S6K2wt and 
S6K2-S1, and GFP protein as a positive control of infection. As seen from 
Figure 4.11A (left panel) GFP expression in infected HEK293 cells was 
detected under the microscope 72h post-infection. The efficiency of 
infection was about 20%, which was lower from expected but still 
sufficient to initiate the production of stable cell lines. For the 
generation of stable clones, transfected cells were grown for 48 h in 
selection media containing puromycin.  Analysing cells infected with 
GFP-expressing Lentivirus under the microscope, we observed that only 
GFP–positive cells remained attached to the plate, while most of GFP-
negative cells were floating in the medium (Figure 4.11A, right panel). 
Cells infected with generated Lentiviruses for EE-tagged S6K2wt and 
S6K2-S1 after applying antibiotic selection displayed the same pattern 
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as GFP-expressing cells, most of the cells were detached from the plate 
and puromycin resistant cells grew well and formed small colonies. 
Western blot analysis of protein expression in generated HEK293 stable 
cell lines showed good level of expression for EE-S6K2wt and EE-S6K2-
S1 (Figure 4.11B). 
Finally, generated HEK293 stable cell lines were tested for the presence 
of mycoplasma contamination, using Mycoplasma PCR Detection Kit. 
Mycoplasma is the simplest and smallest of bacteria, which parasites in 
host cells for their energy and biosynthesis requirements. It is known, 
that cell culture mycoplasma contamination can significantly affect the 
interpretation of biological results, as it affects DNA, RNA and protein 
synthesis, reduces amino acid and ATP levels and can affect the 
expression of many genes such as those encoding for receptors, ion 
channels, growth factors, and oncogenes (Miller CJ. et al., 2003). For the 
Mycoplasma detection, we used a test based on PCR amplification of 
Mycoplasma DNA with a specific set of PCR primers. As seen from 
Figure 4.11C (before mycoplasma treatment) generated stable cell lines 
were infected with Mycoplasma, confirmed by the presence of 2 PCR 
products with the molecular weight of 500 and 700 bp, comparing to a 
positive control. Cells were treated with anti-mycoplasma reagent for 2 
weeks, and then grown in antibiotic free medium for 1 week prior 
repeating Mycoplasma PCR test. Figure 4.11C (after mycoplasma 
treatment) shows a complete elimination of  Mycoplasma,  as only one 
PCR band with the molecular weight of 700 bp was detected in tested 
samples and  negative control. These cells were used in further 
experiments. 
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Figure 4.11 Generation of stable cell lines using Lentivirus constructs for the expression of S6K2wt 
and S6K2-S1. (A) HEK293 cells were infected with Lentiviruses corresponding to the expression of EE-
tagged S6K2wt and S6K2-S1, and GFP protein as a positive control of infection. GFP expression in 
HEK293 cells was observed under the microscope 72h post-infection (left panel). After 48h of 
antibiotic selection only GFP –expressing cells were growing on the plate (right panel). (B) Generated 
HEK293 stable cell lines were checked for the expression of EE-S6K2wt EE-S6K2-S1, cells were 
collected and analysed in Western blotting.  (C) Mycoplasma testing of generated HEK293 stable cell 
lines. The electrophoretic analysis of PCR amplified Mycoplasma DNA in a 2% agarose gel.  Briefly, 
media from growing stable cell lines was collected and analysed for the presence of Mycoplasma 
using Mycoplasma PCR Detection Kit (PAA). Mycoplasma-infected cells were treated with anti-
mycoplasma reagent for 2 weeks, following growing for 1 week in antibiotic free media, and checked 
for the presence of Mycoplasma.  
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4.2.5 Raptor and mTOR coimmunoprecipitate with full length 
S6K2 and splicing isoform S1 in vivo  
Having established that S6K2-S1 specifically interacts with Raptor in 
baculovirus expression system, it was necessary to confirm its 
interaction with Raptor and the formation of a regulatory complex with 
mTOR in mammalian cells.  
In this study we used generated HEK293 stable cells overexpressing EE-
S6K2wt and EE-S6K2-S1. EE-S6K2 and EE-S6K2-S1 from total cell lysate 
were immunoprecipitated with mouse monoclonal anti-EE antibodies 
and the presence of endogenous Raptor in immune complexes was 
determined by Western blotting with anti-Raptor antibodies. As shown 
on Figure 4.12 (top panel), Raptor specifically coimmunoprecipitates 
with both full length and splicing variant of S6K2, when compared to 
control beads. Notably, the level of Raptor in EE-S6K2 and EE-S6K2-S1 
immunoprecipitates was comparable, indicating similar efficiency of 
interaction with Raptor for both S6K2 isoforms. Efficient 
immunoprecipitation of EE-S6K2-S1 and EE-S6K2 was confirmed by 
immunoblotting with specific antibodies (Figure 4.12 top panel). Re-
blotting the same membrane with anti-mTOR antibodies revealed that 
mTOR is also present in the complex with both EE-S6K2-S1 and EE-S6K2. 
The expression level of Raptor, mTOR, S6K2, S6K2-S1 and actin in total 
cell lysates (TCL) was examined with corresponding antibodies (Figure 
4.12, bottom panel).  
Therefore, we can conclude that both S6K2wt and S6K2-S1 specifically 
associate with Raptor and mTOR and integrate into mTORC1. These 
results suggest that S6K2-S1 has the potential to interfere with S6K1/2 
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association with Raptor and therefore may act as a dominant negative 
regulator of the mTORC1 signalling complex.  
 
Figure 4.12 Coimmunoprecipitation of overexpressed EE-S6K2wt and EE-S6K2-S1 with endogenous 
Raptor and mTOR in HEK293 cells. HEK293 stable cell lines overexpressing EE-S6K2wt, EE-S6K2-S1 
and empty vector were grown and collected at the confluency 80%. After cells were lysed and equal 
ammount of each total cell lysate were loaded onto protein G sepharose beads prewashed in cold 
lysis buffer, 2µg of a-EE antibodies were added to each precipitation sample. Cell lysates (TCL) and 
anti-EE immunoprecipitates (IP) were subjected to SDS-polyacrylamide gel electrophoresis and 
analysed by Western blotting using anti-mTOR, anti-Raptor, anti-S6K2 (C-terminal) and anti-S6K2-S1 
antibodies. The results shown are a representative experiment out of three individual experiments. 
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4.3 Discussion  
As described in the introduction for this chapter, both S6K2wt and 
splicing isoform S6K2-S1 possess the N-terminal TOS motif, which is 
required for their integration into the mTORC1 and downstream 
signalling.  
The work presented in this chapter investigates the potential of S6K2-S1 
to associate with Raptor via its N-terminal TOS motif and to form a 
complex with mTORC1. First, using the Baculovirus expression system 
we generated recombinant viruses which drive the expression of FLAG-
tagged S6K2-S1, EE-tagged Raptor and Rictor. Co-infection of Sf21 insect 
cells with generated viruses in various combinantions demonstrated 
that S6K2-S1 specifically binds with Raptor (mTORC1), but not Rictor 
(mTORC2). To validate these findings further, we used Lentiviral 
expression system to generate HEK293 stable cell lines expressing EE-
S6K2-S1 and EE-S6K2wt. Immunoprecipitation of overexpressed 
proteins from established cell lines showed that both EE-S6K2-S1 and 
EE-S6K2 have the ability to form an in vivo complex with Raptor and 
mTOR. These findings suggest that under physiological conditions 
splicing isoform S6K2-S1 might compete with S6K2 full-length for the 
binding to Raptor. Importantly, as S6K2-S1 does not possess the mTOR 
site for phosphorylation and the kinase activity it may act as a dominant 
negative regulator of mTORC1 signalling. The outcome of this 
investigation will be presented in the next chapter.  
It is known that the mTORC1 assembly is affected by nutrients, growth 
factors and rapamycin. Rapamycin is an allosteric inhibitor of mTORC1. 
It binds to ubiquitous protein FKBP12 (FK506-binding protein), and this 
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complex specifically interacts with mTOR and inhibits its downstream 
signalling (Sancak et al. 2010;Yip et al. 2010). Therefore, it would be 
interesting to investigate whether specific interaction of S6K2-S1 with 
Raptor and complex formation with mTOR can be affected by nutrients 
and growth factors deprivation or by rapamycin treatment.  
It is well established that in inactive state acidic N-terminus of S6K2wt 
interacts with the basic C-terminus autoinhibitory domain and thus this 
interaction keeps the kinase in a closed conformation.  In response to 
extracellular stimuli and stresses, the S/T phosphorylation events in the 
C-terminal autoinhibitory domain and the kinase-extension domain 
induce conformational changes leading to further   phosphorylations by 
mTOR and PDK1, and full activation of S6K2 (Gout, Minami, Hara, 
Tsujishita, Filonenko, Waterfield, & Yonezawa 1998;Saitoh, ten, 
Miyazono, & Ichijo 1998;Weng, Kozlowski, Belham, Zhang, Comb, & 
Avruch 1998). Acidic N-terminal end of S6K2wt and splicing isoform 
possess more than ten negatively charged glutamic acid residues. It is 
interesting to note that a unique C-terminal sequence of S6K2-S1 is 
enriched with positively charged arginine and lysine residues, 
resembling basic C-terminus of S6K2 full length.  It is plausible to 
suggest that the basic C-terminal end of S6K2-S1 can be also implicated 
in mediating the interaction with Raptor and mTOR.  
Results presented in this chapter, reviewed the potential of S6K2-S1 to 
integrate into the mTORC1 signalling complex via specific interaction 
with substrate-presenting protein Raptor.  The next chapter describes 
our attempts to investigate the cellular functions of S6K2-S1 splicing 
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isoform and its role in the regulation of mTOR signalling pathway, using 
different approaches and models. 
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5 Functional analysis of the S6K2 S1 splicing 
isoform 
5.1 Introduction 
Having identified that S6K2-S1 forms a complex with mTOR and Raptor, 
it remains unclear how splicing variant may participate in the mTORC1 
signalling pathway. The possibility of splicing isoforms modulating 
mTORC1 functions is high. S6K2-S1 directly interacts with Raptor via the 
TOS motif and forms mTORC1 established in previous chapter. The TOS 
motif is found in three downstream targets of mTORC1: S6K1, S6K2 and 
4EBP1. Taking this into account, we hypothesised that S6K2-S1 splicing 
variant might affect some of mTORC1 multiple functions. In this 
chapter, a functional role of S6K2-S1 splicing isoform in mTOR signalling 
is uncovered. 
First, different cell models overexpressing full length S6K2 and S6K2-S1 
splicing isoform were generated and characterised. Second, the state of 
the mTOR/S6K signalling pathway in cells stably expressing S6K2-S1 
splicing isoform was assessed under different conditions. Next, 
considering a diverse range of cellular processes regulated via the 
mTORC1 pathway, we focused mostly on well-known functions of S6Ks 
in the regulation of cell size, cell migration and cell survival. Different 
cellular models were used and described for each experimental method 
to address these objectives. 
Finally, oncogenic potential of full length S6K2 and a splicing isoform 
was analysed using two approaches: anchorage independent colony 
formation in soft agar and xenograft studies in nude mice.  
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The data presented in this chapter shows that S6K2-S1 splicing isoform 
has the potential to interfere and to downregulate different cellular 
functions controlled via mTORC1/S6K signalling. 
5.2 Results 
5.2.1 Overexpression of full length S6K2 and S6K2-S1 splicing 
isoform affects cell size the opposite way 
As described in detail in the Introduction chapter, the mTOR/S6K 
signalling pathway is a major regulator of cell growth. Genetic studies 
clearly indicate that S6K1−/− deficient flies and mice are smaller than the 
wild type. It was shown that this effect is caused by a decrease in an 
individual cell size, without changing cell proliferation rate (Montagne 
et al. 1999).   
Taking into account the possible role of the spliced isoform as a 
negative regulator of mTOR/S6K signalling, it was interesting to check 
whether S6K2-S1 might affect cell size. 
The most commonly used technique for measuring cell size is a flow 
cytometry, where cells flow in a narrow stream and light from the laser 
beam is reflected from the cell surface. In addition, it can be used for 
counting cells and analyzing their shape and structures. A CASY counter 
is also designed to measure cell size. In this technique, an electrical 
pulse is applied through a narrow pore to measure single cell 
parameters. However, a number of technical factors need to be 
considered.  Firstly, it is essential that the cells are passing through the 
measuring pore individually. Secondly, it is important to have a 
homogenous cell population to get accurate values for average cell size, 
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allowing meaningful comparisons between populations. This is 
particularly significant if the changes are expected to be fairly small.  
Cell size changes dramatically during the cell cycle. During G1/S/G2 
phases the size of a cell is gradually increasing due to DNA replication 
and protein synthesis and finally in the M phase a cell is divided. In 
contrast, apoptotic cells usually shrink and lose up to thirty percent of 
their initial volume. In a population of cells, where one cell might be in 
the process of cell division whereas another cell undergoes apoptosis, 
cell size varies considerably. In addition, physical and environmental 
conditions, such as starvation, stimulation with different growth factors 
or drug-treatment, cell density and others, affect cell size. In order to 
reduce the effect of these factors on cell size, in our experiment the 
same number of cells was plated for each cell line and cell size was 
measured on the second day after seeding.  
Using the CASY machine, we found that generated HEK293 stable cell 
lines overexpressing S6K2-S1 (described in chapter 3.2.3) did not show 
significant differences in cell size when compared to control HEK293 
cells (Figure 5.1). Interestingly, as seen from Figure 5.1 NIH3T3RasC40 
cells overexpressing S6K2-S1 (described in chapter 5.2.4) have a 
tendency to be smaller than the control cells. These conflicting results 
from two cell lines motivated us to search for another cell model, which 
might better reflect the role of the S6K2-S1 spliced variant in the 
regulation of cell size. Additionally, as a positive control cells 
overexpressing S6K2wt were used, as it is known to play an important 
role in the regulation of cell size. 
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Figure 5.1 Cell size analysis of HEK293 and NIH3T3RasC40 cells with stable overexpression of S6K2-S1 
splicing isoform. Cell size was measured by using CASY Model TT cell counter (Innovatis). 50 000 cells 
of each cell line were plated in 6-well plates in normal medium and growth under standard 
condition. Seeded cells were collected after 48h of growth. First, the medium was aspirated and cells 
were washed with PBS. After cells were trypsinized by the addition of 500 µl of trypsin for 2 min at 
37
0
C, cells were resuspended and this suspension was mixed with 500 µl of PBS. 100 µl of 
resuspended cells were added to 10 ml of CASYTON isotonic solution (Innovatis) and samples were 
analysed using CASY machine. Each point represents mean ± SD from three independent 
experiments (*p<0.05). 
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As presented in the introduction chapter, the upstream regulation of 
the mTOR/S6K pathway involves tumour suppressors TSC1 and TSC2. 
Loss of function of the TSC1-TSC2 complex leads to constitutively 
activated mTORC1 pathway. MEF (mouse embryonic fibroblasts) cells, 
derived from TSC1 or TSC2 knockout mouse embryos, show constitutive 
activation of mTORC1 signalling and subsequent increased 
phosphorylation of S6K, S6 and 4E-BP1 proteins. Interestingly, TSC2-/- 
as well as TSC1-/- mouse fibroblasts display early senescence, which can 
be rescued by p53 loss. TSC2-/- p53-/- MEF cells display mTORC1-
dependent feedback inhibition of PI3K signalling and dramatic decrease 
in AKT phosphorylation; additionally they show loss of mTORC2 activity 
(Jing Xiang Huang and Brendan D. Manning 2008; David J. Kwiatkowski 
2009, 2003). Notably, TSC2-/- p53-/- MEF cells are highly dependent on 
the constitutively activated mTORC1 pathway, and its downregualtion 
has a dramatic effect on them. Based on this, TSC2-/- p53-/- MEF cells 
were selected as a good model to study the role of S6K2 splicing 
isoform in the regulation of mTORC1 signalling.  
TSC2-/- p53-/- MEF stable cell lines overexpressing S6K2-S1 splicing 
isoform were produced using Lentiviruses generated previously 
(described in chapter 4.2.4). Briefly TSC2-/- p53-/- MEF cells were 
infected with Lentiviruses corresponding to EE-S6K2 full length, EE-
S6K2-S1 splicing isoform and an empty vector.  After 24 hours post 
infection, cells were seeded into the fresh medium, containing selective 
antibiotic (puromycin at 2μg/ml) and cultured until antibiotic-resistant 
cells produced separate colonies. Notably, TSC2-/- p53-/- MEF cells 
responded to antibiotic selection very quickly.  After two days of 
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selection control uninfected cells died, whereas cells infected with 
Lentiviruses started to form separate colonies. As a positive control of 
infection, cells were infected with GFP-expressing Lentivirus, selection 
of GFP-infected cells was observed under the microscope. After 
antibiotic selection, cells were amplified and analysed in Western 
blotting for the expression of EE-tagged S6K2 full length and the spliced 
isoform. Unfortunately, cells infected with EE-S6K2-S1 Lentivirus did not 
show the expression of the spliced isoform. This may be explained by 
the fact that the overexpression of EE-S6K2-S1 affects the selection 
process, thus cells with high expression level were eliminated from cell 
population during selection.  On the other hand, cells which show 
antibiotic resistance but do not show detectable EE-S6K2-S1 expression 
might express splicing isoform at a very low level. In contrast, 
overexpression of full length EE-S6K2 in TSC2-/- p53-/- MEF cells was 
easy to detect (Figure 5.2A).  
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Figure 5.2 Generation of  MEF TSC2-/- p53-/- stable cell lines overexpressing full-length S6K2 and 
splicing variant S6K2-S1. (A) Analysis of EE-S6K2 and EE-S6K2-S1 expression in generated MEF TSC2-/- 
p53-/- polyclonal stable cell lines in Western blotting, using corresponding antibodies. (B) Generation 
of monoclonal stable cell lines expressing full length S6K2 and splicing isoform. Analysis of EE-S6K2 
and EE-S6K2-S1 expression in selected clones. 50µg of total cell lysate were used for Western 
blotting. Anti-actin antibodies were used as a control of equivalent protein loading. NS-non-specific 
signal. 
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In order to generate TSC2-/- p53-/- MEF stable cell lines overexpressing 
S6K2-S1, a technique of monoclonal selection was used. After infection, 
single cell infected with one of the Lentiviruses (EE-S6K2-S1, EE-S6K2, 
empty vector) formed a small colony of identical cells; these colonies 
were picked up and grown separately. 18 clones for each construct 
were analysed for the expression of EE-tagged S6K2 and S6K2-S1 in 
Western blotting. Among 18 selected clones checked for the expression 
of S6K2-S1, just one clone 8 expressed splicing isoform to a good 
detectable level; two clones had a very low expression whereas in all 
remaining 15 clones the expression of splicing isoform was below the 
detection limit. In contrast, the overexpression of full length EE-S6K2 in 
TSC2-/- p53-/- MEF cells was detected in all selected clones, with the 
highest expression found in clone 3 (Figure 5.2B). Therefore, clone 8 
expressing EE-S6K2-S1 and clone 3 expressing EE-S6K2 were used for 
further analysis. 
Simple observation of growing stable cell lines under the microscope 
revealed different phenotypes of cells overexpressing full length S6K2 
and splicing isoform. As seen from Figure 5.3A, cells expressing full 
length S6K2 appeared to be bigger and more round, whereas S6K2-S1 
expressing cells are visibly smaller and have a tendency to grow in 
groups, when compared to control cells. The overexpression of splicing 
isoform in TSC2-/- p53-/- MEF cells does not affect their proliferation 
rate, as shown on Figure 5.3B.  
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Figure 5.3 Characterisation of MEF TSC2-/- p53 -/- stable cell lines overexpressing full-length S6K2 
and S6K2-S1 splicing isoform. (A) Representative pictures of MEF TSC2-/- p53 -/- stable cell lines 
overexpressing S6K2 wild type (clone 3) and S6K2-S1 splicing variant (clone 8). (B) Overexpression of 
S6K2-S1 in MEF TSC2-/- p53 -/- cells does not affect cell proliferation. 4 000 cells were plated in 6-
well plate in normal medium and grown under standard condition. Seeded cells were collected every 
following day for a period of 4 days. First, the medium was aspirated and cells were washed with 
PBS. After cells were trypsinized by the addition of 500 µl of trypsin for 2 min at 37C, cells were 
resuspended and this suspension was mixed with 500 µl of PBS. 100 µl of resuspended cells were 
added to 10 ml of CASYTON isotonic solution (Innovatis) and samples were analysed using CASY 
Model TT cell counter (Innovatis). Each point represents mean±SD from three independent 
experiments. 
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 Next, to verify our previous findings, cell size measurement of TSC2-/- 
p53-/- MEF cells clone 8 and clone 3, expressing EE-S6K2-S1 and EE-
S6K2 correspondingly (Figure 5.4A), was performed using CASY 
machine. Comparative analysis of cell size distribution of these cell lines 
presented on Figure 5.4B shows that overexpression of splicing isoform 
significantly reduced cell size in contrast to full length S6K2 compared 
to control cells. To verify these findings four subsequent experiments 
were performed. Generated results confirm our previous observations 
obtained in NIH3T3RasC40 cells. Taken together, this study indicates 
that S6K2-S1 splicing variant has the potential to modulate the cell size 
and this effect is possibly mediated via downregulation of the 
mTORC1/S6K signalling pathway. On the other hand, we have shown 
that the overexpression of S6K2wt in TSC2-/- p53-/- MEF cells results in 
the increase in cell size, compared to control (Figure 5.4B). 
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Figure 5.4 Overexpression of S6K2-S1 splicing isoform reduces the size of MEF TSC2-/- p53 -/- cells. 
(A) Analysis of S6K2-S1 (clone 8) and S6K2wt (clone 3) protein expression in MEF TSC2-/- p53-/- 
monoclonal stable cell lines used fpr cell size measurement. 30µg of total cell lysate was used for 
loading. Anti-actin antibodies were used as a control of equivalent protein loading. NS - non-specific 
signal. (B) Graphic representation of cell size distribution of MEF TSC2-/- p53-/- cells overexpressing 
S6K2wt (clone 3) and S6K2-S1 (clone 8), compared to control cells using CASY machine software. The 
same number of cells for each cell line was seeded and after 48h of growth were trypsynised, diluted 
in isotonic solution and cell size was measured using CASY counting machine. Each point on the 
graph represents mean ± SD from four separate experiments (*p<0.001, **p<0.01)). 
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5.2.2 S6K2-S1 isoform does not affect cell proliferation 
Data from the S6K1−/− and S6K2−/− deficient animal models did not 
show any dramatic effect on cell proliferation (Montagne et al. 1999). 
To investigate whether S6K2-S1 splicing variant may affect cell growth, 
cell proliferation assays were performed. Previously generated HEK293 
stable cell lines overexpressing S6K2-S1 clone 1 and clone 9 and a 
control cells (Figure 5.5A) were seeded with the same density into 6-
well plates and every other day cells were collected and counted. 
Analysis of results presented in Figure 5.5B clearly indicates that there is 
no significant difference in the proliferation rate between control cells 
and cells overexpressing S6K2-S1. These results were subsequently 
confirmed in all generated stable cell lines used in this work (data not 
shown). 
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Figure 5.5 Overexpression of S6K2-S1 in HEK293 cells does not affect cell proliferation. (A) The 
expression of S6K2-S1 splicing isoform was monitored in Western blotting. 30µg of total cell lysate 
was used for analysis. Anti-actin antibodies were used as a control of equivalent protein loading. (B) 
30 000 cells of corresponding HEK293 stable cell lines were seeded into a 6-well plate in normal 
medium and grown under standard condition. Seeded cells were collected every following day for a 
period of 4 days. First, the medium was aspirated and cells were washed with PBS. After cells were 
trypsinized by the addition of 500 µl of trypsin for 2 min at 37C, cells were resuspended and this 
suspension was mixed with 500 µl of PBS. 100 µl of resuspended cells were added to 10 ml of 
CASYTON isotonic solution (Innovatis) and samples were analysed using CASY Model TT cell counter 
(Innovatis). Each point represents mean±SD from three independent experiments.  
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5.2.3  S6K2-S1 can modulate the activity of the mTOR/S6K 
pathway in starved condition 
Our findings presented in Chapter 4 of this thesis indicated a direct 
interaction of S6K2-S1 with Raptor and mTOR. These results suggest 
that under physiological conditions the splicing isoform might compete 
with the full length S6K2 for the binding to Raptor. Additionally, it may 
also interfere with S6K1 and 4EBP1 interaction with Raptor and thus 
affect their functions. Importantly, as S6K2-S1 does not have kinase 
activity it may act as a dominant negative regulator of mTORC1 
signalling.  
In order to gain further knowledge about physiological functions of the 
S6K2-S1 spliced isoform, the state of the mTOR/PI3K pathway in normal 
conditions was analysed using a panel of phospho-specific antibodies. 
Phosphorylation level of key downstream effectors of mTORC1: S6K1 at 
Thr389, 4EBP1 protein at Thr37/46 and S6 protein at Ser240/244 was 
assessed. In addition, the phosphorylation state of Akt/PKB at Ser473 
was also examined, as it is known that S6Ks affect the Akt/PKB activity 
via the negative feedback loop to IRS-1 (Harrington, L.S., 2004). 
As seen from Figure 5.6, HEK293 stable cells overexpressing S6K2-S1 
(clone 1 and 9) do not show any significant changes in the 
phosphorylation level of S6K, S6, 4EBP1 and Akt/PKB in normal 
condition, when compared to control cells. The same results were 
obtained in A549, NIH3T3RasC40 and MEFTSC2-/-p53-/- stable cell lines 
overexpressing the spliced isoform (data not shown). There may be 
several explanations for this.  Firstly, although splicing isoform interacts 
with Raptor and forms mTORC1, it may not be involved in the 
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regulation of mTOR and S6K activity and as a result the phosphorylation 
level of downstream targets remains unchanged. Secondly, cell models 
used for this experiment might not be appropriate to study this effect. 
Finally, the most feasible explanation might be that under this 
experimental condition the role of S6K2-S1 is eliminated due to a strong 
interaction between mTOR, Raptor, S6Ks and 4EBP1. 
It is now well established that the mTORC1 assembly is affected by 
nutrients and growth factors. Therefore, we sought to determine 
whether S6K2-S1 can alter the phosphorylation level of S6K at Thr389, 
4EBP1 at Thr37/46, S6 protein at Ser240/244 and Akt/PKB at Ser473 
under serum-starved conditions. HEK293 cells with stable 
overexpression of splicing isoform (clone 1 and 9) were used for this 
analysis, since they express relatively high levels of S6K2-S1. Cells were 
grown to 50-60% confluence and the medium was replaced with DMEM 
without serum for a starvation period of 30 hours and then stimulated 
by the addition of 10% FCS for 1 hour. Cells were collected and analysed 
in Western blotting. Interestingly, three independent experiments 
confirmed that HEK293 cells overexpressing S6K2-S1 (clone 1 and 9) 
showed significant reduction in the phosphorylation of S6 protein and 
4EBP1 under starved conditions, when compared to control cells (Figure 
5.6). Interestingly, the phosphorylation level of Akt/PKB was reduced as 
well. This finding agrees with our suggestion that the S6K2-S1 splicing 
variant can negatively regulate some of mTOR functions and interfere 
with S6K activity.  In addition, it can affect events upstream of mTOR, 
possible though regulating S6K negative feedback loop affecting the 
activation of Akt/PKB or through unknown mechanisms. 
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Figure 5.6 Overexpression of S6K2-S1 in HEK293 cells affects the mTOR/S6K pathway in serum-
starved cells. HEK293 stable cell lines overexpressing S6K2-S1 (clone 1 and 9) and an empty vector 
were seeded at the same density to achieve 50% confluency in 24h. Next day media was changed for 
the starvation media without FBS and left for 30h. Then, cells were stimulated with media containing 
10% FBS for 1h. Cells were harvested, lysed and analysed in Western blotting with corresponding 
antibodies. Anti-actin antibodies were used as a control of equivalent protein loading. The results 
shown are a representative outcome out of three individual experiments. 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 161 
 
 
To further strengthen these novel findings, we examined the effect of 
starvation on the phosphorylation status of mTOR signalling molecules 
in different cell lines. As shown in Figure 5.7, serum deprivation of 
TSC2-/- p53-/- MEF stable cell lines overexpressing S6K2-S1 resulted in 
the significant downregulation of S6K1 and S6 protein phosphorylation 
when compared to control. As a positive control, cells overexpressing 
wild type S6K2 were used and showed higher level of S6K and S6 
protein phosphorylation in normal and starved conditions when 
compared to control. These results were confirmed in three 
independent experiments. When A549 stable cell lines overexpressing 
S6K2-S1 were tested in this experimental set up, no significant changes 
in the phosphorylation level of selected proteins were observed under 
serum deprivation (data not shown). This may be due to the quality of 
cells used, or possibly a longer starvation period should have been 
chosen. However, from results obtained using HEK293 and TSC2-/- p53-
/- MEF stable cell lines, it is obvious that S6K2-S1 splicing variant can 
negatively regulate some of the mTOR functions in serum-starved cells.  
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Figure 5.7 Overexpression of S6K2-S1 in MEF TSC2-/- p53-/- cells affects the mTOR/S6K pathway in 
serum-starved cells. 50 000 cells of MEF TSC2-/- p53-/- stable cell lines overexpressing S6K2-S1 
(clone 8), S6K2wt (clone 3) and an empty vector were seeded into a 6cm plate. Next day media was 
changed for the starvation media without FBS and left for 48h. Then, cells were additionally starved 
for 2h in PBS. Cells were harvested, lysed and analysed in Western blotting with corresponding 
antibodies. Anti-actin antibodies were used as a control of equivalent protein loading. The results 
shown are a representative outcome out of three individual experiments. NS-non-specific signal.  
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5.2.4 S6K2-S1 is implicated in the regulation of cell migration  
The important role of S6K1 in the regulation of cytoskeleton 
reorganisation is well established and described in detail in the 
Introduction chapter. Although few researchers have examined the 
function of S6K2 in this process, we decided to investigate whether the 
S6K2-S1 splicing variant can affect cytoskeleton reorganisation, focusing 
on cell migration.  
A simple approach to study cell migration is a wound healing assay. 
Briefly, cells are grown on a plate and then a long scratch is introduced 
to the cell monolayer disrupting cellular growth.  Cells respond to the 
injury by attempting to fill the gap and close the wound. Not all cell 
lines are suitable for this experiment. HEK293 cells have a weak cell-
ECM and a strong cell-cell attachment; on the other hand A549 cells are 
very strongly attached to the surface, which makes it difficult to inflict a 
“good” wound. A literature search pointed us to the good cell model for 
this assay - mouse embryonic fibroblast (NIH3T3) cell line.  
Considering the potential role of S6K2-S1 as a negative regulator of 
mTORC1 functions in this study we decided to use transformed 
NIH3T3RasC40 cell line.  In comparison to parental NIH3T3, this cell line 
overexpresses Ras GTPase with two independent mutations: a) RasV12 
activating mutation which results in Ras-induced cell transformation; b) 
Ras C40 mutation retains Ras binding to the p110 catalytic subunit of 
PI3kinase, but abrogates the activation of the MAPK signalling pathway 
(Andreas Behren et al., 2005). So, using these cells we can check 
whether the overexpression of S6K2-S1 might suppress cell 
transformation mediated through the PI3K pathway. 
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 As shown in Figure 5.8A, we managed to generate polyclonal stable 
NIH3T3RasC40 cells with a good expression of S6K2-S1 splicing isoform. 
This cell line does not show any changes in their proliferation rate 
compared to control (Figure 5.8B). Interestingly, cells overexpressing 
S6K2-S1 looked morphologically different when compared to control 
cells. Control NIH3T3RasC40 cells have the spindle/fibroblastic shape 
that is characteristic of cells transformed with an oncogene such as Ras 
(Janda E et al., 2003). As seen from Figure 5.8C, cells overexpressing 
S6K2-S1 appear more round and show less actin-rich projections in the 
form of lamellipodia and filopodia, in comparison to parental cells. This 
difference was especially visible just after trypsinization and plating 
cells in the time-scale from 1 to 6 hours (Figure 5.9), while 24 hours 
later the difference was less obvious. These observations do not prove 
anything on their own, but they suggest that S6K2-S1 splicing variant 
might affect cell adhesion and migration. 
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Figure 5.8 Generation and characterisation of NIH3T3 RasC40 stable cell lines overexpressing S6K2-
S1. (A) NIH3T3 RacC40 cells were transiently transfected with pcDNA/S6K2-S1 and an empty vector.  
After 48 hours post transfection, cells were splited into fresh medium with selective antibiotic. After 
selection, cells were harvested and checked for the expression of splicing isoform in Western 
blotting with specific antibodies. 30mg of total cell lysate was used for loading. Anti-actin antibodies 
were used as a control of equivalent protein loading. (B) Overexpression of S6K2-S1 in NIH3T3RasC40 
cells does not affect cell proliferation. 20 000 cells were seeded into a 6-well plate and cell number 
was counted using CASY counting machine every following day. Each point represents mean ± SD 
from three separate experiments. (C) Representative pictures of NIH3T3RasC40 stable cell lines 
overexpressing S6K2-S1 splicing variant and an empty vector.  
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Figure 5.9 Overexpression of S6K2-S1 in NIH3T3RasC40 cells affects early cell attachment to the 
plate. Growing cells were washed with PBS, trypsinized by the addition of of trypsin for 2 min at 37C, 
after cells were resuspended and this suspension was mixed with normal medium. 100 µl of 
resuspended cells were added to 10 ml of CASYTON isotonic solution (Innovatis) and the number of 
cells was counted using CASY Model TT cell counter (Innovatis). 250 000 cells of each cell line were 
seeded into 6cm plate. Representative images of the cells were taken after 1, 3 and 6h after seeding.  
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To investigate if the splicing isoform can regulate cell migration, we 
performed tissue culture wound healing assay. Cells were plated at the 
same density and the wound was introduced to 90% confluent 
monolayer of cells. As seen from Figure 5.10 NIH3T3RacC40 cells 
expressing S6K2-S1 isoform showed lower (up to forty percent) 
migration rate compared to control cells. These results were 
reproduced in four independent experiments. In addition, our 
collaborators from Imperial College London (Prof. M. Seckl and Dr. O. 
Pardo) confirmed our findings and showed that overexpression of S6K2-
S1 isoform in NIH3T3RasC40 cells significantly reduced their migration 
and invasion into collagen in response to EGF treatment (data not 
shown).  
 
 
  
The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 168 
 
 
 
 
 
Figure 5.10 Overexpression of S6K2-S1 in NIH3T3RasC40 cells inhibits cell migration measured by 
wound healing assay.  Representative images of the wound were taken immediately after the scratch 
and 16h later. For the assay, 0.5 million cells were seeded in 6cm plates, when cells reached 90% 
confluence, a single wound was made in the centre of the cell monolayer; media was carefully 
changed to remove cell debris.  The number of migrated cells from the start point to the point of 16h 
incubation was counted. Graphs represent mean ± SD of four independents experiments (*p<0.05).  
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5.2.5 Cells overexpressing S6K2-S1 show higher sensitivity to 
drug-induced apoptosis 
It is now well-established that S6K signalling is implicated in the 
regulation of cell survival. Taking into account the important role of 
S6K2 in mediating pro-survival signalling in chemoresistant NSCLC (non-
small cell lung cancer), the decision was made to study the role of S6K2-
S1 splicing isoform in cell survival in A549 human lung carcinoma cell 
line. A549 cells were infected with the Lentiviruses (described in 
chapter 4.2.4) corresponding to EE-tagged full length S6K2 and S6K2-S1 
splicing variant. Generated stable cell lines showed a relatively high 
level of overexpressed proteins (Figure 5.11A). To assess how the 
overexpression of splicing isoform may affect cell survival generated 
stable cell lines were treated with staurosporine and cisplatin, which 
are commonly used for the induction of apoptosis in various cellular 
models. 
Staurosporine is a general protein kinase inhibitor, which induces 
apoptosis as determined by cell morphology and the activity of 
caspases.  A549 stable cell lines overexpressing full length S6K2 and 
splicing isoform were exposed to 1 µM of staurosporine for 3h and 5h. 
As seen from Figure 5.11B, at this concentration staurosporine induced 
a marked cleavage of poly-(ADP-ribose) polymerase (PARP), dramatic 
downregulation of S6 kinase and S6 protein phosphorylation. PARP (116 
kDa) is proteolytically cleaved during caspase- dependent apoptosis 
resulting in the appearance of the 85 kDa fragment, which is specifically 
detected only in apoptotic cells.  
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Figure 5.11  Staurosporin treated A549 cells with stable overexpression of S6K2-S1 shows higher 
level of cleaved PARP when compared to control cells. (A) A549 stable cell lines overexpressing S6K2-
S1 isoform, EE-S6K2wt and control cells were analysed in Western blotting. Anti-actin antibodies 
were used as a control of equivalent protein loading. (B) 300 000 cells of  A549 stable  cell lines  
overexpressing pLEX empty vector, EE-S6K2-S1 and EE-S6K2 were seeded into 6cm plate. Next day, 
1µM of staurosporine diluted in DMSO was added to each plate. DMSO alone was added as a 
control.  After 3 and 5 hours of incubation cells were collected and lysed in cold lysis buffer. 30µg of 
total cell lysate was used for Western blotting. PVDF membranes were blotted with corresponding 
antibodies. Anti-actin antibodies were used as a control of equivalent protein loading. The results 
shown are representative outcomes out of three individual experiments. 
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It is clear that cells overexpressing S6K2-S1 exhibit higher level of 
cleaved PARP compared to the control, therefore we can conclude that 
the overexpression of splicing isoform downregulates pro-survival 
signalling in A549 cells in response to staurosporine. These findings 
were subsequently confirmed in TSC2-/- p53-/- MEF cell lines stably 
expressing S6K2 and S6K2-S1 (data not shown). 
Next, we investigated how S6K2-S1 splicing isoform would affect DNA 
damage-induced cell death by treating cells with cisplatin, a 
chemotherapy drug that targets actively proliferating cells. Treatment 
of A549 cells with 50 µM of the drug induced cell death as observed 
under the microscope. Apoptotic signalling was detected by measuring 
the level of cleaved PARP by Western blotting.  
Figure 5.12 shows that after 24 hours of treatment cells overexpressing 
S6K2-S1 have slightly higher level of cleaved PARP compared to control, 
which is in line with previous findings. Following cisplatin treatment, the 
level of phosphorylation of S6K at Thr389 and S6 protein at Ser240/244 
was checked. Importantly, as seen from Figure 5.12, treated A549 
stable cells overexpressing S6K2-S1 show reduced phosphorylation of 
S6 protein at Ser240/244 and S6K at Thr389, when compared to 
control. This might indicate that under these experimental conditions, 
S6K2-S1 downregulates the activity of mTOR and S6K measured by the 
phosphorylation level of S6K and S6 protein.  
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Figure 5.12 Cells overexpressing EE-S6K2-S1 show higher sensitivity to cisplatin-induced apoptosis. 
300 000 cells of  A549 stable  cell lines  overexpressing pLEX empty vector, EE-S6K2-S1 and EE-S6K2 
were seeded into 6cm plates. Next day, cells were treated with 50 µM of cisplatin diluted in DMSO. 
DMSO alone was added to control plates. After 24 and 48 hours of incubation, cells were collected 
and lysed in cold lysis buffer. 30µg of total cell lysate was used for Western blotting. PVDF 
membrane was blotted with corresponding antibodies. Anti-actin antibodies were used as a control 
of equivalent protein loading. The results shown are representative outcomes out of three individual 
experiments. 
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Taken together, these results reveal the potential of S6K2-S1 to mediate 
pro-apoptotic signalling and suggest that it may reduce cell resistance 
to apoptosis, possibly by interfering with the mTOR/S6K pathway or 
through yet unknown mechanisms.  
5.2.6 S6K2-S1 is a potential tumour suppressor, whereas full 
length S6K2 exhibits oncogenic properties 
A recent publication showed that the overexpression of p31S6K1 
spliced isoform has the potential to induce transformation of human 
breast epithelial cells, in contrast to full length S6K1 (Karni R et all., 
2012). Taking this into account and the similarity in the spicing 
mechanism of S6K1 and S6K2 genes, it was logical to investigate 
whether S6K2wt and S6K2-S1 splicing isoform had a tumorigenic 
potential. There is no direct evidence that full length S6K2 is an 
oncogene on its own, but high expression level of S6K2 has been found 
in a diverse range of tumours and cancer cell lines (Pardo O et al., 2006; 
Filonenko VV Et al., 2004; Perez-Tenorio G et al., 2011).  
Initially, the oncogenic potential of wild type S6K2 and splicing isoform 
was examined using an anchorage-independent colony formation assay. 
Anchorage-independent cell growth in soft agar is one of the main 
characteristics of cellular transformation. Typically, normal cells are not 
able to grow in a semi-solid medium, as contact between cells and 
extracellular matrix (ECM) is crucial for cell proliferation and survival. 
Disruption of this interaction leads to cell apoptosis. Transformed cells 
are usually resistant to apoptosis and are able to grow in an anchorage-
independent manner. Tumour cells tend to form aggregates in a 
suspension culture which correlates with colony formation in soft agar. 
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These processes play a very important role in tumour development and 
metastasis (Grossmann J et al., 2002). 
To set up a colony formation assay, generated HEK293 stable cell lines 
overexpressing S6K2-S1 isoform (clone 1 and clone 9), S6K2wt and an 
empty vector were used. Briefly, the same number of cells was mixed 
with the semi-solid medium/agarose mixture and left to grow for two 
weeks.  The resulting number of colonies were visualized and counted. 
Data presented in Figure 5.13A clearly show that cells overexpressing 
S6K2-S1 form significantly lower number of colonies in soft agar. 
Moreover, the colonies are much smaller when compared with control. 
Notably, the inhibition of colony formation and growth shows a good 
correlation with the expression level of S6K2-S1 spliced isoform. For 
example, the expression level of S6K2-S1 in clone 1 is higher than that in 
clone 9, which correlates with the number of colonies in a soft agar 
assay. In contrast, overexpression of full length S6K2 increases the 
number and size of the colonies in soft agar. These results were 
reproduced in three independent experiments. Analysis of data 
presented in Figure 5.13B shows that the overexpression of S6K2-S1 in 
HEK293 cells suppresses anchorage-independent growth up to 50%, 
while a significant increase up to 30% in the colonies number is 
observed in cells overexpressing full length S6K2, when compared to 
control. The expression level of S6K2-S1 and full length S6K2 in selected 
cell lines were confirmed in Western blotting (Figure 5.13C).   
To further verify these findings, A549 cells with stable expression of 
S6K2-S1 and wild type S6K2 (described previously in this chapter) were 
also used in the colony formation assay. The results of four independent 
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experiments clearly demonstrate that full length S6K2 promoted 
anchorage-independent growth, whereas S6K2-S1 splicing isoform 
downregulated colony formation (Figure 5.14A). Analysis of data shows 
that the overexpression of S6K2-S1 suppresses colony formation up to 
40%, while overexpression of full length S6K2 leads to 40% increase in 
the colonies number, when compared to control (Figure 5.14B). In 
addition, the colonies of cells with overexpressed wild type S6K2 are 
bigger, when compared to control or S6K2-S1 expressing cells. These 
results completely reproduce data obtained in HEK293 cells. The 
expression level of S6K2-S1 and full length S6K2 in selected cell lines 
were confirmed in Western blotting (Figure 5.14C).   
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Figure 5.13 Overexpression of S6K2-S1 isoform inhibits anchorage-independent colony formation in 
soft agar.  (A) Representative pictures of soft-agar plates with HEK293 stable cell lines 
overexpressing S6K2-S1 (clone 1 and clone 9), S6K2wt and an empty vector. 2 000 cells of each cell 
lines were plated in semi-solid agar, as described in Materials and Methods. Colonies growth was 
monitored over a period of weeks.  (B) Visualized colonies were counted using ImageJ software 
(Colonies with the area more than 25 pixels were counted). Data are mean ± SD of three 
independents experiments (*p<0.005, **p<0.0005). (C) Analysis of S6K2-S1 and S6K2wt protein 
expression in stable cell lines. 30µg of total cell lysate was used for loading. Anti-actin antibodies 
were used as a control of equivalent protein loading.  
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Figure 5.14 Overexpression of S6K2-S1 splicing variant in A549 cells supresses colony formation in 
soft agar. (A) Representative fields from soft-agar plates with A549 stable cell lines overexpressing 
S6K2wt, splicing isoform and an empty vector. 10 000 cells for each cell line were plated in semi-solid 
agar as described in Material and Methods. Colonies growth was monitored over a period of weeks.  
(B) Visualized colonies were counted using ImageJ software (Colonies with the area more than 6 
pixels were counted). Data are mean ± SD of four independents experiments (*p<0.005). (C) Stable 
cell lines overexpressing S6K2-S1 isoform, EE-S6K2wt and control cells were analysed in Western 
blotting. Anti-actin antibodies were used as a control of equivalent protein loading. 
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Taken together, results in colony formation assay obtained in HEK293 
and A549 cell lines demonstrate for the first time that overexpression of 
wild type of S6K2 induces colonies growth, while S6K2-S1 splicing 
isoform acts as a potential tumour suppressor. As we shown in chapter 
5.2.2 that stable overexpression of full length S6K2 and S6K2-S1 in 
several cell lines did not change their proliferation rate in comparison to 
control, it is most likely that other cellular processes contribute to the 
outcome of the colony formation assay. 
To further substantiate our results, the colony formation assay was set 
up with generated TSC2-/- p53-/- MEF stable cells lines everexpressing 
S6K2 wild type and splicing isoform (described in chapter 5.2.1). 
Literature searches revealed no studies on the use of MEFs in an 
anchorage-independent colony formation assay, so soft agar assay for 
TSC2-/- p53-/- MEF cell lines was carried out as described for HEK293 
cells. This study showed that all tested TSC2-/- p53-/- MEF stable cell 
lines started to form colonies after 5-6 days in the assay. However, the 
colonies didn’t expand with time or started to decline gradually. As the 
size of colonies was very small, we were not able to quantitate the 
outcome of this experiment using ImageJ software. Analysis of colonies 
under the microscope confirmed that overexpression of full length S6K2 
leads to the formation of bigger colonies in contrast to S6K2-S1 splicing 
isoform and control (data not shown). These observations are in line 
with data presented in Figure 5.13 and Figure 5.14. 
Based on the fact that anchorage-independent growth is one of 
characteristics of transformed cell phenotype, the data presented 
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above suggest that S6K2 has an oncogenic potential, whereas S6K2-S1 is 
a potential tumour suppressor.  
5.2.7 Xenograft studies in nude mice 
To confirm our findings, one of the most commonly used animal models 
to study human cancer was used. In a xenograft model, human tumour 
cells are injected into mice either under the skin or into the organ type 
from which tumour is originated. In these studies, nude athymic (nu/nu) 
immunocompromised mice deficient for B- and T-cells are used, as they 
do not reject human cells. Established in vitro human cell lines as well 
as human tumour tissue derived from biopsy or autopsy can be 
transplanted directly into these mice, allowing subcutaneous growth 
and reconstitution of solid tumours.  
To explore the oncogenic activity of full length S6K2 and S6K2-S1 in vivo, 
A549 stable cell lines, generated in the frame of this project, were 
injected into the flank of an individual athymic nude mouse. As a 
control, A549 stable cell line overexpressing an empty vector was used. 
Tumour growth was monitored every 3-4 days over a period of two 
months and measurement of the tumour volume began once the 
subcutaneous tumours became palpable and continued until day 50. 
Growth of the tumour xenografts in three groups was compared. As 
seen from the graphs presented in Figure 5.15, mice in group 2, injected 
with A549 cells overexpressing full length S6K2, developed tumours 
more rapidly, whereas tumour growth in S6K2-S1 group 3 was much 
slower, compared to control group 1. On day 50 four mice in S6K2 
group 2 developed big tumours with volume range from 0.68 to 1.13 
cm3 in comparison to control group 1, where just two mice developed 
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tumours with size 0.64 and 0.98 cm3 correspondingly. On the other 
hand, in S6K2-S1 group 3 two mice had small tumours with volume 0.53 
and 0.68 cm3. Analysis of results in Figure 5.16A shows that the 
overexpression of S6K2-S1 splicing variant in A549 cells reduces in vivo 
tumour growth, while full length S6K2 promotes tumour formation in 
nude mice. The expression of S6K2 and S6K2-S1 in tumour samples was 
monitored by Western Blotting (Figure 5.16B). 
Taking together, these results demonstrate for the first time that full 
length S6K2 exhibits oncogenic properties, whereas S6K2-S1 splicing 
variant functions as a tumour suppressor. 
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Figure 5.15 Analysis of tumours growth in a xenograft mouse model. 100 µl of viable A549 cells 
resuspended in normal medium (1 × 10
6
 cells/site) stably expressing S6K2wt, S6K2-S1 and an empty 
vector were mixed with 100 µl of chilled to +4°C Matrigel. This mixture was subcutaneously injected 
into flanks of nu/nu mice (eight mice per group). Tumours were measured twice weekly over a 
period of 50 days, and volumes were calculated as volume = (length×width×depth)/π. Tumour 
volume of each mouse in the group at each time point is shown. 
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Figure 5.16 Overexpression of S6K2-S1 reduces tumour growth in a xenograft mouse model. (A) 
Tumours were measured 2 times weekly over a period of 50 days, and volumes were calculated as 
volume = (length×width×depth)/π. Mean tumour volumes for each group (n=8/group) of mice at 
each time point is shown. The line indicates the nonlinear regression using an exponential growth fit. 
Mean tumour volumes for S6K2-S1 and S6K2wt group (n=8/group) of mice were compared to control 
group at each time point, starting at day 15, after tumour growth were established (mean ± 
SD;*p<0.0005). (B) Expression of S6K2wt and S6K2-S1 in tumour samples were confirmed in Western 
blotting. 
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5.3 Discussion 
The identification of a direct interaction between S6K2-S1, Raptor and 
mTOR, described in previous chapter, laid a strong basis for the study of 
the potential role of the spliced isoform in the regulation of mTORC1 
signalling. The N-terminal TOS sequence is fully functional in S6K2-S1 
and competes with S6K1, S6K2 and 4EBP1 for binding with Raptor, 
which is critical for the formation of mTORC1 and downstream 
signalling. The importance of the TOS motif in mTORC1 downstream 
targets is now well established (Hara K., 2002; Nojima H., 2003). 
To confirm our hypothesis the state of mTORC1 signalling in cells 
overexpressing S6K2-S1 splicing variant was assessed. Although no 
significant differences were detected under normal physiological 
conditions, several interesting results were obtained from the analysis 
of mTORC1/S6K signalling in HEK293 cells with stable overexpression of 
S6K2-S1 in response to serum starvation.  Firstly, serum starvation 
results in a greater reduction in S6K activity compared to control, as 
measured by blotting with phospho-specific antibodies against S6K 
target sites in S6 protein. Secondly, phosphorylation of 4EBP1 protein 
by mTORC1 is significantly reduced under starved conditions in HEK293 
cells overexpressing S6K2-S1, when compared to control. The same 
results were reproduced in TSC2-/- p53-/- MEF stable cell lines, 
indicating that S6K2-S1 splicing isoform has the potential to negatively 
regulate mTORC1 signalling. Finally, we were surprised to find that 
HEK293 cells overexpressing S6K2-S1 show dramatic reduction of 
Akt/PKB phosphorylation in response to serum starvation, when 
compared to control.  
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The revealed role of S6K2-S1 in the regulation of mTORC1 signalling is 
very interesting.  Therefore, our efforts were focused on studying the 
physiological significance of this regulatory event.  Based on known 
functions of S6Ks, we investigated the role of S6K2-S1 in the regulation 
of cell size, proliferation, survival and migration. Using several cell 
models, we showed that the overexpression of S6K2-S1 splicing isoform 
did not show any significant changes in their proliferation rate 
compared to control. Given the crucial role S6Ks play in the control of 
cell size, we assessed whether cells expressing splicing isoform differ in 
their size. In this study, we found that overexpression of S6K2-S1 did 
not affect the size of HEK293 cells, but the reduction in size was 
observed in NIH3T3RasC40 cells. To draw a definite conclusion on this 
issue, we generated TSC2-/- p53-/- MEF cells with stable overexpression 
of S6K2wt and S6K2-S1 splicing variant. The outcome of the cell size 
analysis in this cell model revealed that the overexpression of the 
spliced isoform dramatically decreased the size of TSC2-/- p53-/- MEF 
cells, whereas full length S6K2 overexpression resulted in the 
upregulation of the cell size. These findings clearly indicate that full 
length S6K2 and splicing isoform exhibit opposite effects on signalling 
pathways which regulate cell size. 
Studying the role of splicing isoform in the regulation of cell migration 
in NIH3T3RasC40 cells, we have shown that S6K2-S1 reduced cell ability 
to migrate up to forty percents, checked in wound healing assay. Taking 
these results into account, we can speculate that S6K2-S1 spliced 
isoform interferes with cell migration signalling coordinated via the 
mTORC1/S6K pathway. These data were subsequently confirmed by our 
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collaborators from Imperial College London (Prof. M. Seckl and Dr. O. 
Pardo).  
mTORC1/S6Ks signalling play an important role in the regulation of cell 
survival. To check whether the splicing isoform may affect cell survival 
in A549 cells, we treated them with staurosporine and cisplatin. 
Interestingly, in contrast to full length S6K2, the overexpression of 
splicing isoform in A549 cells resulted in a higher sensitivity to 
staurosporine treatment as measured by the level of cleaved PARP. The 
same results were obtained in TSC2-/- p53-/- MEF cell lines stably 
expressing S6K2wt and S6K2-S1. Surprisingly, A549 cells overexpressing 
splicing isoform showed dramatic downregulation of mTORC1/S6K 
signalling in response to cisplatin treatment, when compared to control 
cells. These results demonstrate that S6K2-S1 downregulates pro-
survival signalling in A549 cells, possibly by interfering with the 
mTORC1/S6K pathway. 
It has been recently demonstrated that a short splicing isoform of S6K1, 
in contrast to full length protein, possesses an oncogenic potential in 
human breast epithelial cells (Karni R et all, 2012).  Based on this, 
tumorigenic potential of S6K2 and S6K2-S1 splicing isoform was 
examined using two different approaches: anchorage-independent 
colony formation assay and xenograft studies in nude mice. First, in 
colony formation assay stable expression of full length S6K2 in HEK293 
and A549 cells resulted in a significant increase (30%) of the number of 
colonies, while cells overexpressing S6K2-S1 suppressed anchorage-
independent colony growth up to 50%, when compared to parental 
cells. Second, to confirm our findings tumourogenic potential of S6K2 
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and splicing isoform was assessed by performing xenograft studies in 
nude mice using A549 stable cell lines. This study showed that 
overexpression of the full length S6K2 in A549 cells resulted in the 
formation of bigger tumours, whereas S6K2-S1 splicing isoform had an 
opposite effect and suppressed tumour formation in nude mice, 
compared to control group. These findings are in good agreement with 
the data obtained in soft agar assay and show for the first time that 
S6K2wt is a potential oncogene, whereas S6K2-S1 splicing variant acts 
as a tumor suppressor. 
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6 General discussion and future studies 
 The important role of S6 kinase signalling in health and pathologies, 
particularly cancer, has been described in detail in chapter one. S6K is 
an important signalling component of mitogen- and nutrient-stimulated 
signalling cascades implicated in the regulation of cell growth, 
biosynthetic processes and energy metabolism (Fenton & Gout 
2011;Iadevaia et al. 2012;Proud 1996).  
A family of 70kDa ribosomal S6 kinases include S6K1 and S6K2 proteins, 
which are encoded by two different genes. Most of the published 
research has been done on S6K1, which was discovered more than 
twenty-five years ago.  Ten years later, S6K2 was cloned by several 
groups (Gout et al. 1998). These two kinases possess highly similar 
kinase domains; have the same mechanism of activation by common 
upstream pathways and a number of overlapping substrates.  
Much of the information we know about the functions of S6Ks was 
obtained from genetic studies in mice and flies. Drosophila has only one 
S6K gene and its deletion leads to the death of most flies during early 
development, whereas survived S6K1−/− flies are smaller than the wild 
type (Montagne et al. 1999).  Studies in mice showed that deletion of 
S6K1 was not lethal, but the mice were smaller and S6 phosphorylation 
was not significantly affected (Pende et al. 2000). On the other hand, 
S6K2−/− mice grew to a normal size, but had a significantly decreased 
level of S6 phosphorylation (Pende et al. 2004). Therefore, different 
phenotypes displayed in animal models with the deletion of S6K1 or 
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S6K2 genes points toward distinct downstream targets and functions. 
The studies revealing S6K1- or S6K2-specific substrates have started to 
emerge, which are essential for providing more information on their 
different cellular functions (Goh et al. 2010;Richardson, Broenstrup, 
Fingar, Julich, Ballif, Gygi, & Blenis 2004;Sridharan & Basu 2011).  
Recent identification of a novel S6K1 splice variant, named S6K1-
isoform 2, makes the situation more complex and provides a new 
insight into the S6K1 genetic studies. As seen from Figure 6.1, S6K1-
isoform 2 is generated by the inclusion of three additional exons (a-b-c) 
located between exon 6 and 7. These exon inclusions generate an early 
stop codon in exon 6c in mice and in exons 6a or 6c in humans. 
Generated transcripts contain half of the original S6K1 coding sequence 
and a significant part of the kinase domain (Karni, Hippo, Lowe, & 
Krainer 2008). 
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Figure 6.1 Mechanism of alternative splicing of S6K1 gene. Rectangles represent the coding exons of 
the S6K1 gene.  Black rectangles show the inclusion of three additional exons (a-b-c) located 
between exon 6 and 7 into coding sequence. These exon inclusions generate an early stop codon in 
exon 6c in mouse and in exons 6a or 6c in humans. 
 
 
Interestingly, in animal model S6K1 gene disruption was created by 
homologous recombination and a targeting construct was produced by 
replacing 1.2 kb of the genomic sequence in exons 8-10 with a 
neomycin resistance cassette (Pende et al. 2004;Shima et al. 1998;Um 
et al. 004). Thus, half of the gene up to exon 8 is transcribed producing 
shorter splicing isoform. Taking into account that this splice variant 
possesses an oncogenic potential, whereas the full length S6K1 does 
not, it is difficult to assess whether the observed phenotype of S6K1-/- 
mice is not affected by the expression of S6K1-isoform 2.  
Karni et al. 2008. Proc.Natl.Acad.Sci.U.S.A, 
105, (40) 15323-15327 
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As described in chapter 3 of this thesis, three new splicing isoforms of 
S6K2 were identified in our laboratory. Detailed bioinformatics analysis 
of isolated cDNA clones and EST sequences from various databases 
indicates that the S6K2-S1 and S6K2-S2 splicing variants are generated 
by alternative splicing of exon 9. Analysis of cDNA nucleotide sequence 
corresponding to S6K2-S3 shows that it is generated by aberrant 
splicing of intron 5, resulting in the inclusion of a cryptic exon in the 
transcript. Similarly to the S6K1 strategy, S6K2 gene disruption in S6K2-
/- mice was created by replacing genomic sequence corresponding to 
exons 8-10 with a neomycin resistance cassette (Figure 6.2). 
 
 
 
 
Figure 6.2 Generation of an S6K2-/- allele. Murine S6K2 gene map and targeting vector. Rectangles 
represent the coding exons of the S6K2 gene. The exons containing the T loop and APE sequences 
and the start and stop codons are indicated. The four exons deleted following the homologous 
recombination event are shown in grey. Restriction sites: B, BamHI; Sp, SpeI; E, EcoRI; P, PstI; Sm, 
SmaI. 
 
Pende M. et al., 2004. Mol.Cell Biol., 
24, (8) 3112-3124 
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In this case, S6K2-S1 and S6K2-S2 splicing variants will not be present as 
they contain exon 8 in their coding sequence. On the other hand, S6K2-
S3 will be expressed in S6K2-/- model, as the stop codon is localised in 
exon 6 of the coding sequence. Taking into account the abundance of 
this isoform in the EST database, it may play an important role in 
cellular functions and can dramatically affect the phenotype of S6K2-/- 
knockout mice generated by M. Pende et al.  
With the knock in mice model, all S6K2 splicing variants would be 
expressed and form specific cellular complexes. In this model S6K2 full-
length would lack its kinase activity and the phenotype of S6K2 knock in 
mice would not be dramatically affected by the other splicing isoforms.  
More studies have to be performed to address this question. 
Both S6K1 and S6K2 were found to contain at their N-termini TOS 
motifs, responsible for the direct interaction with Raptor, which 
presents them for the phosphorylation by mTOR (Nojima et al. 
2003;Schalm et al. 2003b). As discussed in chapter 3, all three S6K2 
splicing variants are identical to the full length S6K2 at their N-termini. 
Additionally, S6K2-S1 and S6K2-S2 proteins have a unique 38 amino 
acids extension at their C-termini, which was used for generation of 
specific polyclonal antibodies. Affinity purified anti-S6K2-S1 antibodies 
specifically recognized overexpressed protein, as well as an additional 
immunoreactive band of slightly lower molecular weight, which might 
represent endogenous splicing variant in HEK293 cells. Unfortunately, 
generated affinity purified polyclonal antibodies exhibited high non-
specific immunoreactivity in Western blotting, which significantly 
restricted their application. Generation of specific monoclonal 
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antibodies against splicing S6K2-S1 variant would give us the 
opportunity to study the functions of splicing isoform using 
immunoprecipitation and immunohistochemistry. 
Significantly, the results presented in chapter 3 suggest a direct physical 
interaction between S6K2-S1, Raptor and mTOR. Using different 
experimental approaches, we showed that S6K2-S1 splicing isoform and 
the full length S6K2 have the ability to interact with Raptor via their N-
terminal TOS sequence. This finding provides a valuable clue as to the 
potential function of S6K2-S1, suggesting that under physiological 
conditions it may compete not only with S6K2, but also with S6K1 and 
4EBP1 for the binding to Raptor. It is now well known that these 
mTORC1 downstream targets are characterised by the presence of the 
TOS motif in their sequences (Hara et al. 2002;Nojima et al. 2003).  
Importantly, as S6K2-S1 does not possess the mTOR site for 
phosphorylation and lacks half of the kinase domain, it may act as a 
dominant negative regulator of mTORC1 signalling.  
The identification of a direct interaction between S6K2-S1, Raptor and 
mTOR, laid a strong basis for us to study the potential role of this 
isoform in the regulation of mTORC1 signalling described in detail in 
chapter 5. 
The mTOR/S6K signalling pathway has been implicated as a main 
regulator of cell growth and cell size. Genetic studies clearly show that 
S6K1−/− deficient animals have smaller cell size when compared to the 
wild type (Montagne et al. 1999). In a view of these findings, the role of 
S6K2-S1 splicing isoform in the regulation of cell size was investigated. 
Using TSC2-/- p53-/- MEF cells, we were able to show that 
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overexpression of the S6K2-S1 splicing isoform results in the decrease 
of cell size, when compared to control or cells with overexpressed 
S6K2wt.  
With the use of phospho-specific antibodies, we showed that S6K2-S1 
did not affect the mTOR/S6K signalling pathway in cells cultured under 
normal physiological conditions. Interestingly, serum deprivation 
resulted in a significant reduction in the phosphorylation of rpS6 and 
4EBP1 proteins in cell lines overexpressing S6K2-S1 when compared to 
control. These findings suggest that S6K2-S1 splicing isoform may be a 
negative regulator of mTORC1 signalling in serum-starved cells. 
Surprisingly, in starved condition the phosphorylation state of Akt/PKB 
at Ser473 was also significantly reduced compared to control. It is 
interesting to note that both S6K1 and S6K2 were shown to play an 
important role in a feedback loop, implicated in the inactivation of the 
PI3K/PKB/Akt signalling via IRS1 (Harrington et al. 2004). But on the 
other hand, it was shown that in MCF-7 cells, S6K1 and S6K2 played an 
opposite role in Akt/PKB activation and cell survival (Sridharan & Basu 
2011). Taking this into account it is difficult to speculate about the role 
of S6K2-S1 splicing isoform in the Akt/PKB signalling and more work 
should be done to address this issue.  
Another interesting question to answer in future studies would be 
whether Rapamycin treatment has the same effect on S6K2-S1 
expressing cells as serum starvation. It is known that both experimental 
conditions affect mTORC1 assembly and downregulate its signalling. In 
our study, we did not investigate the physiological relevance of the 
inhibition of 4EBP1 phosphorylation by mTORC1 in S6K2-S1 expressing 
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cells during starvation. Based on known functions of 4EBP1 protein, we 
can assume that it may affect cap-dependent translation. More 
experiments have to be conducted to prove our suggestions. 
 Although the S6K2-S1 splicing isoform does not affect cell proliferation 
under normal cell culturing conditions, it would be interesting to 
examine its role in regulating cell proliferative signalling in serum-
starved cells.  
One of the important cellular processes controlled via the mTOR/S6K 
pathway is cytoskeletal reorganisation, which coordinates cell 
migration, invasion and cell adhesion. These cellular processes play a 
significant role in malignant transformation, invasion and metastasis. 
The importance of S6K1 in the regulation of cell migration was 
demonstrated in different cellular models, including Swiss 3T3 
fibroblasts, chicken embryo fibroblast (CEF) and in ovarian cancer cells 
(Berven & Crouch 2000;Ip, Cheung, Ngan, & Wong 2011;Qian, Corum, 
Meng, Blenis, Zheng, Shi, Flynn, & Jiang 2004). Studying the role of the 
S6K2 spliced isoform in the regulation of cell migration we were able to 
show that its overexpression decreased the ability of NIH3T3RasC40 
cells to migrate up to forty percent. These data were confirmed by our 
collaborators from Imperial College London (Prof. M. Seckl and Dr. O. 
Pardo). As discussed in the Introduction chapter, S6K1 can stimulate 
actin cytoskeleton reorganization and cell migration by activating Rac1, 
Cdc42 and p21-activated kinase (PAK1). Rac1, Cdc42 are members of 
the Rho GTPases family of proteins, which play a central role in cell 
motility and cell adhesion (Ip, Cheung, Ngan, & Wong 2011;Khotskaya 
et al. 2014;Yang, Wang, & Zheng 2006). Another question to answer in 
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future experiments would be whether S6K2-S1 is implicated in the 
regulation and/or downstream signalling from Rho GTPases. It is 
important to understand that cell adhesion is a complex process that 
involves many different molecular interactions and changes in the 
intracellular signalling pathways. Cell-ECM and cell-cell interactions are 
important for cell migration and adhesion, mediated by specific 
molecules, such as cadherins and integrins. It has been shown that S6K1 
can modulate the expression level of E-cadherin, N-cadherin and 
vimetin (Pon et al. 2008). Therefore, it would of interest to investigate 
whether S6K2-S1 splicing isoform can modulate the level and function 
of these cell adhesion molecules.  
The mTOR/S6K signalling pathway, especially via S6K2, has been shown 
to play an important role in cell survival in lung and breast cancer 
(Pardo et al.  2011). To check how S6K2-S1 splicing isoform may affect 
cell survival, we treated A549 cells overexpressing full length S6K2 and 
splicing variant with cytotoxic drugs. We were able to show that A549 
cells overexpressing S6K2-S1 splicing isoform showed higher sensitivity 
to staurosporine, in contrast to control or cells with overexpressed 
wtS6K2. These results were confirmed in TSC2-/- p53-/- MEF cell lines 
with stable overexpression of S6K2wt and S6K2-S1. Surprisingly, 
cisplatin treatment of A549 cells overexpressing splicing isoform 
resulted in a dramatic downregulation of mTOR/S6K signalling, when 
compared to control cells. These results demonstrate that S6K2-S1 
activated pro-apoptotic signalling in A549 cells, possibly by interfering 
with mTOR/S6K signalling. 
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There is growing evidence that S6Ks can contribute to the development, 
growth and spreading of tumours. S6K1 gene amplification has been 
reported in almost 10 percent of breast carcinomas which correlated 
with poor prognosis (Couch et al. 1999;van der Hage et al. 2004). 
Additionally, a recent publication shows that S6K1 increases the 
invasiveness of breast cancer and specific pharmacological inhibition of 
S6K1 activity could be used for the prevention of cancer metastasis and 
improving poor prognosis (Khotskaya et al. 2014). Clinical potential of 
S6K1 and S6K2 inhibition in breast cancer has been reviewed recently 
(Perez-Tenorio et al. 2011). It has been also demonstrated that the 
short isoform of S6K1, in contrast to full length protein, possesses an 
oncogenic potential in human breast epithelial cells (Karni, Hippo, Lowe, 
& Krainer 2008). So far, very little is known about the potential 
oncogenic role of S6K2. The overexpression of S6K2 has been reported 
in small cell lung cancer cell lines and breast tumors (Pardo et al. 
2001;Savinska et al. 2004).  To our knowledge, there are no published 
studies describing oncogenic properties of S6K2. In the frame of this 
project, we examined oncogenic potential of S6K2 and S6K2-S1 splicing 
isoform using two different approaches: anchorage-independent colony 
formation assay and xenograft studies in nude mice. Firstly, expression 
of full length S6K2 in HEK293 and A549 cells resulted in significant 
increase in the formation of colonies in soft agar, while S6K2-S1 
suppressed anchorage-independent colony growth up to 50 percent in 
both cell lines. Secondly, in line with previous results, we demonstrated 
that full length S6K2 promoted tumour formation in nude mice, 
whereas S6K2-S1 splicing isoform had an opposite effect and inhibited 
tumour growth.  
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Another important question to answer in future experiments would be 
to check the expression level of different splicing isoforms in normal 
and cancer tissues. Tissue microarray assay with specifically designed 
primers can be used to show the relative expression of all S6K2 splicing 
variants in different tissue samples. 
In conclusion, this study describes for the first time the existence of 3 
novel S6K2 splicing isoforms and reveals the functional role of S6K2-S1 
as a negative regulator of mTOR/S6K signalling. Firstly, both full-length 
S6K2 and S6K2-S1 we found to bind directly to Raptor and to be an 
integral part of mTORC1. Secondly, S6K2-S1 splicing isoform 
downregulated mTOR/S6K signalling in serum-starved HEK293 cells and 
suppressed pro-survival signalling in A549 cells in response to cytotoxic 
drugs. Importantly, the overexpression of S6K2-S1 splicing variant in 
MEF TSC2-/- p53-/- cells resulted in smaller cell size, in contrast to 
S6K2wt.  Additionally, S6K2-S1 was able to affect cell migration of 
NIH3T3RasC40 cells. Finally, we showed for the first time that full length 
S6K2 can function as a potential oncogene, whereas S6K2-S1 splicing 
variant exhibits tumour suppressor properties. 
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7 Appendix A 
S6K2gene        GGAGAGATGATGTTTAGGTCCGGGACTGTCAGTCAGTGCGCGGCCAGGTACGGGCCGACG 60 
S6K2mRNA        GGAGAGATGATGTTTAGGTCCGGGACTGTCAGTCAGTGCGCGGCCAGGTACGGGCCGACG 60 
                ************************************************************ 
 
S6K2gene        GGCCCGCGGGGCCGGCGCCGCCATGGCGGCCGTGTTTGATTTGGATTTGGAGACGGAGGA 120 
S6K2mRNA        GGCCCGCGGGGCCGGCGCCGCCATGGCGGCCGTGTTTGATTTGGATTTGGAGACGGAGGA 120 
                ************************************************************ 
 
S6K2gene        AGGCAGCGAGGGCGAGGGCGAGCCAGAGCTCAGCCCCGCGGTGAGTGCCCTGCCCTGGCG 180 
S6K2mRNA        AGGCAGCGAGGGCGAGGGCGAGCCAGAGCTCAGCCCCGCG-------------------- 160 
                ****************************************                     
 
_____________________________________________________________________________________                                                                             
 
 
S6K2gene        GGCACCTTCCTTGGCTCTTACCCCTCGGTTTCTCACAGGACGCATGTCCCCTTGCCGAGT 540 
S6K2mRNA        --------------------------------------GACGCATGTCCCCTTGCCGAGT 182 
                                                      ********************** 
 
S6K2gene        TGAGGGCAGCTGGCCTAGAGTGAGTGAGGGTCGTGTTGGGGGAGGGGGGAATGGAGTGGG 600 
S6K2mRNA        TGAGGGCAGCTGGCCTAGA----------------------------------------- 202 
                *******************                                         
 
S6K2gene        GAAGGGGAACTGGGGAGCACTGGAGCCTTGTCCTCATTAACTCCTTGTGTCCGTAGGCCT 660 
S6K2mRNA        --------------------------------------------------------GCCT 205 
                                                                        **** 
 
S6K2gene        GTGGGACACTATGAAGAGGTGGAGCTGACTGAGACCAGCGTGAACGTTGGCCCAGAGCGC 720 
S6K2mRNA        GTGGGACACTATGAAGAGGTGGAGCTGACTGAGACCAGCGTGAACGTTGGCCCAGAGCGC 265 
                ************************************************************ 
 
S6K2gene        ATCGGGCCCCACTGCTTTGAGCTGCTGCGTGTGCTGGGCAAGGGGGGCTATGGCAAGGTA 780 
S6K2mRNA        ATCGGGCCCCACTGCTTTGAGCTGCTGCGTGTGCTGGGCAAGGGGGGCTATGGCAAG--- 322 
                *********************************************************    
 
S6K2gene        GGGGCGGGCGCACCCTCCTCCTGGCCTCACAGCCTCCATCTGGAGGCAGCAAAGGGTTCT 840 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
_____________________________________________________________________________________                                                                             
 
 
S6K2gene        GGATGTGGAGAGGGAAGTTGATCCTGTCTCCCCTGCCCTACAGGTGTTCCAGGTGCGAAA 1080 
S6K2mRNA        -------------------------------------------GTGTTCCAGGTGCGAAA 339 
                                                           ***************** 
 
S6K2gene        GGTGCAAGGCACCAACTTGGGCAAAATATATGCCATGAAAGTCCTAAGGAAGGTGAGTCA 1140 
S6K2mRNA        GGTGCAAGGCACCAACTTGGGCAAAATATATGCCATGAAAGTCCTAAGGAAG-------- 391 
                ****************************************************         
 
S6K2gene        CTCGTTCAGCCAACGAATACTGTGTGGCTGCCATTCCCAACATGCTGTACCAGGCTTTGG 1200 
S6K2mRNA        ------------------------------------------------------------ 
 
_____________________________________________________________________________________                                                                             
 
 
S6K2gene        TCTAACCAATTCCTGTATCTCCAGGCCAAAATTGTGCGCAATGCCAAGGACACAGCACAC 2940 
S6K2mRNA        ------------------------GCCAAAATTGTGCGCAATGCCAAGGACACAGCACAC 427 
                                        ************************************ 
 
S6K2gene        ACACGGGCTGAGCGGAACATTCTAGAGTCAGTGAAGCACCCCTTTATTGTGGAACTGGCC 3000 
S6K2mRNA        ACACGGGCTGAGCGGAACATTCTAGAGTCAGTGAAGCACCCCTTTATTGTGGAACTGGCC 487 
                ************************************************************ 
 
S6K2gene        TATGCCTTCCAGACTGGTGGCAAACTCTACCTCATCCTTGAGTGCCTCAGTGGTATGAGT 3060 
S6K2mRNA        TATGCCTTCCAGACTGGTGGCAAACTCTACCTCATCCTTGAGTGCCTCAGTG-------- 539 
                ****************************************************         
 
S6K2gene        GCGGGCCCAGGCAGGGGTGCTGGGGGTCGCGGGGGGGCAGCGAGCCAGCAAAGGAAGCTC 3120 
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S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
_____________________________________________________________________________________ 
 
 
S6K2gene        ATCTCAGCATCCCCTTAAAGTCCCAGCAAACCGCGCTTTCTCTGTTCTGTTCTGTTGGGA 3780 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        TTCACTCTGTCTTCCCTGTCTTCTCTGCGAGATCTTTTGGGCTAAGCTCTTGGAGCTGTG 3840 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        GCCTGGGCCTGGCGTATTAGAGCCGTTGTGTACATGTCTGTCTCCCCAGTAGACTGAGCG 3900 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        TCCTGAGGGCAGTGGCTGGGTCTCTTCATCCTGTCCCCAGCTTCACCCAGCACAGGGCCA 3960 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        GGCACCGAGTAGGCGTCGGTAGATGTTTGCTGAATTGAATTGAATCCCCACGGCAGCTCT 4020 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        GTGAGGCAGGTAGGGCGGGAATTATGAGCCCCTCTTTCCCCAAGAAGAAATAAAGACTCA 4080 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        GAAAGCACAAAGGGGCTTGGACCCAGCACGTGGCTGCTGACGTGTTTGTGTGGCAGGTGG 4140 
S6K2mRNA        --------------------------------------------------------GTGG 543 
                                                                        **** 
 
S6K2gene        CGAGCTCTTCACGCATCTGGAGCGAGAGGGCATCTTCCTGGAAGATACGGCCTGGTGGGT 4200 
S6K2mRNA        CGAGCTCTTCACGCATCTGGAGCGAGAGGGCATCTTCCTGGAAGATACGGCCTG------ 597 
                ******************************************************       
 
S6K2gene        GTTAATCCTCCGCTTTCCTGAGGCTGCCAGGTCCCTGCTCTACTCCCGCCTTCACCCTGT 4260 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        CTTGTTTCTGCAGCTTCTACCTGGCTGAGATCACGCTGGCCCTGGGCCATCTCCACTCCC 4320 
S6K2mRNA        -------------CTTCTACCTGGCTGAGATCACGCTGGCCCTGGGCCATCTCCACTCCC 644 
                             *********************************************** 
 
S6K2gene        AGGGCATCATCTACCGGGACCTCAAGCCCGAGAACATCATGCTCAGCAGCCAGGGTGCGC 4380 
S6K2mRNA        AGGGCATCATCTACCGGGACCTCAAGCCCGAGAACATCATGCTCAGCAGCCAGG------ 698 
                ******************************************************       
 
S6K2gene        ATGTGTGTGCGGGCAGCTGCAGGCGGGGTCTGCAATCTGTGGGGAGGGCTGAGGACCTCT 4440 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        GTGGGTGGGGTGGGGCCCTGGTCACGCCTCTCCAACACCCTTCCTCAGGCCACATCAAAC 4500 
S6K2mRNA        ------------------------------------------------GCCACATCAAAC 710 
                                                                ************ 
 
S6K2gene        TGACCGACTTTGGACTCTGCAAGGAGTCTATCCATGAGGGCGCCGTCACTCACACCTTCT 4560 
S6K2mRNA        TGACCGACTTTGGACTCTGCAAGGAGTCTATCCATGAGGGCGCCGTCACTCACACCTTCT 770 
                ************************************************************ 
 
S6K2gene        GCGGCACCATTGAGTACATGTAAGTGGCACCTGGCTGGCCCAGGGGTCGGGAGGACAGCC 4620 
S6K2mRNA        GCGGCACCATTGAGTACAT----------------------------------------- 790 
                *******************                                        
 
S6K2gene        CGAAGGGGCACGGCCTGACTGACAGTTCCACCTGGACCCCAGGGCCCCTGAGATTCTGGT 4680 
S6K2mRNA        ------------------------------------------GGCCCCTGAGATTCTGGT 807 
                                                           ***************** 
 
S6K2gene        GCGCAGTGGCCACAACCGGGCTGTGGACTGGTGGAGCCTGGGGGCCCTGATGTACGACAT 4740 
S6K2mRNA        GCGCAGTGGCCACAACCGGGCTGTGGACTGGTGGAGCCTGGGGGCCCTGATGTACGACAT 867 
                ************************************************************ 
 
S6K2gene        GCTCACTGGATCGGCAAGTCCAGCCCCCGGGGAGGAGGAGGGGCAGGGGCAGAGGTGGGA 4800 
S6K2mRNA        GCTCACTGGATCG----------------------------------------------- 880 
                *************                                                
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S6K2gene        GTAGCCCCCCTCCTGGGGCAAGGGCAGGGCCTGGTGGGAGGCCCACAAGGCTCCTCTCAC 4860 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
 
S6K2gene        CTTCCTCCTCCTCCAGCCGCCCTTCACCGCAGAGAACCGGAAGAAAACCATGGATAAGAT 4920 
S6K2mRNA        ----------------CCGCCCTTCACCGCAGAGAACCGGAAGAAAACCATGGATAAGAT 924 
                                ******************************************** 
 
S6K2gene        CATCAGGGGCAAGCTGGCACTGCCCCCCTACCTCACCCCAGATGCCCGGGACCTTGTCAA 4980 
S6K2mRNA        CATCAGGGGCAAGCTGGCACTGCCCCCCTACCTCACCCCAGATGCCCGGGACCTTGTCAA 984 
                ************************************************************ 
 
S6K2gene        AAAGGTGCAGCTCCCTTCTCTCTTCTCCGGGGCCCTGCCAGCCATTCTGCACGTGTTCCT 5040 
S6K2mRNA        AAAG-------------------------------------------------------- 988 
                ****                                                         
 
S6K2gene        GAGTCTCTCTGGGCTGTGGGGAAGCCAGGGCCACCCCGGCCTGTGCAGTTTGCCTCTGGG 5100 
S6K2mRNA        ------------------------------------------------------------ 
                                   
___________________________________________________________________________________ 
 
 
S6K2gene        GCTAGCCCTGGGACCCGGGGACACATGAGCAGTACTTGCCCAGGCCCTCACCCTCTCTCC 5520 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        TGGTCCCGCAGTTTCTGAAACGGAATCCCAGCCAGCGGATTGGGGGTGGCCCAGGGGATG 5580 
S6K2mRNA        -----------TTTCTGAAACGGAATCCCAGCCAGCGGATTGGGGGTGGCCCAGGGGATG 1037 
                           ************************************************* 
 
S6K2gene        CTGCTGATGTGCAGGTGGGTTTGGGACCACCACCAGGGGTAGGGCTGAGTCTCCAAGGGT 5640 
S6K2mRNA        CTGCTGATGTGCAG---------------------------------------------- 1051 
                **************                                               
 
S6K2gene        GCCGGGAATGGGGGCAGGGCCCCAGGGCAGAGGGAGTGACCGGGGGGCAAGCAGGGTGAG 5700 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        CTGTTAGTGGGTTTGGTGCATTCTCTACCTACAGAGACATCCCTTTTTCCGGCACATGAA 5760 
S6K2mRNA        ----------------------------------AGACATCCCTTTTTCCGGCACATGAA 1077 
                                                  ************************** 
 
 
S6K2gene        TTGGGACGACCTTCTGGCCTGGCGTGTGGACCCCCCTTTCAGGCCCTGTCTGGTGAGCAG 5820 
S6K2mRNA        TTGGGACGACCTTCTGGCCTGGCGTGTGGACCCCCCTTTCAGGCCCTGTCTG-------- 1129 
                ****************************************************         
 
S6K2gene        CAGGGCTGGTGGCCAGTGGCCGGTGGCGGGTGGCAAGTGGAGAACCTGCATCTTGGTGCC 5880 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        CTCTGACCCCTCCCCACTCTGGTCGGCCCACAGCAGTCAGAGGAGGACGTGAGCCAGTTT 5940 
S6K2mRNA        ---------------------------------CAGTCAGAGGAGGACGTGAGCCAGTTT 1156 
                                                 *************************** 
 
S6K2gene        GATACCCGCTTCACACGGCAGACGCCGGTGGACAGTCCTGATGACACAGCCCTCAGCGAG 6000 
S6K2mRNA        GATACCCGCTTCACACGGCAGACGCCGGTGGACAGTCCTGATGACACAGCCCTCAGCGAG 1216 
                ************************************************************ 
 
S6K2gene        AGTGCCAACCAGGCCTTCCTGGTGAGTGCGGGGGCCTGAGGCCTGTGGGACCAGGGCACG 6060 
S6K2mRNA        AGTGCCAACCAGGCCTTCCTG--------------------------------------- 1237 
                *********************                                        
 
S6K2gene        GATCGTGACTAAGGATGGCAGGCACTGAGTGTCGCATGGCCCTGCCTCCGCCCCCCAGGG 6120 
S6K2mRNA        ----------------------------------------------------------GG 1239 
                                                                          ** 
 
S6K2gene        CTTCACATACGTGGCGCCGTCTGTCCTGGACAGCATCAAGGAGGGCTTCTCCTTCCAGCC 6180 
S6K2mRNA        CTTCACATACGTGGCGCCGTCTGTCCTGGACAGCATCAAGGAGGGCTTCTCCTTCCAGCC 1299 
                ************************************************************ 
 
S6K2gene        CAAGCTGCGCTCACCCAGGCGCCTCAACAGTAGCCCCCGGGCCCCCGTCAGGTACTGAGG 6240 
S6K2mRNA        CAAGCTGCGCTCACCCAGGCGCCTCAACAGTAGCCCCCGGGCCCCCGTCAG--------- 1350 
                ***************************************************          
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S6K2gene        GACGTGGGGGTGTGTGGCTGGGTTAGGGACGCTGGCAGGCAGGATGCCAGCTCCAGCCTT 6300 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
_____________________________________________________________________________________                                                                         
 
 
S6K2gene        GCCTGTGTGCCTGGGCAGGTGGGAAAGGCTGCCTTCCCTGACTGAGTGCTGGGAGCCTCT 6480 
S6K2mRNA        ------------------------------------------------------------ 
                                                                             
 
S6K2gene        GGCAGGGCCTAGGAGGCTCTTATTCTGCCTTGGTTTCCCCTGCAGCCCCCTCAAGTTCTC 6540 
S6K2mRNA        ---------------------------------------------CCCCCTCAAGTTCTC 1365 
                                                             *************** 
 
S6K2gene        CCCTTTTGAGGGGTTTCGGCCCAGCCCCAGCCTGCCGGAGCCCACGGAGCTACCTCTACC 6600 
S6K2mRNA        CCCTTTTGAGGGGTTTCGGCCCAGCCCCAGCCTGCCGGAGCCCACGGAGCTACCTCTACC 1425 
                ************************************************************ 
 
S6K2gene        TCCACTCCTGCCACCGCCGCCGCCCTCGACCACCGCCCCTCTCCCCATCCGTCCCCCCTC 6660 
S6K2mRNA        TCCACTCCTGCCACCGCCGCCGCCCTCGACCACCGCCCCTCTCCCCATCCGTCCCCCCTC 1485 
                ************************************************************ 
 
S6K2gene        AGGGACCAAGAAGTCCAAGAGGGGCCGTGGGCGTCCAGGGCGCTAGGAAGCCGGGTGGGG 6720 
S6K2mRNA        AGGGACCAAGAAGTCCAAGAGGGGCCGTGGGCGTCCAGGGCGCTAGGAAGCCGGGTGGGG 1545 
                ************************************************************ 
 
S6K2gene        GTGAGGGTAGCCCTTGAGCCCTGTCCCTGCGGCTGTGAGAGCAGCAGGACCCTGGGCCAG 6780 
S6K2mRNA        GTGAGGGTAGCCCTTGAGCCCTGTCCCTGCGGCTGTGAGAGCAGCAGGACCCTGGGCCAG 1605 
                ************************************************************ 
 
S6K2gene        TTCCAGAGACCTGGGGGTGTGTCTGGGGGTGGGGTGTGAGTGCGTATGAAAGTGTGTGTC 6840 
S6K2mRNA        TTCCAGAGACCTGGGGGTGTGTCTGGGGGTGGGGTGTGAGTGCGTATGAAAGTGTGTGTC 1665 
                ************************************************************ 
 
S6K2gene        TGCTGGGGCAGCTGTGCCCCTGAATCATGGGCACGGAGGGCCGCCCGCCACGCCCCGCGC 6900 
S6K2mRNA        TGCTGGGGCAGCTGTGCCCCTGAATCATGGGCACGGAGGGCCGCCCGCCACGCCCCGCGC 1725 
                ************************************************************ 
 
 
S6K2gene        TCAACTGCTCCCGTGGAAGATTAAAGGGCTGAATCATGGTGCTGA------------ 6945 
S6K2mRNA        TCAACTGCTCCCGTGGAAGATTAAAGGGCTGAATCATGGTGCTGAAAAAAAAAAAAA 1782 
                                                                              
*****************************************************     
 
 
 
 
 
Appendix A. ClastalW alightment of S6K2 gene and mRNA coding sequence. Human S6K2 gene is 
located on chromosome 11 q13.2, (chr11:67,195,935-67,202,878). NN – classic intron ends, NN – 
non-classic intron ends, NNN – standard start/stop codon, NNN – alternative stop codon, NNNNN – 
exon skipped during alternative splicing in S6K2-S1, NN – alternative intron ends in S6K2-S2 isoform, 
NNNNN – “pseudoexon”, fragment of the intron 4 spliced into mRNA between exon 4 and exon 5 in 
splicing isoform S6K2-S3, NN – classic intron ends used in “pseudoexon” splicing of S6K2-S3 
isoform,NNNNN – represents polyadenylation signal. 
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8 Appendix B 
List of primers designed for molecular cloning in this study 
 
Forward: S6K2 
 
Forward: S6K2 N-terminal EE-tag 
 
Forward: S6K2 N-terminal FLAG-tag  
 
Forward: S6K2 N-terminal HIS-tag 
 
Forward: S6K2 N-terminal Strep-tag 
 
Reverse: S6K2 
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Reverse: S6K2-S1 C-terminal FLAG-tag 
 
 Forward: Raptor N-terminal EE-tag 
 
Reverse: Raptor 
 
 Forward: Rictor, N-terminal EE-tag 
 
 Reverse: Rictor 
 
RT-PCR primers: 
 Forward:  
TCAAACTGACCGACTTTGGA 
 Reverse: 
AAGGTCGTCCCAATTCATGT 
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